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Synthetic cathinones represent threatening and high abuse-potential designer drugs. These 
are analogs of cathinone (the β-keto analog of amphetamine (AMPH)) a naturally 
occurring stimulant found in the plant Catha Edulis. Methcathinone (MCAT) was the first 
synthetic analog of cathinone to be identified in 1987 by Glennon and co-workers and it 
exerted its action primarily through the dopamine transporter (DAT). Most central 
stimulants exert their action via monomaine transporters by causing either the release (e.g. 
cathinone analogs such as MCAT) or by preventing the reuptake (e.g. cocaine) of the 
neurotransmitter dopamine (DA) thus increasing the extracellular synaptosomal 
concentration of this neurotransmitter. In 2010, a new class of designer cathinone-like 
drugs called ‘bath salts’, initially a combination of methylenedioxypyrovalerone (MDPV), 
 xxvii 
methylone (methylenedioxymethcathione, MDMC) and mephedrone (MEPH), soared to 
popularity. It caused extremely detrimental side effects; it was exceedingly popular for its 
recreational use and posed a threat to public health. At the time, their mechanisms of action 
were unknown. Our group identified that MDPV produced actions distinct from other 
cathinone analogs (i.e., it was identified as the first cathinone-like compound to act as a 
reuptake inhibitor at the dopamine transporter (DAT)). These findings suggested that not 
all cathinone-like compounds act uniformly and this insinuated that unique structural 
features on the cathinone scaffold might contribute to different effects at the transporter 
level. The overall goal of this project was to study the mechanisms of action of synthetic 
cathinones (including ‘bath salts’) at the monoamine transporters. We investigated the 
contribution of each of various structural features on the cathinone scaffold (i.e, the 
terminal amine, α and β positions, and the phenyl ring). We also constructed homology 
models of the human dopamine and serotonin transporters (hDAT and hSERT 
respectively) to help explain differences in selectivity between the neurochemical and 
behavioral aspects of DAT and SERT. Overall we found that structural features 
contributed to similar or distinctive mechanisms of action and also contributed to 
selectivity at monoamine transporters. Our studies provide information that can be useful 
to drug and health regulatory agencies to help prevent, treat, or curb the future abuse of 
such drugs. 
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I. Introduction 
 
 
 
 
 
Monoamine transporters are vital to maintaining neurotransmitter homoeostasis and a 
disruption of their normal functioning can result in several disease states such as 
Parkinson’s disease, depression, and attention deficit hyperactivity disorder (ADHD). In 
addition to being targets for the above disease states, they are also targets for 
psychostimulants, such as AMPH and cocaine.1 The mechanism of stimulant action at 
monoamine transporters can be exerted via two main mechanisms. For example both 
AMPH and cocaine exert their stimulant action primarily via DAT but by two distinct 
mechanisms. AMPH exerts its action by causing a release of dopamine (DA) into the 
synapse by acting as a substrate (or releaser)2 whereas cocaine increases synaptic DA 
concentrations by preventing the reuptake of synaptic DA.3  
 
Cathinone, the β-keto analog of AMPH, is a naturally occurring stimulant in the plant 
Catha edulis.4 Its N-methyl analog, MCAT, was identified in 1987 as its first and more 
potent analog. It exerted its action similar to AMPH (i.e., as a releasing agent at DAT).  It 
was notorious for its effects in the 1980’s.5 Between the rise of MCAT and 2010 there 
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were other cathinone-like compounds but none that were extremely popular, produced 
striking and harmful adverse effects or had a very high abuse potential.6 
 
In 2010 a new class of designer drugs called “bath salts” made their debut.7 Their toxic and 
bizarre effects and increased abuse potential brought them to the focus. The original 
constituents of bath salts include all, or at least one, of the following: 
methylenedioxypyrovalerone, methylenedioxymethcathinone or methylone, and 
mephedrone (MDPV, MDMC, and MEPH, respectively).8 At that time their mechanisms 
of action were not known. Our group reported in electrophysiological assays that MDPV 
was the first synthetic cathinone to exert its action similar to cocaine (i.e., by acting as a 
reuptake inhibitor).9-11 These findings suggested that structural features of cathinone-like 
compounds have an integral effect on transporter action. The exact mechanism of action of 
synthetic cathinones at a molecular level was not exactly understood.  
 
Since then the last few years have seen the increasing presence, reports, and misuse of at 
least a few hundred newer analogs.12,13 Bath salts can today be referred to as one or a 
combination of synthetic cathinones.  
 
In the most recent report by the European Monitoring Centre for Drugs and Drug 
Addiction, synthetic cathinones were the largest group new psychoactive substances 
identified (i.e., 31 out of the 101 new drugs).14  
 
 3 
It is thus significant that the mechanisms of action of synthetic cathinones be investigated 
to not only delineate their actions but also provide information to help regulate such drugs 
and also provide predictions as to what the next generation of synthetic cathinones could 
be. 
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II. Background 
 
 
 
 
A.  Synthetic cathinones: A brief introduction 
“Synthetic cathinones” represent a novel class of abused drugs whose widespread abuse, 
especially in the last five years, globally, has called for immediate attention. Synthetic 
cathinones, though recognized only recently, are analogs of cathinone (1), a naturally 
occurring stimulant in the khat plant that was identified in the early 19th century.15,16 
Cathinone (1) is not an entirely new entity; in fact, it is the β-keto analog of amphetamine 
(AMPH; 2). Both cathinone (1) and AMPH (2) are also referred to as phenylalkylamines 
(PAAs).  
                                                     
Over the last five years a plethora of synthetic cathinones have steadily made their way 
into the illicit drug market making them one of the major classes of abused drugs, and 
these are now collectively termed as ‘new psychoactive substances (NPSs)’ by the United 
Nations and account for the second highest percentage (25%) of NPSs reported between 
CH3
O
NH2
Cathinone (1)   AMPH (2)
CH3
NH2
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2008-2013.12,17 Their prevalent use, ease of synthesis, availability of synthetic precursors, 
and abuse has caused the scheduling of various synthetic cathinones over the years by the 
Drug Enforcement Agency (DEA).18-21 Synthetic cathinones constitute a broad class of 
agents, though structurally similar to each other and several other related drugs of abuse in 
the PAA family, requires them to be studied individually for their mechanisms of actions at 
monoamine transporters, and for their pharmacological effects.22  
 
B. Phenylalkylamine drugs of abuse 
Abused PAAs can be subdivided into two broad groups: structurally and 
pharmacologically.23,24 Structurally, the two groups are the phenylethylamines (PEAs) and 
the phenylisopropylamines (PIAs) (Figure 1), where X can be any substituent, and NR1R2 
can be a primary, secondary or a tertiary amine.23 Pharmacologically, from a drug abuse 
perspective, they can be classified mainly as central stimulants or hallucinogens depending 
upon their stimulus generalization to the stimulant AMPH (2) or the hallucinogen DOM 
(1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane) (3).24 The present study deals with 
central stimulants only and examples of these will be discussed.                                                   
                                            
Figure 1. General structural features of phenylalkylamines23 
N
X
R1 R2
Phenylethylamines
(PEAs)
CH3
N
X
R1 R2
Phenylisopropylamines
(PIAs)
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1. Cathinone 
a. Origin 
(-)Cathinone (S(-)1) is a naturally occurring stimulant found in the fresh leaves of the 
shrub Catha edulis. This shrub is also called khat (qat, k’at, miraa, tschat, kat, cat, ghat, 
Arabian tea, Somali tea and Abyssinian tea), and belongs to the Celastraceae family, 
which is a dicotyledonous evergreen shrub.25,26 Forskal, a Swedish botanist, was the first to 
scientifically describe khat in Flora-Aegyptiaco-Arabia; however the first mention of khat 
was as early as the 13th century in the Ethiopian king Amda Seyon’s chronicle (as reported 
by Alles et al.).25 Legend has it that a Yemeni herder first ingested khat leaves after he 
observed the effects of the leaves on his goat.26 
 
The khat plant is cultivated mainly in Yemen, South Africa, Uganda, Tanzania, Rwanda, 
Zimbabwe, and certain reports also suggest Turkistan and Afghanistan (as reviewed by Al-
Hebshi and Skaug).26 Khat is a high-income yielding crop that grows on moist hillsides at 
altitudes of 1670-2590 meters with no specific conditions of soil and climate, and can 
survive for about 100 years. The shrub is ready for harvesting 3-5 years from planting; 
before selling them in the market, their shoots at the tip are cut during dawn and then the 
leaves are wrapped in banana leaves in order to preserve their freshness and are transported 
DOM (3)
CH3
NH2
CH3
OCH3
H3CO
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to the market where they are sold by early afternoon (as reviewed by Al-Hebshi and 
Skaug26 and Kalix and Braenden16).  
 
Chewing of khat leaves has been considered a social and cultural tradition especially in the 
Arabian peninsula; however, they are also consumed by the working class, (i.e.; farmers, 
students, and laborers), to help increase their physical and mental alertness. Khat is also 
consumed in other parts of the world but more so for its recreational purposes with alcohol 
and other drugs (as reviewed by Al-Hebshi and Skaug26 and Kalix and Braenden16).  
 
The khat chewing sessions, especially for men in Yemen, are called majlis al-qat where an 
estimated 100-200 g of the leaves are consumed.27 In these sessions, a group of men gather 
in a warm comfortable room in the afternoon and begin to chew on the khat leaves one at a 
time; the young and fresh leaves are preferred for their greater effect.27 Women, too, enjoy 
these khat sessions that are called tafruta but these are limited only to older and married 
women and the consumption of khat is much less compared to that used by the men.27  
 
The khat chewing experience is described as a rather interesting one, mixed with various 
pleasant and unpleasant experiences. Some of the desirable effects are experienced within 
the first 2 hours of the session and can be described as those filled with increased 
confidence, alertness, ability to express ones views, and animated discussions; this stage is 
referred to as kayf.27 Some chewers also experience a state of detachment and are lost in 
their thoughts; this stage is called as sulimania.27 Towards the end of the session some 
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people experience either an increase in stamina or sometimes even depression, paranoia 
and nervousness.27  
 
b. The active constituents of khat 
The first attempt to identify the active constituents of khat was in 1887 by two scientists, 
Flückeriger and Gerock, who were able to identify a basic alkaloid of unknown structure 
which they called katin, and they were also able to confirm the absence of caffeine in the 
leaves.28 Four years later, in 1891, Mosso also identified a basic constituent which he 
named celastrine; he found that it exerted sympathomimetic-like effects in frogs (e.g. 
dilation of pupils) (as reported by Alles et al.).25 In 1901 Beiter identified a basic fraction 
that he was able to crystallize;29 but it wasn’t until 1930 when Wolfes purified and 
identified this basic fraction found by Flückeriger, Gerock, Mosso and Beiter.30 This basic 
fraction was characterized and found to be (+)norpseudoephedrine and was called cathine 
(4).31 It is important to note here that these early studies were performed on dried khat 
leaves due to lack of efficient transportation and the state-of-the-art separation techniques 
available at that time.31  
 
However, the belief that cathine (4) was, indeed, the main active constituent of khat was 
challenged by several scientists such as Brücke, who explained that the potency of cathine 
HO CH3
Cathine (4)
NH2
 9 
(4) as a stimulant was too low to account for the effects of khat leaves.32 However years 
later the work by Hoffman et al. in 195533 and Alles et al. in 196125 also supported cathine 
(4) as the active constituent of khat.  
 
 As indicated by Kalix,15 international attention was received on the problems associated 
with khat and organizations such as the League of Nations on the Traffic of Dangerous 
Drugs highlighted reports which suggested the khat plant needed further investigation.15 It 
was the UN Commission on Narcotics Drugs in 1971 that suggested reinvestigation of the 
active constituents of the khat plant for its active constituents, and biological effects.34 This 
led the United Nations Narcotics Laboratory to investigate the fresh khat leaves in its own 
laboratories in Geneva. They identified and characterized a new alkaloid from the fresh 
leaves as (-)-α-aminopropiophenone which they named (-)cathinone (S(-)1), the other 
enantiomer, (+)cathinone (R(+)1), was absent.4 Cathinone (1) is thus referred to as a 
phenylisopropanonamine. It was found that as the plant ages, or as the cut leaves wilt,  
(-)cathinone (S(-)1)  is rapidly converted into cathine (4) (about 80%) and to  
(-)norephedrine (20%), and the amount of (-)cathinone (S(-)1) was found to be more than 
two-thirds of the total phenylalkylamine content and it is for this reason that the fresh 
leaves are sold based on their cathinone content.15,16 
 
                                                
 
 
 10 
c. Pharmacological properties of the khat alkaloids 
Due to the close structural resemblance of cathinone (1) to AMPH (2), differing only in a 
β-keto group (Figure 2); it was thought that cathinone (1) might have AMPH-like 
sympathomimetic and stimulant effects.  
                                                          
Figure 2. Structural comparison of the optical isomers of cathinone (1) with those of 
AMPH (2). 
 
i. Peripheral effects 
Many studies were aimed at identifying the peripheral effects of cathinone (1) and only a 
few are summarized below (Table 1). In conclusion, from these studies, it was reported 
that (-)cathinone (S(-)1)  has peripheral effects similar to those of (+)AMPH (S(+)2)  (as 
reviewed by Kalix 1984 and 1985).15,16  
 
 
 
 
 
 
CH3
O
NH2
S(-)1
CH3
O
NH2
R(+)1
CH3
NH2
S(+)2
CH3
NH2
R(-)2
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Table 1.  Peripheral effects of khat consumption by humans and animals: A 
comparison.15,16  
 
 
Effects of khat chewing in humans 
 
Effects of cathinone in animals 
Hyperthermia Hyperthermia (rabbits) 
 
Arrhythmia Positive inotropic and chronotropic effects 
(guinea pig atrium) 
 
Mydriasis Mydriasis (Monkeys) 
 
Increased blood pressure Increase in blood pressure 
(anaesthetized rat and cat) 
 
 
ii. Behavioral effects 
a. Stimulant effects 
 Yanagita35 conducted early investigations on the central stimulant effects of cathinone (1) 
in rats for their locomotor activity. It was found that (+)AMPH (S(+)2) and cathinone (1) 
were equipotent in their locomotor effects.35 Since (-)cathinone (S(-)1) was the naturally 
occurring constituent of khat, its stimulant effects were of interest to be evaluated. Knoll36 
evaluated (-)cathinone (S(-)1) and found it be as potent as AMPH (2) in stimulating 
locomotor activity in mice.36 In a study by Glennon and Showalter,37 it was found that  
(-)cathinone (S(-)1) was twice as potent as cathinone (1), slightly more potent than its (+) 
enantiomer (this was also found by Rosecrans et al.),38 and was ≈7-fold less potent 
compared to (+)AMPH (S(+)2) at stimulating locomotor activity in mice.37 A study by 
Valterio and Kalix,39 also demonstrated that (-)cathinone (S(-)1) was less potent than 
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(+)AMPH (S(+)2) by ≈4-fold and showed an inverted bell-shaped dose-response curve 
that is characteristic of stimulants.  
 
To investigate if (-)cathinone (S(-)1) activates postsynaptic DA receptors during locomotor 
activity, mice were  pre-treated with DA antagonists such as haloperidol, spiroperidol, and 
pimozide in concentrations found to antagonize DA; locomotor activity due to (-)cathinone 
(S(-)1)  was blocked.39 Reserpinization only marginally affected (-)cathinone (S(-)1) and its 
hypermotility was inhibited by mazindol and nomifensine.   
 
These studies indicated that (-)cathinone (S(-)1) has comparable effects to (+)AMPH 
(S(+)2) in locomotor activity tests and also resulted in the activation of postsynaptic DA 
receptors.39   
 
Cathine (4), the other constituent of khat, was found to be a locomotor stimulant but was 
10 times less potent than (+)AMPH (S(+)2).40 While evaluating the pharmacological 
effects of each of the enantiomers of cathinone (1) in a locomotor activity test, both 
enantiomers showed a characteristic bell-shaped curve but (-)cathinone (S(-)1) was twice 
as potent as its opposite enantiomer and, in a time-course of locomotor activity study, both 
had the same onset time of action, and their peak effect was reached in the same time; 
however, the effect of (+)cathinone (R(+)1) decayed more rapidly.41 
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b. Drug discrimination 
In drug discrimination studies in rats trained to discriminate racemic cathinone from 
vehicle, cathinone (1) was found to be equipotent to (+)AMPH (S(+)2) and also had 
parallel dose-response curves to (+)AMPH (S(+)2) which suggested a common mechanism 
of action and/or common site of action between the two drugs.42 Another drug 
discrimination study by Glennon et al.,43 found that (-)cathinone (S(-)1) was 3-fold more 
potent than its enantiomer, and 7-fold more potent than cathine (4) in rats trained to 
discriminate cathinone (1) from saline. The effects of cathinone (1) also generalized to 
other simulants such as methamphetamine (METH, 5),44 cocaine,45 and methylphenidate 
(6) but failed to generalize to non-stimulant drugs such as fenfluramine (7), haloperidol, 
and chlordiazepoxide.46   
                                                 
 
Also, cathinone (1) and its enantiomers were found not to have DOM-like hallucinogenic 
effects in a drug discrimination study where animals were trained to discriminate DOM (3) 
from vehicle indicating that cathinone (1) is not a PAA hallucinogen.47 
 
 METH (5)
CH3
HN
CH3
Methylphenidate (6)
H3CO
O HN
Fenfluramine  (7)
CH3HN
CF3
CH3
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In a conditioned place preference assay, rats trained to discriminate (-)cathinone (S(-)1)  
spent more time in a non-preferred environment ((-)cathinone associated environment) and 
this effect was decreased with a dopamine antagonist CGS 10746B.48 
 
c. Stereotypy 
Another behavioral effect common to khat alkaloids and AMPH (2) was stereotyped 
behavior at high doses.37,49 Stereotyped AMPH-like behavior of head movements was 
observed with cathinone (1) and cathine (4) in rats and these effects were more pronounced 
with cathinone (1) as compared to cathine or (+)AMPH (S(+)2). When comparing 
cathinone (1), (+)AMPH (S(+)2) and cathine (4) effects to apomorphine, less 
verticalization was seen.  These stereotyped behaviors could be reduced either by DA 
antagonists such as haloperidol or by the catecholamine synthesis blocker α-
methylparatyrosine.50 Apomorphine acts postsynaptically on DA receptors and these 
studies indicated that cathinone (1) exerted its effects presynaptically similar to (+)AMPH 
(S(+)2).50 This finding was supported by Zelger and Carlini,51 where cathinone (1) 
produced AMPH-like ipsilateral movements whereas apomorphine produced contralateral 
rotation in rats with unilateral lesions of the substania nigra.  
 
d. Anorectic effects 
Knoll et al.,36 first observed the anorectic effects of (-)cathinone (S(-)1) upon 
intraventricular injection and these effects were more potent than AMPH (2). Later studies 
found that, when rats were given i.p. injections of cathinone (1)  and cathine (4), a decrease 
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in body weight was observed but that cathine (4) was less potent than cathinone (1), which 
was less potent compared to AMPH (2).52 However, tolerance to cathinone (1) developed 
rapidly within a week and the anorectic effects were lost after about 4 weeks of continuous 
drug administration, and tolerance to AMPH (2) developed within two weeks but the 
anorectic effects existed even after 7 weeks of continuous drug administration, also cross 
tolerance developed for both the drugs.52 Foltin and Schuster,53 also observed anorectic 
effects when they studied the effects of (+)AMPH (S(+)2) and cathinone (1)  when rats 
were given sweetened milk. Cross tolerance and tolerance effects were also observed in 
this study which caused a shift in the dose response curve to the right by about 8- to 12-
fold for cathinone (1) and a smaller shift by about 2-fold for (+)AMPH (S(+)2).  
 
e. Conditioned taste aversion 
Cathinone (1), similar to other psychostimulant drugs, was found to induce conditioned 
taste aversion in rats that were given sweetened milk,54 and it was also found to be less 
aversive than (+)AMPH (S(+)2) by 17-fold in a conditioned taste aversion test in rats; this 
implied that cathinone (1) might be a more preferred drug of abuse.55 
 
f. Effects on primates 
In order to study drug dependence behavior, monkeys were trained to lever-press for 
cocaine injections. When cocaine was replaced by (-)cathinone (S(-)1), it was found to be a 
more potent reinforcer and the  rate of lever-pressing was increased and was higher than 
that for (+)AMPH (S(+)2).56 In a drug-drug choice procedure between cocaine and 
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cathinone (1) where monkeys were trained to lever-press for the choice of drug, cathinone 
(1) was found to be as reinforcing as cocaine.57 Yanagita,58 evaluated (-)cathinone (S(-)1) 
in a continuous self-administration assay as well as a progressive-ratio self-injection test. 
In the self-administration test monkeys showed cocaine-like behavior, where the monkeys 
exhibited a pattern of self-administration followed by exhaustion and stopping the self-
administration and then resumed a phase of self-administration. During this cycle, the 
monkeys showed anorexia, restlessness, tremors and mydriasis. In the progressive-ratio 
self-injection test, the number of blank injections the monkey is wiling to take to receive 
the drug provides the maximal ratios of their effects, (-)cathinone S(-)1 had lower  ratios 
compared to cocaine for each dose tested.58   
 
g. Early structure-activity relationship (SAR) studies in vivo  
 Several cathinone analogs were studied in various behavioral assays. In a locomotor 
stimulation study in mice; cathinone analogs (Table 2), including 2-methoxy (8), 4-
methoxy (9), 2,4-dimethoxy (10), and 4-fluoro cathinone (11) did not produce locomotor 
stimulation whereas α-desmethylcathinone (12) reduced locomotor activity.37  
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Table 2. Substituted cathinones examined in early SAR studies.37,43,59 
                                                                
Compound number R1 R2 R3 
8 OCH3 H CH3 
9 H OCH3 CH3 
10 OCH3 OCH3 CH3 
11 H F CH3 
12 H H H 
13 H Cl CH3 
14 H OH CH3 
15 CH2 H CH2 
 
In a discriminative stimulus study of cathinone (1) and some of its structural analogs in rats 
trained to discriminate cathinone (1) from saline, it was found that cathinone-like activity 
was lost for the structural analogs of cathinone (1) with substitution in the 4-position (see  
Table 2) with chloro (13), hydroxyl (14) and methoxy (9) groups at doses comparable to 
the training dose of cathinone (1).43 Another structure-activity study compared (-)cathinone 
(S(-)1), (+)AMPH (S(+)2) and four cathinone analogs: (α-desmethylcathinone (12), 2-
amino-1-tetralone (15), β-aminopropiophenone (16), and N,N-
R3
O
NH2
R1
R2
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dimethylaminopropiophenone (17). In the drug discrimination study rats were trained to 
discriminate (+)AMPH (S(+)2) from saline; (-)cathinone (S(-)1) was the only agent that 
produced AMPH-like effects; and, the former was antagonized by haloperidol.59 
 
iii. Cellular effects 
a. Dopaminergic effects 
Since (-)cathinone (S(-)1) was found to produce similar behavioral and peripheral effects 
as AMPH (2), it was of interest to understand if it exerted its effect presynaptically through 
release of catecholamines similar to AMPH (2), or if it acted by blocking the uptake of DA 
into presynaptic neurons similar to cocaine.   
 
In experiments to measure the efflux of radioactivity in rat striatial slices labeled with 
[3H]DA, (-)cathinone (S(-)1) caused a reversible and  a dose-dependent efflux of  [3H]DA 
and also in preparations pretreated with (+)AMPH (S(+)2), (-)cathinone (S(-)1) was found 
to be half as potent compared to (+)AMPH (S(+)2) in retaining radioactivity.60 The effects 
of (-)cathinone (S(-)1) were reversibly blocked by cocaine similar to (+)AMPH (S(+)2). 
Thus (-)cathinone (S(-)1) was found to act by a mechanism similar to (+)AMPH (S(+)2) at 
dopaminergic synapses.60  
 
O N
R
R1
16: R=R1= H 
17: R=R1= CH3
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b. Adrenergic effects 
 Since a number of sympathomimetic cardiovascular effects were observed due to khat 
consumption, the effect of (-)cathinone (S(-)1) at norepinephrine (NE) storage sites was 
important to investigate. In experiments where rat atrium was prelabelled with [3H]NE a 
rapid increase in efflux was observed and also it was found to be half as potent as 
(+)AMPH (S(+)2).  The potency of  (-)cathinone (S(-)1) was found to be one order of 
magnitude higher than that of (+)AMPH (S(+)2) to release DA from the central nervous 
system (CNS) storage sites. Pharmacological properties similar to (+)AMPH (S(+)2) were 
observed upon reserpinization, where the first dose of (-)cathinone (S(-)1) caused a greater 
efflux than the untreated tissue; however, rapid development of tachyphylaxis was also 
observed.61 Pretreatment with cocaine and desipramine blocked the release of NE, and for 
cocaine it was shown that its efflux inhibition property was not related to its local 
anesthetic properties.61 Thus, it was concluded that the peripheral side effects of khat 
consumption are due to the release of NE from peripheral storage sites.61  
 
c. Serotonergic effects 
AMPH (2) has been shown to release serotonin (5-HT) in a dose-dependent manner in rat 
corpus striatial tissue.62  In the case of the serotonergic system it was found that the affinity 
of (-)cathinone (S(-)1) was four times greater than (+)AMPH (S(+)2) for 5-HT receptors in 
the rat fundus; thus, it was important to understand if cathinone (1) exerts AMPH-like 
effects at the serotoninergic system.63 In rat striatial slices pretreated with [3H]5-HT, (-
)cathinone (S(-)1) was one-third as potent as (+)AMPH (S(+)2) in releasing 5-HT. 
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Therefore the release profile of (-)cathinone (S(-)1) is the same as that for (+)AMPH 
(S(+)2)  (i.e,. NE > DA > 5-HT).64 
 
When comparing the effects of (-)cathinone (S(-)1) and cathine (4), (-)cathinone (S(-)1) 
was 8 times more potent than cathine (4) in releasing DA from rat nucleus accumbens 
tissue, however both were equipotent in releasing epinephrine from rat atrial tissue.65 Thus, 
these results suggested that (-)cathinone (S(-)1), due to its higher lipophilicity, penetrates 
the blood-brain barrier better and hence has a more CNS stimulant-type effect. Therefore, 
khat leaves that are fresh and have an increased (-)cathinone (S(-)1) content are preferred, 
however both (-)cathinone (S(-)1) and cathine (4) have similar extent of peripheral 
effects.65 While evaluating the pharmacological effects of each of the enantiomers of 
cathinone (1) for their peripheral effects in guinea pigs, no difference was observed in their 
potencies.41 
 
d. Early SAR studies in vitro 
A structure-activity study compared (-)cathinone (S(-)1), (+)AMPH (S(+)2) and four 
cathinone analogs (α-desmethylcathinone (12), 2-amino-1-tetralone (15), β-
aminopropiophenone (16), and N,N-dimethylpropiophenone (17)) (Table 2) for their in 
vitro effects to release [3H]DA from rat caudate nucleus. In the in vitro release assay 
 (-)cathinone (S(-)1) was found to be the most potent compared to its analogs except for 
N,N-dimethylpropiophenone (17) which had an effect of similar magnitude.59 
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2. Amphetamine  
a. Background 
Cathinone (1) and its analogs are structural relatives of AMPH (2). Hence, a brief review 
of the pharmacology and SAR of AMPH (2) is provided here for comparative purposes. 
AMPH (2) is a phenylalkylamine. It belongs to the group of PIAs,23 it was initially referred 
to by its chemical name alpha-methylphenylethylamine but was given the name 
amphetamine by the Council on Pharmacy and Chemistry of the American Medical 
Association when they wanted to include this compound as a part of New and Nonofficial 
Remedies.66 AMPH (2) was first synthesized as early as 1887 by the chemist Edeleano and 
he documented the volatile amine as a phenylpropylamine. In 1910 Henry and Dale 
studied AMPH (2) amongst other aliphatic and aromatic amines for their sympathomimetic 
effects on decerebrate cats, but it was Alles in 1927 who synthesized racemic AMPH (2) as 
its sulphate salt while he was working towards identifying synthetic substitutes for 
ephedrine (18), and reported on its sympathomimetic effects.67  
 
His work was patented in 1932 around the same time that the Nabenhauer from Smith, 
Kline and French recommended the use of AMPH (2) as a volatile base for an inhalant to 
relieve nasal decongestion.67 Alles partnered with Smith, Kline and French and the 
racemate of AMPH (2) as its sulphate salt was introduced as the Benzedrine Inhaler in 
 Ephedrine (18)
CH3HN
CH3
HO
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1935.67 Some of the earlier uses of benzedrine was for narcolepsy, epilepsy, post-
encephalic Parkinsonism, fatigue and depression.66 Bradley in 1937 studied 30 children 
who had severe behavioral problems (referred to as ADHD today), and observed some 
positive improvements in their school performance, emotional and psychological changes. 
This study formed the basis of using AMPH (2) for the treatment of ADHD.68 
 
Two years later Smith, Kline, and French synthesized both the isomers of AMPH (2) and 
marketed the (+)AMPH (S(+)2) as dexedrine.67,68 Around 72 million tablets of benzedrine 
were also supplied under the name “Energy tablets” to the British and U.S armed forces to 
help troops prevent fatigue and promote alertness and stimulate energy during World War 
II.66 Due to its central stimulant properties it became a popular drug of abuse and was 
referred to as “Bennies” around the 1940s and 1950s. Drug abusers would crack the 
inhalant open and either swallow or have with coffee or alcohol the strip soaked with 
AMPH (2).69 Doctors were then vigilant about prescribing AMPH (2) and the Food and 
Drug Administration (FDA) controlled its use initially by making it a prescription drug.69  
 
METH (5) is the N-monomethyl analog of AMPH (2), and the Japanese scientist 
Nagayoshi first synthesized it from ephedrine (18) in 1893 a few years after the discovery 
of AMPH (2); in 1919 Ogata also synthesized METH (5) from ephedrine (18) by using red 
phosphorus and iodine.70  
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Today it is popularly known by several names such as; meth, crystal meth, speed, ice, jib, 
crank (as reviewed by Paneka et al.).70 In the most recent 2014 UNODC report the number 
of clandestine laboratories synthesizing AMPH-type stimulants has increased from 12,571 
to 14,322 from 2011 to 2012 and 96% of these laboratories are producing METH (5), and 
the amount of METH (5) seized has increased four-fold from 24 tons in 2008 to 114 tons 
in 2012.71  
 
AMPH (2) and METH (5) are both U.S. Schedule II drugs.72 Today the main uses of 
AMPH (2) clinically are to treat attention deficit/hyperactivity disorder (ADHD) and 
narcolepsy,68 and METH (5) can also be used as a second-line treatment for the same.73 
 
b. Mode of action 
The primary mode of action for AMPH (2) and METH (5) is by producing a release of 
DA, 5-HT and NE from their corresponding presynaptic transporters, another suggested 
mechanism is via the vesicular monoamine transporter 2 (VMAT2) and, additionally, 
inhibition of monoamine oxidase (MAO) (as reviewed by Seiden et al. and Paneka et 
al.).70,74 A more detailed description of its actions will be discussed under the topic of 
monoamine transporters. 
 
c. Behavioral effects 
AMPH (2) is a sympathomimetic agent and has effects similar to epinephrine and 
norepinephrine during ‘fight or flight’. Some of the effects are central stimulation, 
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euphoria, increased heart rate and blood pressure, decreased appetite, dilated pupils, 
hallucinations, and increased alertness.74,75 AMPH (2) has been extensively studied in in 
vivo assays such as self-administration by laboratory animals, and drugs such as cocaine 
can substitute for AMPH (2) in drug discrimination studies. It also has anorectic effects 
and has been shown to decrease activity in hyperactive rat models (this effect parallels 
patients with ADHD).74 Chronic AMPH (2) administration leads to stereotypy and these 
animal models have been used to study schizophrenia (as reviewed by Seiden et al.).74 
METH (5) also produces similar effects (as reviewed by Paneka et al.).70 
 
d. General structure activity relationship studies 
The effects of PAAs can be grouped broadly into two categories; stimulants and 
hallucinogens.76 The SAR of AMPH (2) contributing only to its stimulant character will be 
discussed in detail.  
                                                       
Figure 3. SAR of AMPH (2) as central stimulants.76 
 
A- Terminal amine 
Changing the nature of the terminal amine from primary, to secondary and tertiary 
decreases activity. The exception to this is METH (5), which is the N-methyl analog of 
CH3
NH2
A
CD
B
E
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AMPH (2) and is about two to three times more potent than AMPH. The N-ethyl (19) and 
N-n-propyl (20) derivatives are half as potent and the N,N-dimethyl (21) compound was 
five-fold less potent compared to AMPH. The N-ethyl (19) and N-hydroxy (22) derivatives 
substituted for S(+)AMPH in S(+)AMPH-trained rats in drug discriminations studies.77 
            
          
 
 
 
B- Chiral center 
Both the enantiomers have been previously investigated and (+)AMPH (S(+)2) has been 
found to be several-fold more potent than (-)AMPH (R(-)2) as a central stimulant, but both 
enantiomers are equipotent peripherally.76  
 
C- Side chain 
The α-desmethyl analog, PEA (23) lacks central effects because it is rapidly metabolized 
by MAO. Further increase in chain length from methyl results in loss in potency. (+)-α-
Ethylamphetamine (S(+)24) did not substitute for (+)AMPH (S(+)2)  in rats trained to 
N
CH3
R1R2
19: R1 = H, R2 = CH2CH3
20: R1 = H, R2 = CH2CH2CH3
21: R1 = R2 = CH3
22: R1 = H, R2 = OH
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discriminate saline from (+)AMPH (S(+)2). Another analog, α-ethyl-N-
methylamphetamine (25) substituted for (+)AMPH (S(+)2) but was ten-fold less potent.77 
        
Conformationally constrained analogs: When the side chain of AMPH (2) was constrained 
into 2-aminoindane (26), 2-aminotetralin (27), 6-amino- and 7-amino-6,7,8,9-tetrahydro-
5H-benzocycloheptane (28 and 29, respectively), only 2-aminotetralin (27) was active and 
was half as potent as AMPH (2).The seven carbon ring compounds did not substitute for 
(+)AMPH (S(+)2), indicating that  2-aminotetralin (27) might be the most optimum 
conformation to produce AMPH-like stimulant effects for the constrained analogs.78  
 
D- β-Position 
Hydroxylation at this position results in ephedrine (18) and norephedrine (30) but both 
have reduced central stimulant character compared to AMPH (2).76  
The presence of a β-keto group leads to cathinone (1), a central stimulant that retains 
activity and potency. Another compound with a benzylic keto group is diethylpropion (31) 
that has anorectic properties. 
 
A related group of compounds that retains central stimulation properties has a benzylic 
oxygen atom that forms an ether and these are, for example, the anorectics phenmetrazine 
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(32), aminorex (33) and pemoline (34) (the later has been used for the treatment of 
ADHD).76  
                             
 
E- Aromatic substituents 
In general an unsubstituted ring is preferred for activity. The 4-hydroxy AMPH (35) lacks 
central stimulant character and this could be due to its low lipophilic character that 
prevents its passage through the blood brain barrier. The 4-methoxy analog (PMA) (36) 
was a weak central stimulant and is a 5-HT releasing agent.76 It was a popular drug of 
abuse called ”death” around the 1970s and its use was controlled under the U.S. Controlled 
Substances Act in 1973 (Schedule I).79 AMPH analogs with methyl substitution 
(tolyaminopropanes; TAPs) at the para (pTAP) (37) or meta (mTAP) (38) position failed to 
produce a full AMPH-like effects, and only the ortho (oTAP) (39) produced AMPH-like 
effects but was ten-fold less potent compared to (+)AMPH (S(+)2) in drug discrimination 
studies.80 All three analogs have weak central stimulation character.80 Fenfluramine (6), a 
drug marketed initially as an appetite suppressant, and p–chloroAMPH (PCA) (40) are a 
few examples of AMPH-related phenylalkylamines that act via release of neuronal 5-
HT.76,77  
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When the aromatic ring is substituted with larger groups, for example the two naphthyl 
analogs of racemic AMPH (2) formed by the fusion of the b-face (41) and the c-face (42), 
central stimulant action was lost, implying that the larger hydrophobic groups at these 
positions was not tolerated.78 The 3,4-methylenedioxy analogs of AMPH (2) and METH 
(5), MDA (43) and MDMA (44), respectively, were also found to retain central stimulant 
character and have been extensively studied.77 Their pharmacology and SAR and will be 
discussed in greater detail later. Multiple substitutions on the phenyl ring, for example, 
DOM-like compounds, result in a transition from a stimulant to a hallucinogen.76,77 A 
summary of the structural requirements for AMPH-like stimulant actions or hallucinogenic 
DOM-like effects is shown in Table 3.  
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Table 3. SAR for AMPH-like stimulant actions and DOM-like hallucinogenic effects of 
PAAs (adapted from Foye’s Principles of Medicinal Chemistry).76 
 
Position Amphetamine-like action DOM-like action 
A: Terminal amine N-Methyl > NH2 > NHR > NR2 NH2 > NHR> NR2 
 
 
B: Chiral center S(+) > (±) > R(-) R(-) >  (±) > S(+) 
 
 
C: α-Methyl group Increasing the chain length 
decreases potency 
Replacement by H decreases 
potency 
Increasing chain length 
decreases potency 
Replacement by H 
decreases potency 
D: β-Position β-OH: reduces potency 
β =O: retains activity and potency 
 
 
β-OH: not well 
investigated 
β =O: not well investigate 
E. Aromatic 
substitution  
Unsubstituted aromatic ring 
preferred 
2,5-Dimethyl-substitution 
is optimal 
4-Substitution further 
modulates potency 
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3. N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) 
a. Background 
MDMA (44) is a PAA popularly known as Adam, Molly, Ecstasy, and XTC.81,82 It’s 
pharmacological property as an empathogen separates it from DOM-like hallucinogens and 
AMPH-like stimulants.83 As reported by Benzehofer and Passie,84 Koellisch from Merck 
first synthesized MDMA (44) in 1912 and his work was patented in 1916. Between this 
time and the late 1950s Merck conducted some toxicology and pre-clinical studies and in 
1960 two Polish scientists reported on the synthesis of MDMA (44) as an intermediate in 
their synthesis.84 It was Shulgin who resynthesized MDMA (44) in the 1970s and self-
administered the agent (80-120 mg) and reported on its effects: 
“All the next day I felt like 'a citizen of the universe' rather than a citizen of the planet, 
completely disconnecting time and flowing easily from one activity to the next.” 85 
“Everyone must get to experience a profound state like this. I feel totally peaceful. I have 
lived all my life to get here, and I feel I have come home. I am complete.”85 
He shared the effects of this drug with his friend, the psychotherapist Leo Zeff.86 MDMA 
(44) helped patients in psychotherapy to deal with emotional issues by feeling a state of 
openness, by increasing the ability to reach within and introspect, hence improving 
communication.87 In 1980s, due to its empathogenic effects, it became a popular “club 
drug” and was increasingly abused at “raves” in Europe and the United States.86  Its 
popularity spread through word of mouth and also through stories published in the media. 
The drug was also extremely popular amongst undergraduate students in the United 
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States.87 Its use was restricted in 1985 when it was emergency scheduled in May 1985 and 
was given Schedule I status.87 
 
b. Mode of action 
MDMA (44) exerts its empathogenic effects primarily as a releasing agent at the serotonin 
transporter (SERT) but also at DAT and the norepinephrine transporter (NET). A detailed 
description of its mechanism of action will be discussed later under the monoamine 
transporters section.88,89 
 
c. Behavioral studies 
MDMA (44) is self-administered both by monkeys and baboons.90,91 It also disrupts 
complex operant behavior in monkeys,92 and also decreases operant responding in mice.93 
MDMA (44) produced a lowering of dose-related reward threshold in intracranial self 
stimulation studies (ICSS),94 a loss of grooming and social interactions in primates,95 and 
rotational activity in rats.96 It was also shown to produce antinociceptive,97 and motor 
stimulation effects.98  
 
d. Structure activity relationship studies (discussed from two book chapters: Nichols 
and Oberlender, 99  and Nichols, 77 unless referenced) 
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Figure 4. SAR of MDMA (44) as an empathogen.99 
 
A. N substitution 
The N-desmethyl analog of MDMA, methylenedioxyamphetamine (MDA, 43) retains 
certain pharmacological properties of MDMA (44). It is known as the “love drug” and has 
a very interesting pharmacological profile. Its (+) enantiomer possesses an AMPH-like 
stimulant profile due to its releasing effects on 5-HT and other catecholamines and the (-) 
enantiomer exhibits a DOM-like hallucinogenic effect due to its interaction with 5-HT2 
receptors.100,101 In comparison with MDMA (44), MDA produces some hallucinogenic 
effects. The N-ethyl MDA analog 45 also retains MDMA-like effects in drug 
discrimination studies.  The N-OH MDA analog 46 could be a prodrug of MDA (43) and 
this compound did not substitute for DOM or (+)AMPH (S(+)2) in drug discrimination 
studies.102 The N,N-dialkyl MDA analog 47 was inactive in vivo and Shulgin reported 
that it lacked effects in humans.85 
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B. Chiral center 
An interesting difference to highlight between MDMA (44) and hallucinogenic 
phenylalkylamines is their difference in stereoselectivity. For hallucinogens the R 
enantiomer is the more potent isomer (i.e., eutomer) in animals and humans.99 However in 
the case of MDMA (44) the S isomer is found to be a more potent releaser of DA, 5-HT 
and NE,88 and also in in vivo tests assessing different kinds of motor activities.98 Only 
(+)MDMA (S(+)44) and (+)MDA (S(+)43) but not their corresponding enantiomers, 
substituted for (+)AMPH (S(+)2); hence the AMPH-like effect of these enantiomers are 
stereospecific.101,103   
C. Side-chain modifications 
Extension of the α-methyl group of MDMA (44) to α-ethyl (48) leads to a compound that 
retains a pharmacological profile similar to MDMA (44) in studies in man and drug 
discrimination studies in rats. The analog, however, is less effective in the release and/or 
reuptake of DA compared to MDMA (44), and AMPH (2) does not substitute for it in 
drug discrimination studies.  
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D- Aromatic ring  
Substitution on the 1,3-dioxole ring: Subsequent addition of methyl groups to the ring to 
give 49 and 50 resulted in compounds which were less potent than MDA (43) in drug 
discrimination studies in rats trained to discriminate MDMA (44) from saline. In in vitro 
release assays for DA and 5-HT both analogs were comparatively less potent than MDA 
(43). The ring-expanded analog ethylenedioxymethamphetamine (EDMA, 51) was 
reported by Shulgin to be inactive at a dose twice that of the active dose for MDA (43).85  
 
Subsequent removal of the oxygen atoms divulged that the oxygen atoms were not 
important for reuptake activity of [3H]5-HT into rat whole brain synaptosomes and the 
resultant carbocyclic compounds retained activity (52, 53, 54, 55).77 
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Substitution on the aromatic ring: 3,4-methylenedioxy-5-methoxyamphetamine (56) was 
shown to have 5-HT reuptake properties.77 
 
4. Methyl 2-phenyl-2-piperidin-2-ylacetate (Methylphenidate)  
a. Background 
Methylphenidate (6) is another CNS stimulant belonging to the piperidine-substituted PAA 
class of compounds. Synthesized by Ciba-Geigy Pharmaceutical Company in 1944 for the 
treatment of narcolepsy, lethargy, and psychosis associated with depression amongst 
others.104 Today, its U.S. FDA-approved use is mainly for the treatment of ADHD, and the 
United Nations International Narcotic Control Board reports that the main consumer of 
methylphenidate (6) is the U.S., accounting for 69% of the global consumption.105 Due to 
its central stimulant effects it is also a drug of abuse but unlike drugs such as AMPH (2) 
and METH (5), there is no clandestine synthesis of methylphenidate (6). It is abused 
mainly through fake prescriptions or pharmacy thefts.105 According to the Drug Abuse 
Warning network in 2011 the nonmedical emergency visits due to methylphenidate (6) 
were 6395 and the National Forensic Laboratory Information System reported 2164 
methylphenidate (6) seizures in 2012. Its use in the U.S has been controlled under the 
Schedule II status.105 Methylphenidate (6) has four stereoisomers (Figure 5); of the four 
only the dl-threo enantiomers are employed as constituent Ritalin®. The dl-erythro isomers 
have been excluded due to their hypertensive side effects and improve the therapeutic 
index of pharmaceutical products containing methylphenidate (6).106 
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Figure 5. Diasteriomers of methylphenidate (6). 
  
b. Mode of action 
Methylphenidate (6) exerts its stimulant effects similar to cocaine, (i.e., it is a reuptake 
inhibitor) primarily at DAT but also exerts its actions at NET.107 Radiographic studies 
indicated that methylphenidate (6) and cocaine share the same binding site in the human 
striatum.108 
 
c. Pharmacological effects 
Methylphenidate (6) in addition to its central stimulating effects also increases alertness, 
heart rate, and body temperature.105 Its behavioral/abuse conferring effects have been 
evaluated in numerous rewarding, and discriminative stimulus assays in various animal 
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models such as rats, monkeys and dogs as well as in human subjects (reviewed in Kollins, 
et al.,109 Askenasy, et al.110 and Arnold.111). 
 
d. Structure-activity relationship studies on the diastereomers 
The dl-threo isomers ((d-(2R:2’R)-6) and (l-(2S:2’S)-6)) are the pair bestowing 
pharmacological central stimulating properties. Both the threo enantiomers were evaluated 
for their central and peripheral effects and the d-threo isomer (d-(2R:2’R)-6) was found to 
be the more potent isomer. In locomotor stimulation assays d-threo isomer ((d-(2R:2’R)-6) 
was more potent than dl ((d-(2R:2’R)-6) and (l-(2S:2’S)-6)) and l-threo isomer (l-
(2S:2’S)-6). The d-threo isomer (d-(2R:2’R)-6) was about ten-fold more potent than the l-
threo isomer (l-(2S:2’S)-6) in reuptake studies for [3H]DA and [3H]NE. Both the isomers 
were ten-fold more potent as uptake inhibitors at NET than at DAT. Neither of the isomers 
produced effects on release of [3H]DA and [3H]NE. Diastolic blood pressure in 
anesthetized rats was significantly potentiated only for the d-threo isomer.106 
 
C. Monoamine transporters   
Effective neurotransmitter-mediated communication is crucial for regulating both the 
central and peripheral nervous systems. Monoamines DA, 5-HT and NE play vital roles in 
the human body in for example, controlling mood, reward, motor function, appetite, sleep, 
motivation, arousal, and attention-stress responses.1,112  
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In 1961 Julius Axelrod introduced the concept of reuptake as a method of inactivating 
neurotransmitters when he explained how the sympathetic nervous system took up 
norepinephrine.1 At a molecular level, monoamine transporters are principally responsible 
for control of extracellular (synaptic) neurotransmitter concentration via reuptake of 
released monoamines into the presynaptic neuron and, hence, maintain homeostasis at the 
presynaptic neuron. DAT, SERT and NET regulate the synaptic levels of DA, 5-HT, and 
NE, respectively, and disruption in this normal physiological process can lead to some 
serious conditions, for example, ADHD, Parkinson’s disease, anxiety, schizophrenia, 
Tourette’s syndrome, and depression.112 Several synthetic compounds exert their action via 
monoamine transporters, for example, cocaine and AMPH (2) act primarily via DAT, 
MDMA (44) and fluoxetine act primarily via SERT, and nisoxetine and reboxetine act 
primarily via NET.1 Thus, understanding monoamine transporters is not only important as 
they serve as therapeutic targets, but are also targets for drugs of abuse.113 
Monoamine transporters specifically belong to the solute carrier 6 (SL6) family, they 
utilize Na+ as a driving force to transport substrates, and are also referred to as secondary 
active transporters. In addition to Na+, Cl- is also co transported; hence, they are also given 
the name Na+/Cl- neurotransmitter family and in the case of SERT, K+ ion is counter 
transported. Since they transport the substrate and Na+ in the same direction, they are 
synonymously referred to as neurotransmitter sodium symporters (NSSs).112 The 
stoichiometry of ions differs for each of the transporters:112 NET [Na+(1): Cl-(1)]   DAT 
[Na+(2): Cl-(1)]   SERT [Na+(1): Cl-(1): K+ (1)]. 
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1. Structure 
The crystal structures of the human DAT, NET and SERT remain to be elucidated. The 
human DAT, NET and SERT contain 620, 617 and 630 residues, respectively.112 However 
the crystal structures of the various conformations of the leucine transporter (LeuT) from 
Aquifex aeolicus and the recent crystal structures of DAT from Drosophila melanogaster 
(dDAT) have aided our understanding of the architecture, pharmacology, mechanism of 
action of NSSs, and in addition also have helped provide an insight for substrate, inhibitor 
and ion binding sites.114-118 The dDAT structure shares greater 50% sequence identity 
whereas LeuT has about 20% sequence identity with human NSSs. Conservation of TMs 
(transmembranes) within the monoamine transporters is higher than that of the N and C-
terminals.117  
 
Both dDAT and LeuT crystal structures displayed 12 TMs with intracellular C and N-
terminals. TMs 1-5 and 6-10 are related to each other by a pseudo axis.117,119 Some of the 
structural features discussed here will be those from dDAT as this structure is more 
comparable to its eukaryotic counterparts.  
 
The extracellular loop (EL) 2 has been predicted as a site for N-linked glycosylation and 
disulphide bonds for NSSs. The crystal structure revealed a disulphide bond between the 
two conserved cysteines. In addition, a cholesterol molecule is found wedged between 
TM5, TM7, and TM1a. The authors proposed that the cholesterol plays an important role 
in holding the transporter in an outward open conformation. The C-terminus sequence 
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conservation is relatively poor among the NSSs, in the dDAT structure a new and unique 
feature was observed in this region. There is C-terminal latch, which contains 2.5 turns 
(residues 586-595). Despite of the low homology at the C-terminus, Penmatsa et al.117 
identified this as a conserved feature in the NSSs. This small helix also interacts with 
TM1a via its interactions with the intracellular loop 1(IL1) and this could be very 
important for transporter activity since the C-terminus has been studied as a site for 
phosphorylation and trafficking.117 Recent crystal structures based on dDAT show a 
common binding site for substrates and inhibitors. This site is referred to as the primary 
binding site (S1).116-118 
  
2. Transport mechanisms 
Several models have been proposed for the transport mechanism of monoamine 
transporters. 
a. Alternate access model- This model was initially proposed by Jardetzky,120 and this 
model alternates between three states. First is the outward-facing conformation where the 
substrate-binding pocket is open towards the extracellular side only. Second is the 
occluded state where the transporter is closed from both the intra and extra cellular sides, 
and the third is the intracellular-facing conformation where the substrate-binding site is 
open towards the intracellular side only and this cycle repeats (reviewed in Kristensen et 
al.,112 and Rudnick121). Molecular simulation studies and the LeuT structures in various 
conformations have provided some credibility to explain this mode of transporter 
function.114,115,119,122,123  
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The proposed mechanism is that the transporter undergoes the following stages 
(Figure 6) 
1. Apo state that is defined by the absence of ions/substrate 
2. Binding of ions promotes a more stable outward facing conformation 
3. Subsequent binding of the substrate to the primary binding site (S1) 
4. This induces conformational changes and promotes the closure of the extracellular    
gate and formation of the inward-facing conformation. 
5. Release of Na+ is promoted by water dissemination into the inner vestibule and 
eventually leading to the release of the substrate. 
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Figure 6. An illustration of the putative substrate translocation cycle for the DAT protein. 
In the absence of bound ions or ligands, the transporter protein exists in dynamic flux 
between outward- and inward-facing states. Binding of Na+ at the S1 site stabilizes a fully 
outward-facing conformation with an open extracellular gate, primed to bind substrate 
molecules. Substrate binding at the S1 site induces closure of the extracellular gate, 
establishing an occluded conformation (closed-to-out). It has been suggested that 
interaction of a second substrate molecule with the S2 site helps facilitate opening of the 
intracellular gating network, giving rise to a fully inward-facing (open-to-in) conformation 
capable of releasing the S1-bound substrate and ions; however, no crystallographic 
evidence for simultaneous interaction of two substrate molecules with an NSS protein has 
been found. Apo, an unbound, ligand-free conformational state of a protein.124 
 
 
Shi et al.125 reported that binding of a second substrate molecule (leucine) simultaneously 
to the primary binding site (S1) and the extracellular site S2 can facilitate the transition 
from the occluded state to the inward-facing state to release ions and substrate into the 
intracellular compartment (Figure 6).  
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Other ligands such as tricylic antidepressants and fluoxetine have been shown to bind to 
the S2 site, however there is no crystal structure with a substrate in the S2 site.126,127 
 
b. Channel like model- Another model that explains the transport mechanism considers the 
transporter to function as an ion channel due ion channel-like uncoupled ion conductance 
seen with transporters.128,129 
              
3. Cellular regulation 
a. Post-translational modification- This can occur by glycosylation, phosphorylation, 
ubiquitylation, and palmitoylation mediated by various kinases that interact with specific 
residues on the N- and/or C-terminal.130 The three transporters possess 2-4 sites for 
glycosylation on EL2.112 The roles of some of the important kinases and phosphatase are 
briefly summarized (Table 4). 
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Table 4. Role of kinases and phosphatases in monoamine transporters. (Table adapted 
from Rammamoorthy et al.)131 
 
Regulators Effect at DAT Effect at SERT Effect at NET 
Protein kinase C 
(PKC) 
Activation: 
Regulates AMPH-
mediated DA efflux, 
decreased DAT 
surface proteins, 
increased DAT 
endocytosis, 
increased DAT 
phosphorylation, 
decreased uptake of 
DA. 
 
 
Activation: 
Increased SERT 
endocytosis and 
phosphorylation and 
decreased surface 
proteins and uptake 
of 5-HT. 
Activation: 
Decreased NET 
Vmax and surface 
proteins, unaltered 
NE Km. Increased 
NET endocytosis 
and phosphorylation. 
Movement of NET 
from lipid-rafts to 
non-lipid rafts. 
p38MAPK Inhibition: 
Decreased DAT 
phosphorylation, 
transport and 
activity.112  
Inhibition: 
Decreased SERT 
Vmax, Km and basal 
phosphorylation with 
or without changes 
in SERT proteins. 
 
Inhibition: 
Decreased NET 
Vmax and NE Km 
CaMKII Phosphorylation at 
the N-terminal and 
mediates AMPH-
induced DAT 
mediated DA efflux. 
 
Inhibition: Decreases  
AMPH-induced 
SERT mediated 5-
HT efflux.132  
Inhibition: 
Decreased Ca2+ 
induced NE uptake, 
AMPH induced NET 
down regulation. 
Tyrosine kinase Inhibition: 
Decreased DAT 
Vmax and decreased 
DAT proteins. 
 
Inhibition: 
Decreased 5-HT 
uptake and Vmax. 
Inhibition: 
Decreased NET 
Vmax and NE Km. 
Protein 
phosphatase 2A  
(PP2A) 
Inhibition: Reduced 
DA uptake and 
increased DAT 
phosphorylation. 
Inhibition: Reduced 
5-HT uptake and 
increased SERT 
phosphorylation. 
Inhibition: Reduced 
NE uptake and 
increased NET 
phosphorylation. 
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b. Secretory pathway  -  Transporter oligomerization and the C-terminal play an important 
role in the passage of the transporters through the endoplasmic reticulum and golgi.112 
 
c. Regulated trafficking- The most well investigated mechanism in the NSS family is PKC-
dependent internalization.  
 
In addition to the above a nonconventional conserved motif FREKLAYAIA has also been 
identified in the C-terminus of all the NSSs. It has been implicated in DAT and NET 
internalization.112 
 
d. Substrate and inhibitor mediated trafficking- In the case of DAT it has been shown that 
there is a decrease in DAT surface expression post the application of releasers such as 
AMPH (2). However DAT reuptake inhibitors such as cocaine and methylphenidate have 
been shown to increase DAT surface expression.112 There are several experiments and 
theories that have tried to explain this. One of them is that a biphasic effect has been 
observed after the application of AMPH (2). Initially there is a PKCβ-dependent increase 
in the expression of DAT at the surface this is followed by a disruption of the soluble N-
ethylmaleide-sensitive factor attachment protein complex that causes DAT internalization. 
Another theory is that Akt and CaMKII together cause a decrease in DAT surface 
expression. For NET as well, AMPH (2) has been shown to increase internalization due to 
CaMKII and syntaxin1A and also due to GTPase Rab11. In contrast to DAT and NET, 
SERT surface expression has been shown to increase upon prolonged exposure to 5-HT. 
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However newer studies have demonstrated an increase in surface expression of SERT at 
low doses of 5-HT and a decrease in expression at higher concentrations of 5-HT.112 
 
e. Role of lipid rafts and membrane proteins- Association of lipid/membrane rafts has been 
shown to be important for transporter regulation. They can act as messengers by bringing 
in close proximity the transporter to its signal transduction molecule to cause various 
mechanisms.131 Flotillin-1 helps DAT interact with lipid rafts and also plays an important 
role in AMPH-induced efflux, CaMKII and PKC regulation.130 Cholesterol is located 
between TMs 1a, 5 and 7 in the recently crystallized (dDAT) protein and promotes the 
outward facing conformation of the transporter and cholesterol diminution has shown to 
reduce monoamine transporter activity.117 Membrane raft association was first suggested 
for PKC-activated lipid raft-mediated internalization of NET and SERT.131 
Phosphoinositide phosphatidylinositol-4,5-biphosphate (PIP2)  is another lipid shown to 
affect both DAT and SERT. Mutation of PIP2 binding sites on the N-termimus eliminated 
AMPH-mediated efflux.130 
 
f. Protein interactions – 
i. Syntaxin 1A is a SNARE protein and its role in the activity and cell surface 
expression of monoamine transporters at their N-terminal has shown to be 
important. It also plays a role in CaMKII-mediated AMPH (2) efflux in DAT and 
SERT.112 
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ii. Postsynaptic Density 95/discs-large/zona occludens (PDZ) domain contains a 
protein PICK1 in the C-terminal of DAT and NET. The functional importance of 
the PDZ and PICK1 interaction at DAT is still not well understood. At the C-
terminal of SERT, neuronal nitric-oxide synthase (nNOS) interaction at the PDZ 
domain causes a decrease in SERT activity and cell surface expression.112 
iii. Hydrogen peroxide-inducible clone-5 (Hic-5) is another protein found to interact 
with DAT, SERT and NET and its association with SERT has shown to cause 
internalization.112 
iv. Sec24D, a part of the coat protein COPII, is an important regulator for moving the 
transporter from the ER to the golgi apparatus and this motif is conserved across all 
the monoamine transporters.112 
v. The dopamine D2 receptor located presynaptically has been shown to interact with 
DAT and augment the surface expression of DAT and uptake of DA. The role of 
the DAT/D2 interaction has been shown to be important in schizophrenia.112 
vi. α-Synuclein is a presynaptic protein that is responsible for the pathogenesis of 
Parkinson’s disease. It was found to interact with all of the NTTs and studies 
indicated that it regulated cell surface expression of the transporters, however its 
role in the regulation as inhibitory or stimulatory is yet to be determined. Studies 
this far has been unsuccessful in displaying any changes in DAT function in α-
synuclein KO mice.112 
vii. Trace amine receptor (TAAR1) – Trace amines include compounds such as p-
tyramine and β-phenethylamine which are similar to monoamines but are present in 
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lower quantities in the brain than them. Studies have demonstrated that the uptake 
of [3H]DA was inhibited in a concentration- and time-dependent due to activation 
of TAAR1 and AMPH (2) and METH-mediated DA uptake was also affected by 
TAAR1 regulation. TAAR1 was also shown to affect DA efflux/reuptake due to 
phosphorylation and mediate DAT internalization.133  
 
h. Transporter oligomerization- The recent crystal structures of dDAT with various 
ligands have been crystallized in its monomeric form, however there are studies which 
suggest that NSSs might exist as oligomers. Several studies at SERT have indicated 
oligomerization; for example, fluorescence resonance energy transfer experiments in 
HEK 293 cells showed oligomers of SERT. Co-immunoprecipitation studies have also 
provided verification for the connection of SERT monomers and in another study 
SERT dimers and tetramers retained uptake activity (reviewed by Torres et al.).1 In the 
case of DAT, the cysteine residues in TM6 were observed to be important for 
crosslinking and causing DAT to exist as dimers. Another mutational study of glycine 
residues that form a glycophorin-like motif in TM6 further adds support that TM6 is 
important for oligomerization. The role of TM2 is predicted to be important in 
transporter assembly and trafficking to the cell surface (reviewed by Torres et al.).1 
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4. Psychostimulant action at monoamine transporters 
Drugs that are psychostimulants exert their action by increasing the synaptic levels of 
monoamines. They can be grouped into two categories based on their mode of action at the 
transporters.134 
 
a. Reuptake inhibitors- Axelrod’s group first showed that catecholamine reuptake was 
blocked by cocaine (reviewed in Sulzer).113 Reuptake inhibitors bind to the transporters, 
but are not transported, thus preventing the uptake of monoamines from the synapse and 
causing an increase in synaptic monoamine levels.3 Two popular DAT reuptake inhibitors 
are cocaine and methylphenidate (6) (Table 5).  
 
Table 5. Binding of cocaine and methylphenidate at NET, DAT and SERT107 
Drug NET 
(IC50) nM 
DAT 
(IC50) nM 
SERT 
(IC50) nM 
Cocaine 2100 120       190 
Methylphenidate (6)  514  84 >50,000 
 
b. Releasers- This class of drugs binds to the transporter and is transported into the 
presynaptic terminal causing an increase in synaptic monoamine levels by releasing 
monoamines into the synapse via reverse transport and/or channel like activity (reviewed 
in Sulzer,113 and Sulzer et al.135). Psychostimulant releasers, MDMA (44),89 AMPH 
(2)2,136 and METH (5)70 act via this mechanism. There are two theories that explain how 
these releasers enter into vesicles. First is the weak base hypothesis- Due to the acidic 
environment within the vesicles, AMPH (2) for example is a weak base (pKa 9.9) and will 
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be protonated and accumulate in the vesicles, alkalinize the pH and thus reduce the energy 
required to accumulate the neurotransmitters.136 This theory however has its drawbacks 
and requires additional research to prove its significance at physiological concentrations 
of AMPH (2).135 Another mechanism is via competition with neurotransmitters at 
VMAT2 thus increasing the cytosolic pool of neurotransmitter.137 For the transporter to 
engage in reverse transport either one or an integrated mechanism of two or more of the 
following could be important: facilitated exchange diffusion, channel like mode of the 
transporter, and in addition putative phosphorylation and protein kinases sites that also aid 
in AMPH-mediated release of neurotransmitters.113,135  
 
Another mechanism that contributes to the mode of action of AMPH (2) is inhibition of 
the enzyme MAO. This enzyme is located in the presynaptic terminals and is responsible 
for the metabolism of monoamines; hence, inhibition of MAO would lead to an increase 
in cytosolic concentrations of neurotransmitters.138 
 
Crystal structures of dDAT bound to releasers and inhibitors provide insight into 
differences between both classes of drugs. Both classes of drugs bind to the central 
binding cavity formed by TMs 1, 3, 6 and 8. Since AMPH (2) and METH (5) occupy 
binding sites within the transporter similar to those observed for DA they serve as 
substrates and can compete with DA for transport. Even though cocaine occupies the 
same binding site as DA, Wang et al.118 suggest that due to the bulky tropane and 
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aromatic groups of cocaine it can restrict the movement of transporter and latch the 
transporter in an outward-open conformation.118  
 
Table 6. Actions of a few releasers at NET, DAT and SERT,139 and VMAT2.137 
Drug NET 
(EC50) nM 
DAT 
(EC50) nM 
SERT 
(EC50) nM 
VMAT2 [3DA] 
(EC50) nM 
(+)AMPH (S(+)2) 
 
    7.07    24.8 1765     2.5 
(+)METH (S(+)5) 
 
  12.3     24.5 736 11 
(-)METH (R(-)2) 
 
    28.5 416 4640 34 
MDMA (44) 
 
110 278   72 27 
(+)MDMA (S(+)44) 
 
136 142  74 22 
(-)MDMA (R(-)44) 560 3700 340 47 
  
D. Synthetic cathinone analogs 
1. Methcathinone 
a. Background 
Methcathinone (MCAT, 57) or 2-methylaminopropiophenone is considered the first 
synthetic analog of cathinone (1).5 MCAT (57) can be structurally related to METH (5), 
analogous to cathinone (1) and AMPH (2) (Figure 7). 
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Figure 7. Structural comparison of cathinone (1) and AMPH (2) analogs.   
 
A German scientist, Eberhard, first reported its synthesis in 1915,140 and later in 1924 two 
French scientists, Fourneau and Kanao, reported MCAT (57) (although it was not termed 
as such at that time) as an intermediate in the synthesis of ephedrine (18) and norephedrine 
(30).141  The synthesis most popularly followed is the one reported in 1928 by Hyde et 
al.142   
 
The optical isomers were first reported in 1936 in a German patent,143  and later in 1957  
(-)MCAT (S(-)57)  was reported as an analeptic agent in a patent by Parke Davis.144 
MCAT (57) was initially referred to as ephedrone in the Soviet Union countries; it was 
popularly abused in the early 1980’s under several names such as jeff, effendi, cosmos and 
mul’ka.145 Its popularity, easy methods of clandestine synthesis (oxidation of ephedrine, 
18) and abuse liability gained impetus in the U.S. around the late 1980’s and early 1990’s 
which caused it to become a U.S. Schedule I drug.22                                                          
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O
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b. Behavioral effects 
The behavioral effects of MCAT (57) were evaluated in vivo in AMPH-trained mice, and 
it was found to be twice as potent as cathinone (1) and AMPH (2).5 In locomotor activity 
studies MCAT (57) was several-fold more potent than cathinone (1).5 In ICSS studies 
MCAT (57) was found to produce dose-and time-dependent facilitation of ICSS (i.e., it 
had an abuse-related effect).146 Also in baboons it was shown that it had cocaine-like self-
administration properties.147  
 
 In an enantiomeric potency comparison, (-)MCAT (S(-)57) was five times more potent 
than its enantiomer as a locomotor stimulant in mice.148 In drug discrimination studies 
using cocaine- and (+)AMPH (S(+)2)-trained rats, (-)MCAT (S(-)57) was found to be 3- 
and 2-fold more potent, respectively, than its enantiomer and twice as potent as (+)AMPH 
(S(+)2). The potency of the racemate was in between the two isomers. Thus, (-)MCAT 
 (S(-)57)  is the more potent enantiomer.148 MCAT (57) was employed as a training drug in 
drug discrimination studies and was found to be 2-fold, 4-fold, 8-fold and 2-fold more 
potent than MCAT (57), (+)MCAT (R(+)57), cocaine and (+)AMPH (S(+)2), respectively, 
and its stimulus was blocked by the dopamine antagonist haloperidol.148  
 
c. Mode of action 
In an in vivo experiment reported by Glennon et al,5 MCAT (57) was found to release 
[3H]DA from pre-labeled rat caudate nucleus.5 Cozzi et al.149 also supported this finding, 
where they evaluated the effects of MCAT (57) to release monoamines at DAT, SERT, 
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NET or vesicular monoamine transporter 2 (VMAT2) and it was found that MCAT (57) 
exerted its effects primarily through plasma membrane DAT versus SERT, NET and 
VMAT2.149  
 
d. Early SAR 
Analogs of MCAT (57) where the chain length at the terminal amine was varied for 
example, N-monoethylcathinone (58), N-mono-n-propylcathinone (59), N,N-
dimethylcathinone (60) and (-)-N,N-dimethylcathinone (S(-)60) were evaluated in drug 
discrimination studies in (+)AMPH (S(+)2)-trained rats it was observed that they were less 
potent than MCAT (57) (around 2-fold).145 
                                                              
 
2. Bath salts 
a. Background 
During the period between the 1920’s to early 2010 reports on the abuse of synthetic 
cathinones was brief. A few synthetic cathinones did make their appearance during this 
period (Figure 8); most of them were initially patented for their therapeutic effect potential 
were then not pursued because of their abuse potential. 
CH3
O
N R1R2
58: R1= H, R2 = CH2CH2CH3
59: R1= H, R2 = CH2CH3
60: R1= R2 = CH3
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Figure 8. Timeline of a few synthetic cathinones (adapted from Prosser et al).6 
 
In 2010 a seemingly novel group of compounds called “bath salts” made their debut in 
Europe.7 These compounds were falsely marketed under names such as “plant food”, 
“research chemicals” or “bath salts” and were labeled “not for human consumption” to 
escape legislation. They were sold at head shops, convenience stores, gas stations and on 
the Internet under alluring names such as Ivory Wave, Vanilla Sky, Explosion, and White 
Rush amongst others. The use of these agents became prevalent due to their central 
stimulant effects.8  
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“Bath salts” initially was a combination of all or at least two of the following; methylone 
(61), mephedrone (MEPH, 62), and methylenedioxypyrovalerone (MDPV, 63) (Figure 9).8  
                                             
Figure 9. The original components of bath salts.8 
 
Iversen reported that MEPH (62) accounted for 89% of the cathinone seizures by the UK 
forensic department.7 A survey conducted by the dance magazine Mixmag in the UK in 
2010 revealed that MEPH (62) was the fourth most commonly used drug.7 Iversen also 
reported on the toxicology and deaths due to MEPH (62) in UK.7 Their abuse was not 
limited to Europe and soon the U.S. reported cases of bath salt abuse. The DEA noted that 
in 2011 the American Association of Poison Control Centers reported a total of 4137 calls 
related to bath salts exposure and the National Forensic Laboratory Information Systems 
(NFLIS) for the period between January 2009-June 2011 reported 1429 cases of synthetic 
cathinones of which MDPV (63) accounted for (791) 55%, MEPH (62) (331) 23% and 
methylone (61) (279) 20%.8 The NFLIS also reported 15 seizures of bath salts from 8 
states, but by 2010 there were 560 reports from 29 states. The U.S. Customs and Border 
Protection (CBP) also encountered 96 shipments just in the month of July 2011 containing 
bath salts.8 Some of the routes for ingesting bath salts include snorting, swallowing tablets, 
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rectal, intramuscular injections, and ingestion by bombing.8 These agents are often mixed 
with other drugs such as AMPH (2), MDMA (44), caffeine, lidocaine, and other synthetic 
cathinones to exacerbate or weaken their effects.8  People abusing bath salts can experience 
a number of severe effects such as hallucinations, tachycardia, chest pains, blurred vision, 
agitation, confusion, hypertension, hyperthermia, multi organ failure, anxiety, aggressive 
behavior, psychosis, and death.150-152 
 
b. The three components 
Methylone (61) is the cathinone, (i.e., the β-keto) analog of MDMA (44) and is also named 
as methylenedioxymethcathinone (MDMC). Peyton and Shulgin first synthesized MDMC 
(61) in 1996 and it was patented for its effects as an antidepressant and anti-Parkinson 
agent.153 In 1997, Glennon and co-workers.145 reported that in drug discriminations studies, 
MDMC (61) substituted for (+)AMPH (S(+)2) and MDMA (44) but not DOM (3).145  
 
MDMC (61) also exerts its CNS stimulant effects by acting as an AMPH-like releaser at 
monoamine transporters.145 Cozzi et al.149 studied the effects of MDMC (61) on DAT, 
SERT and NET, respectively.149 Upon comparing the two analogs, MDMC (61) and 
MDMA (44) in in vitro and in vivo assays, MDMC (61) was found to be about half as 
potent as MDMA (44).145,149  
 
MDPV (63) was initially patented in 1969 for its central stimulant effects,154 but its abuse 
potential was realized only in 2007 with a study demonstrating an extracellular increase in 
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DA levels in mouse brain.155 It is structurally similar to pyrovalerone (64) developed to 
treat chronic fatigue and lethargy.156  
                                                           
MEPH (62) is the p-methyl analog of MCAT (57) and its synthesis was first reported in 
1929,157 but its rise as a designer drug of abuse only began around 2007.7  
 
Some of the reasons there was a sudden interest, curiosity, and eruption in the use of bath 
salts was because users experienced central stimulant effects, they were initially without 
any legal restrictions, and they were easily available in shops and over the Internet. They 
also were not detected by common screening tests and required more sophisticated 
methods such as gas and mass spectrometry. Their use might be preferred over other 
stimulants such as cocaine and MDMA (44), which were experiencing a decrease in 
purity/availibility.158 
 
Due to a tremendous and sudden escalation in the number and severity of bath salts abuse 
cases, in October 21, 2011 MEPH (62), MDMC (61) and MDPV (63) were temporarily 
placed in the U.S. Schedule I category but eventually were given permanent Schedule I 
status.18-20 
N
O CH3
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c. Mode of action  
When psychoactive bath salts made their debut very little was known about their 
pharmacology and mechanism of action. Our laboratory in collaboration with Dr. De 
Felice was amongst the first to report on their mechanism of action.11 In 
electrophysiological experiments conducted on Xenopus laevis oocytes expressing hDAT, 
MEPH (62) produced an inward depolarizing current,9,10 similar to that seen with releasers 
such as (-)MCAT (S(-)57) and (+)METH (S(+)5) (Figure 10).9 (-)MCAT (S(-)57)  was 
found to be the most potent amongst the three and (+)METH (S(+)5) and MEPH (62) were 
almost equipotent.9 
MDPV (63), in contrast to MEPH (62), produced an outward cocaine-like hyperpolarizing 
current indicating that MDPV (63) was a DAT reuptake inhibitor (Figure 11).10,11  
 
The actions of MDPV (63) and MEPH (62) were further assessed in DA uptake 
experiments in HEK cells expressing hDAT and MDPV (63, IC50= 28 nM) was found to 
be 35-fold more potent than cocaine (IC50 = 995 nM) and 40-fold more potent than MEPH 
(62, IC50 = 3950 nM).10 
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 Figure 10. Currents generated in hDAT expressed in Xenopus oocytes at a -60 mV by the 
application of 10 µM of a) (+)METH (S(+)5); b) (-)MCAT (S(-)57); c) MEPH (62) and d) 
DA.9 
                                    
Figure 11. Currents generated in hDAT expressed in Xenopus oocytes at -60 mV by the 
application of 10 µM of MDPV (63) and cocaine.10 
 
In an I(V) assay, MDPV (63)  produced a curve similar to cocaine and was found to be a 
more potent reuptake inhibitor than cocaine, and MEPH (62) produced a curve similar to 
DA.10 
 
MDPV (63) also produced similar effects to cocaine after pretreatment with MEPH (62) 
but its inhibitory effects lasted for more than 30 min (Figure 12).10 
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Figure 12. Panels A and B show traces of 30-secs blocker application (MDPV (63) and 
cocaine 10 µM) during the persistent leak current induced by 60 secs of MEPH (62) 10 µM 
at -60 mV at hDAT expressed in Xenopus oocytes.10  
 
Bath salt components might act synergistically; MEPH (62) has a faster onset of action 
than MDPV (63) causing a release of DA that MDPV (63) then blocks the uptake of 
contributing to the psychoactive actions of these bath salt components.10 
 
Baumann et al.159,160 evaluated the in vitro actions of bath salts on DAT, NET and SERT in 
rat brain synaptosomes for their release and reuptake actions (Table 7).159,160 MDMC (61) 
has been known from previous studies to act as a releaser.149 From the data below, MEPH 
(62) and MDMC (61) act as substrates at all the three transporters and MEPH (62) was 
about twice as potent as MDMC (61) at all the three transporters.159 MDPV (63) was 
shown to act as a reuptake inhibitor at all the three transporters with greatest potency at 
DAT vs NET and SERT (Table 7).160 
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Table 7. Effects of bath salts on transporter-mediated uptake and release assays in rat brian 
synaptosomes.159,160 
 
 
Drug 
NET 
 
SERT DAT 
EC50 nM IC50 nM EC50 nM IC50 nM EC50 nM IC50 nM 
MDMC (61)   152.3 1031 242.1 1017 133 1232 
MEPH (62)    62.7 487 118.3 422    49.1 762 
MDPV (63) 13 
 (Emax 
24%) 
26 Inactive 3349    2.3 
(Emax 
24%) 
     4.1 
 
MDPV (63), structurally, also belongs to the cathinone family similar to MEPH (62) and 
MDMC (61) but it was the first synthetic cathinone shown to exert its mechanism of action 
as a reuptake inhibitor at the monoamine transporters.9-11,159,160 
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III. Specific aims 
 
 
 
 
Cathinone (1) was identified in 1975;4 since then there have been at least a few hundred 
synthetic analogs of cathinone (1) synthesized.22 Some of them are well known, and their 
mechanisms of action have been investigated. For example, MCAT (57) is thought to act 
primarily as a DAT releasing agent.5 Today, synthetic cathinones represent one of the 
latest global drug-abuse problems and the analogs are known by multiple street names.12,17 
Periodically (especially in the last 5 years) there has been an ingress of newer synthetic 
cathinones. These are structurally simple, can be readily synthesized in clandestine 
laboratories, and are exceedingly popular for their stimulant character. They are not 
uniform pharmacologically, or in their mechanism of action. Hence studying each of them 
case-by-case is imperative.22 Elucidation of the mechanism of action of drugs of abuse 
will/should 
• Allow for their pharmacological classification 
• Assist in understanding their behavioral effects 
• Assist in determining potential treatments for these agents 
• Provide information to regulatory agencies (e.g. the DEA) for scheduling purposes 
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Thus, the overall aim of this research is to better understand the mechanism(s) of action, 
and formulate the SAR, of the designer stimulants known as “synthetic cathinones”. The 
specific aims of this research can be divided into the following and each aim will be 
discussed in separate chapters. 
 
 AIM I. Structure-activity relationship studies of MDPV and its effects at the 
dopamine transporter. 
 
MDPV (63) was the first synthetic cathinone to be identified as a reuptake inhibitor at 
DAT.9,10  
 
The goals of this project are to: 
a. Identify what parts of the MDPV (63) molecule structurally contributes to its mechanism 
of action as a reuptake inhibitor. We will “deconstruct” MDPV (63) (Figure 13), and study 
MDPV (63) and its analogs by electrophysiological and affinity studies at hDAT expressed 
in Xenopus laevis oocytes and HEK 293 cells respectively. 
b. After determining the minimal structural features that contribute to MDPV’s activity as 
a reuptake inhibitor we will “elaborate” on the structural features identified important for 
activity. These compounds will be evaluated by in vitro release and uptake inhibition in rat 
synaptosomes for their activity at DAT. 
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Figure 13. MDPV (63) and its analogs to be investigated in AIM I. 
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AIM II. Quantitative structure-activity relationship analysis, molecular modeling and 
hydropathic interaction analysis of the pharmacology of p-substituted methcathinone 
analogs. 
 
MEPH (62), another bath salt component, is the p-methyl analog of MCAT (57) but was 
identified by our group to be different from MCAT (57) in its behavioral and 
neurochemical effects.146 Other groups have studied the p-fluoro and p-methoxy analogs of 
MCAT (i.e., flephedrone (72) and methedrone (73), respectively, Table 8) and concluded 
that the p-substituent influences pharmacological activity.161,162 With this evidence it was 
important to understand the SAR of p-substituted MCAT analogs that are responsible for 
their distinct pharmacological effects.         
                                    
The goals of this project are to: 
a. Synthesize 4-substituted analogs of MCAT (57) with different electronic, lipophilic and 
steric properties (Table 8). 
b. Evaluate these analogs by in vitro release and uptake inhibition in rat synaptosomes (for 
activity at DAT and SERT) and the ICSS assay in rats for their behavioral effects.  
c. To conduct quantitative structure-activity relationship (QSAR) studies by examining the 
effect of electronic, lipophilic and steric parameters of the 4-position substituent of these 
analogs on pharmacological activity. 
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d. After identifying the parameters important for activity, to then explain the role of these 
parameters by possible interactions with the transporters by constructing homology models 
of hDAT and hSERT. 
 
Table 8. MCAT (57) and its 4-position analogs to be investigated in AIM II. 
 
Agent R 
Methcathinone (57) -H 
Flephedrone (72) -F 
Methedrone (73) -OCH3 
4-Chloromethcathinone (74) -Cl 
4-Bromomethcathinone (75) -Br 
Mephedrone (62) -CH3 
4-Trifluoromethylmethcathinone (76) -CF3 
 
 
 
 
CH3HN
CH3
O
R
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AIM III. Structure-activity relationship studies on the “bath salts” component 
“methylone” at dopamine and serotonin transporters. 
 
MDMC (61) is the β-keto analog of MDMA (44). The SAR of MDMA (44) has been 
studied previously;99 but, relatively little is known about the SAR of MDMC (61). 
Specifically, the DEA has also sought information on PAAs that are not yet scheduled but 
could be potential threats as drugs of abuse e.g. EDMA (51).163   
 
The goals of this project are to: 
a. Study the effect of ring expansion of the methylenedioxy ring of MDMA/MDMC 
(Figure 14). 
•  Synthesize the ethylenedioxy analogs of MDMC (61) and MDMA (44) (i.e., 
EDMC (77), EDMA (51)). 
b. Study the effect of N-alkyl chain extension of MDMC (Figure 14) 
• To synthesize N-ethyl and N-propyl analogs of methylone 
(61) (i.e., 3,4-methylenedioxy-N-ethylcathinone (ethylone, 78), 3,4-
methylenedioxy-N-propylcathinone (propylone, 79)). 
c. Evaluate these analogs by in vitro release and uptake inhibition in rat synaptosomes (for 
activity at DAT and SERT). 
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Figure 14. Compounds to be investigated in AIM III. 
 
AIM IV. Investigation of the N-alkyl chain length of 4-methylamphetamine analogs: 
An examination of its pharmacological effects at the DAT and SERT. 
 
Results from Aims I, II and III will identify structural features that contribute towards 
DAT/SERT selectivity and also the mechanism of actions at monoamine transporters.  
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The goals of this project are to: 
a. Understand how the structural features of the terminal amine contribute towards activity 
and selectivity at DAT and SERT (Figure 15).  
• We will synthesize four p-methylamphetamine homologs (see Figure 15) with 
varying substituents at the terminal amine (4-methyl-N-methylamphetamine (80), 
4-methyl-N-ethylamphetamine (81), 4-methyl-N-propylamphetamine (82), 4-
methyl-N-butylamphetamine (83)). 
b. Evaluate these analogs for their electrophysiological properties at hDAT and hSERT 
expressed in Xenopus leavis oocytes, in vitro release and uptake inhibition in rat 
synaptosomes (for activity at DAT and SERT) and the ICSS assay in rats for their 
behavioral effects. 
 
 
Figure 15. Compounds to be investigated in AIM IV. 
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AIM V. Effects of psychoactive synthetic cathinones and amphetamine analogs at the 
norepinephrine transporter. 
 
Synthetic cathinones such as MCAT (57) and MDPV (63) have similar selectivity for at 
DAT and NET compared to SERT. Our goal was to evaluate compounds investigated in 
AIMS II-IV at NET and compare their activity with the results from DAT and SERT. 
 
AIM VI. Comparison of the structural features of methylphenidate and synthetic 
cathinones and investigation of the role of the carbonyl group on synthetic 
cathinones: A preliminary investigation. 
 
Methylphenidate  (6) is a reuptake inhibitor at DAT and is a PAA used clinically for 
ADHD.106 Given the structural similarity between methylphenidate (6) and the synthetic 
cathinones, in particular MDPV (63) it was of interest to compare them.  
 
The goals of this project are to: 
a. Compare  two structural features of methylphenidate (6) (i.e., the ester and the piperidine 
ring) to the corresponding features of MDPV (63) (i.e., the carbonyl and pyrrolidine ring). 
• We will synthesize compounds that are hybrids of the two (84 and 85). In 84, the 
ester of methylphenidate (6) was replaced by a carbonyl group, whereas 85 is an 
MDPV-type analog where the carbonyl group has been replaced by an ester 
(Figure 16). 
 72 
    
      
Figure 16. Compounds to be investigated in AIM VI. 
 
b. A parallel aim was also to investigate the role of the carbonyl group on synthetic 
cathinones. 
• To better understand if the sp2 nature of the carbonyl carbon atom of synthetic 
cathinones is a contributor to activity, we will synthesize the methoxy analogs 86 
and 87 where the hybridization state of the carbon atom is sp3 (Figure 16).  
 
• We will synthesize one of the bioisosteres of a carbonyl group (i.e., the oxime 
analog 88) (Figure 16). Bioisosteres are compounds or groups that have similar 
chemical and physical properties and produce similar biological effects.164 
c. Evaluate their effects at hDAT and hSERT using electrophysiological studies. 
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AIM VI. Understanding the role of a charged terminal amine: A preliminary 
investigation. 
 
AMPH (2) as well as cathinone-based drugs of abuse all have a terminal amine that is 
protonated at physiological pH. Recent crystal structures of dDAT with (+)AMPH (S(+)1), 
DA and METH (S(+)5) have shown an ionic interaction between an aspartate  and the 
terminal amine of the above PAAs.118  
 
The goal of this project is to: 
a. Investigate the role of the nitrogen atom on cathinone analogs specifically MCAT (57)  
• We will synthesize the desnitrogen analog 89 of MCAT (57) because, lacking a 
basic nitrogen atom this compound cannot form the ionic interaction with 
aspartates D79 in hDAT and D98 in hSERT. 
 
   
• If this ionic interaction is important for activity, then replacement of a protonated 
tertiary amine with an isosteric sulfonium group could result in retention of action. 
We will synthesize the sulfonium salt 90 such that it is permanently charged and 
CH3HN
CH3
O
MCAT (57)
CH3
CH3
O
89
CH3S
CH3
90
O
H3C
+
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would maintain the ionic interaction with the conserved aspartate at the substrate-
binding site.  
b. Evaluate their effects at hDAT and hSERT using electrophysiological studies. 
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IV. Outcomes 
 
 
Outcomes of all the AIMS will be discussed here individually. 
  
AIM I. Structure-activity relationship studies of MDPV and its effects at the 
dopamine transporter 
 
a. Introduction 
Boehringer Ingelheim reported the synthesis of the hydrochloride salt and a few 
pharmacological properties of MDPV (63) in 1969 while they were working on 
heterocyclic α-substituted-ketones containing an α-pyrrolidino group.154 At that time, 
MDPV (63) was not known by this abbreviation but, rather, by its IUPAC name “1-(3’,4’-
methylenedioxyphenyl)-2-pyrrolidinopentanone”. They reported on its therapeutic index 
(875), toxicity (LD50 = 175 mg/kg) and the dose required to produce central nervous 
system stimulation (0.20 mg/kg) in mice.154  
 
 In 2010 MDPV (63) made its presence quite conspicuous7 when it was identified as a 
primary constituent of the psychostimulant designer drug “bath salts”.151 It became 
notorious for its abusive properties that led to severe side effects.150-152 At the time it made 
its debut on the drug abuse scene, its mechanism of action was still not known. 
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Both MDPV (63) and MEPH (62) are synthetic cathinones and, consequently, it was 
initially thought that they would have similar mechanisms of action. However we 
identified that MEPH (62) produces hDAT-mediated inward currents similar to (+) METH 
(S(+)5) and (-)MCAT (S(-)57) whereas MDPV (63) produces hDAT-mediated outward 
currents similar to cocaine. MDPV (63) was distinctive as it was the first synthetic 
cathinone to be identified as a reuptake inhibitor at DAT.9-11 Various groups have 
substantiated assessment of its abuse potential. MDPV (63) produces locomotor 
stimulation in rats,160,165 and mice.155,166 Its effects on the brain reward system were 
observed by a decrease in ICSS.146 It was also found to be self-administrated in rats.165 In 
drug discrimination studies in mice it fully substituted for MDMA (44) and METH (5) but 
not morphine or the synthetic cannabinoid JWH-018.166 MDPV’s actions have been shown 
to be mediated via DAT, and in a voluntary wheel-running test in rats, it produced effects 
different from that of MDMA (44), an agent found to be mainly serotonergic.167  
 
 The goal of this project was to identify what structural features of MDPV (63) contribute 
to its unexpected mechanism of action as a reuptake inhibitor at DAT. MDPV (63) is 
structurally unique from other synthetic cathinones such as MCAT (57) and MEPH (62) 
because it has a tertiary amine, in the form of a pyrrolidine ring, and an extended α-n-
propyl side chain. 
We used one of the classical medicinal chemistry principles, (i.e., deconstruction), to 
investigate MDPV (63). Deconstruction, removal of each of the molecular substituents of 
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MDPV (63) one at a time, will allow us to determine their importance on the 
target/biological activity; hence, it helps to identify the minimal structural features of the 
molecule that contribute to its biological activity.168  
 
MDPV (63) has four structural features that could be potential contributors to its activity 
(Figure 17, highlighted in different colors); a total of seven deconstructed analogs of 
MDPV were synthesized (Figure 18). 
                                                          
Figure 17. Structural features of MDPV (63) to be deconstructed. 
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Figure 18. MDPV (63) and its deconstructed analogs. 
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b. Methods 
i. Synthesis – This was a joint effort by several members of our group. Dr. Kolanos 
synthesized Compounds 63, 67, 69, 70, and 71, and details of their synthesis have been 
described in Kolanos et al.169 The synthesis of compounds 65, 66 and 68 is described in 
Scheme 1.  
 
Scheme 1. Synthesis of compounds 65, 66, and 68a 
 
 
                                        
aReagents: (a) SnCl4, CH2Cl2, propionyl chloride (92)/ valeroyl chloride (93); (b) Br2, 
AlCl3, Et2O; (c) benzene, pyrrolidine (65)/ Me2NH in MeOH (66) /MeNH2 in EtOH (68). 
 
 
 
O
O
O
O
XO
R1 = CH3 (92)
R1 = CH2CH2CH3 (93)
a
91
O
O
R1
O
Br
O
O
R1
O
N R3R2
b c
R1 = CH3, R2 = R3 = (CH2)4 (65)
R1 = CH3, R2 = R3 = CH3 (66)
R1 = CH2CH2CH3, R2 = H, R3 = CH3 (68)
R1 = CH3 (94)
R1 = CH2CH2CH3 (95)
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ii. Two electrode voltage clamp technique (TEVC)  
This assay was performed in Dr. De Felice’s laboratory at Virginia Commonwealth 
University and is reported in Kolanos et al.169 
 
Expression of hDAT in Xenopus laevis oocytes.  
Oocytes were harvested and prepared from adult Xenopus laevis females following 
standard procedure; 32−34 Stage V−VI oocytes were selected for cRNA injection within 
24 h of isolation.  
 
cRNA was transcribed from the pOTV vector using the mMessage Machine T7 kit 
(Ambion Inc.,Austin, TX). Oocytes were injected with 50 ng of hDAT cRNA(Nanoject 
AutoOocyteInjector, Drummond Scientific Co., Broomall,PA) and incubated at 18 °C for  
4−8 days in Ringers solution supplemented with sodium pyruvate (550 µg/mL), 
streptomycin (100µg/mL), tetracycline (50 µg/mL), and 5% dialyzed horse serum 
Electrophysiology.  
 
Two-electrode voltage-clamp (TEVC) recordings were at room temperature (23−25 °C). 
Electrodes having a resistance of 1−5 MΩ were filled with 3 M KCl. Xenopus laevis 
oocytes expressing hDAT were voltage-clamped to −60 mV with a GeneClamp 500 (Axon 
Instruments), and the holding current was recorded using a Clampex10 (Axon 
Instruments). Extracellular buffer consisted of (in mM): 120 NaCl, 7.5 HEPES, 5.4 
potassium gluconate, and 1.2 calcium gluconate, pH 7.4. In a typical recording, 
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extracellular buffer was perfused until stable baseline currents were obtained, followed by 
experimental drugs (perfusion duration is indicated by a horizontal line on the trace). 
 
iii. Radiolabeled [3H]DA Uptake competition assay 
This assay was performed in Dr. De Felice’s laboratory at Virginia Commonwealth 
University and is reported in Kolanos et al.169 
 
Maintenance of Cells Stably Expressing hDAT (hDAT-HEK). 
Cells were prepared in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 
penicillin (100 units/mL), streptomycin (100 mg/mL), and G418. 
 
Radiolabeled [3H]DA Uptake Competition Assay.  
hDAT-HEK cells in DMEM suspension were counted, and 200,000 cells were placed in 
individual Eppendorf tubes and incubated for 15 min at room temperature (23−25 °C) with 
mixtures of 1% [3H]DA.  
 
The compounds (MDPV (63) and analogs (65-71)) were tested at a broad range of 
concentrations. Ice-cold (4 °C) PBS was added to the samples, cells were centrifuged for 1 
min at 2000 rpm, supernatant was removed, and cells were washed twice with PBS, 
centrifuged, and supernatant was removed. Cells were solubilized with Ecoscint H 
(NationalDiagnostics, Atlanta, GA), and the [3H]DA remaining was measured using a 
scintillation counter. To determine IC50 values, uptake values were plotted against 
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concentration and data were fit using the Hill equation y = Vmax + (Vmin − Vmax) * 
xn/(kn + xn) using Origin 8 (OriginLab Corporation, Northampton, MA). 
 
c. Results 
Results from TVEC  
 TVEC studies conducted on MDPV (63) and all the analogs in Xenopus laevis oocytes 
expressing hDAT (clamped at -60 mV) are shown in Figure 19.  
 
For each of the traces in Figure 19 there is first an hDAT-mediated inward (i.e., 
depolarizing current), after the initial application of 5 µM of DA. Subsequent application 
of MDPV (63) or any of its analogs (65-71) (10 µM, 1 min) produced an outward hDAT-
mediated current (i.e., a hyperpolarizing current). This was followed by a washout period 
in which the current did not return to baseline after which there was an another application 
of 5 µM of DA, that now produced a reduced hDAT-mediated inward current. All the 
compounds tested produced qualitatively similar hyperpolarizing currents with similar 
amplitudes but differed in their percentage of recovery after the second application of DA 
(see Table 9 and Figure 19). MDPV (63) produced the smallest recovery whereas 
compounds 66 and 69 produced a full recovery of the hDAT-mediated inward current. 
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Figure 19. Currents produced MDPV (63) and its analogs 65-71 in Xenopus laevis oocytes 
expressing hDAT clamped at -60 mV.169 
69          DA          
DA          DA 
 DA 68       
DA 
    70        DA 
DA 
71            DA 
MDPV (63)       DA 
DA DA 
65          DA 
66        
DA 
DA        
DA 
67          DA        
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Table 9. Magnitude of the effect produced by MDPV (63) and its analogs 65-71 (10 µM), 
and percent recovery following a subsequent application of 5 µM DA, and the IC50 values 
obtained from HEK-cells expressing hDAT. 
 
Drug % Response 
(±SEM)a 
% Recovery 
(±SEM)b 
N IC50 nM      
(±SEM) 
MDPV (63) 16.4 (2.4) 12.1 (1.1) 7 135 (±20) 
65 18.0 (1.2) 91.9 (1.9) 6 3540 (±470)  
66 18.7 (2.2) 102.0 (0.8) 5 22300 (±3270)  
67 14.1 (1.7) 57.5 (2.4) 3 715 (±120)  
68 16.9 (2.0) 75.7 (4.5) 5 1950 (±270)  
69 19.2 (3.4) 102.6 (1.5) 5 27100 (±6000) 
70 15.3 (1.7) 90.0 (1.6) 5 1150 (±130) 
71 14.8 (2.1) 25.4 (1.7) 5 205 (±60) 
aPercent response relative to the amplitude of the inward current produced by 5 µM DA. 
bPercent recovery upon the application of 5 µM DA 1 min following the outward current 
produced by MDPV (63) and its analogs (65-71).  
 
Results from Radiolabeled [3H]DA Uptake Competition Assay 
The affinities of MDPV (63) and its analogs were determined by measuring the uptake of 
[3H]DA in HEK cells expressing hDAT. The IC50 values were spread over a 200-fold (see 
Table 9, Figure 20) range with none of the analogs being more potent than MDPV (63, 
IC50 = 135 nM). Removal of the methylenedioxy ring resulted in compound 71 (IC50 = 205 
nM) with comparable affinity to MDPV (63). The AMPH analog of MDPV (i.e., the des-
keto analog 70), was 10-fold less potent than MDPV (63). Shortening the extended α-n-
propyl side chain to α-n-methyl side chain resulted in a compound (65, IC50 = 3540 nM) 
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with 25-fold decreased potency, and a subsequent 6-fold decease in potency was observed 
when 65 was converted to its N,N-dimethylamine analog (66, IC50 = 22,300 nM). 
Deconstructing the pyrrolidine ring of MDPV (63) to the N,N-dimethylamine (67, IC50 = 
715 nM), N-methyl (68, IC50 = 1950 nM), and primary amine (69, IC50 = 27,100 nM) 
resulted in a systematic decrease in potency by 5-,14-, and 200-fold, respectively. 
 
 86 
 
Figure 20. Results from radiolabeled [3H]DA uptake competition assay for MDPV (63) 
and its analogs 65-71 expressed in nM. 
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d. Discussion 
All the deconstructed analogs of MDPV (63) produced hyperpolarization. A notable 
difference was the percent recovery following subsequent administration of DA (Table 9, 
Figure 19). The contributions of the various structural features of MDPV (63) to affinity 
can be correlated to the recovery of the current due to DA (applied after exposure to 
MDPV and the analogs) (Table 9 and Figure 19). The percent recovery is highly correlated 
with affinity (r = 0.916, p = 0.0014), (Figure 21). Compounds with the greatest recovery 
were the ones with the least affinity.  
 
Figure 21. Relationship between pIC50 for inhibition of DAT versus % DA recovery (r = 
0.916, p = 0.0014) for compounds 63, 65-71.  
 
MDPV (63) is a compound with long-lasting effects as seen that the percent recovery is 
only 12.1%. The compound without the methylenedioxy ring 71 is the only one with 
affinity comparable to MDPV (63) and confers similar long lasting effects with only 
25.4% recovery. The carbonyl group is a contributor to affinity but its lack does not 
produce the long-lasting effect of MDPV (90% recovery, 70). The side chain shortened 
r = 0.916 
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analog 65 is 25-fold less potent than MDPV (63) and this difference parallels the effect on 
DA recovery, MDPV (63) 12% vs 90% for 65. Changing the nature of the terminal amine 
from a bulky tertiary amine to a ring opened tertiary amine, secondary and primary amine 
produced a systematic decrease in potency (spanning >200-fold), this same order is also 
seen with their effects on DA recovery: MDPV (63) 12% vs 67; 57.5%, 68; 75.7%, 69 
102.6%). On comparing the effects of the 5-membered pyrrolidine ring of MDPV (63) 
with analogs 65, 67 and 66 we can see that these analogs are not only relatively less potent 
but they also showed a higher recovery of DA compared to MDPV (63) (65: 91.9%, 66: 
102%), 67: 57.5%).  
 
The recovery currents were examined at one concentration (i.e., 5 µM) and this needs to be 
further investigated in greater detail. It is important to note that our group also saw 
MDPV’s long lasting effects in previous studies where the current due to MDPV (63) did 
not return to baseline even after a washout period of over 30 minutes10 and in ICSS studies 
it showed facilitation even beyond 300 minutes.146 
 
All the analogs tested were reuptake inhibitors similar to MDPV (63), but with different 
potencies. It can be concluded that the key structural contributors to reuptake activity at 
hDAT are the tertiary amine and the extended side chain. Either of these structural features 
is sufficient for high affinity, but having both of these structural features together 
contributes to optimal affinity. The methylenedioxy ring is not required for activity and the 
carbonyl group contributes to activity but is not essential. 
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Due to the stringent legislative regulations imposed on “bath salts”, a second wave of 
synthetic cathinones had already emerged by the time we completed our studies. The 
primary goal of our study was to identify the structural features that made MDPV (63) 
distinct from other cathinones such as MCAT (57) and MEPH (62) but an inadvertent 
outcome of the present investigation was to provide information on four of the analogs (71 
(α-PVP), 65 (MDPPP), 66 (bk-MDDMA) and 68 (bk-MBDP)) that were coincidentally 
identified on the clandestine market at the time as potential drugs of abuse. We provided 
the first study on their mechanisms of action.  
 
Later, our group also prepared and tested the two enantiomers of MDPV (63) for their in 
vitro effects in rat brain synaptosomes and their in vivo effects in ICSS assays and 
established that the abuse liability of MDPV (63) is due to its S(+) isomer. In in vitro 
studies S(+)63 was about 200-fold more potent than R(-)63, and about twice as potent as a 
reuptake inhibitor at DAT. Stereoselective facilitation of ICSS was observed, both S(+)63 
and MDPV (63) produced facilitation in ICSS but the former was marginally more potent 
than the racemate. R(-)63 failed to produce any significant effects in ICSS even at doses 
100 times that of the lowest effective dose of S(+)63.170 
 
One of the analogs, α-PVP (71), encompassed the minimum structural features that 
contributed to reuptake inhibition at hDAT. In our assay in HEK-cells it was nearly half as 
potent as MDPV (63) (Table 9), and in rat brain synaptosomes it was 3 times less potent 
than MDPV (63) as a reuptake inhibitor at DAT.171 Following the completion of our 
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studies, others assessed in different behavioral assays its CNS stimulant character and 
abuse potential. In locomotor stimulation assays, it displayed a locomotor stimulatory 
effect in mice comparable to METH (5)172 and MDPV (63) in both mice and rats.171,173 In 
self-administration assays in rats it was similar in potency and efficacy to MDPV (63),173 
and showed a decrease in ICSS effects similar to METH (5).174 In drug discrimination 
studies it substituted fully for both METH (5),175,176 and cocaine,176 and also showed a 
decrease in conditioned place preference in a dose-dependent manner.176 In recent news α-
PVP (71) soared to popularity under the names of “gravel” and “flakka” in most states in 
the United States and has been reported to cause some severe and bizzare effects.177 The 
NFLIS has included it as one of the 25 most frequently encountered drugs for the period 
between January through June 2014 and it was temporarily scheduled in March 2014.13 
Psychosis,178 tachycardia, hallucination, anxiety, increased heart and respiratory rate, and 
death,179,180 have also been reported due to α-PVP (71).179 
 
Early results indicated that the α-n-propyl substituent of α-PVP (71) might be optimal for 
action as a DAT reuptake inhibitor. Consequently we extended and branched the α-
substituent in order to obtain additional information concerning the role of bulk in this 
region of the molecule on reuptake potency. The next part of this project was to study the 
effects of the length and bulk of the extended (i.e., α-n-propyl) side chain of α-PVP (71), 
and the size of the terminal amine ring (expansion of the 5-membered pyrrolidine ring) 
(Table 10). This might be considered as the “elaboration” phase of this study based on 
what was already known. 
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Table 10. Analogs of α-PVP (71) investigated in the current study. 
 
                                                                   
Compound 
number 
R 
96 -H 
97 -CH3 
98 -CH2CH3 
71 -CH2CH2CH3 
99 -CH(CH3)2 
100 -CH2(CH2)2CH3 
101 -C5H9 
102 -C6H11 
103 -CH3 
104 -CH2CH2CH3 
 
e. Methods 
i. Synthesis- Compounds 99, 101, 102, and 104 were synthesized by Dr. Kolanos and 
compound 100 by Dr. Jain and their synthesis is discussed in Kolanos et al.181 Synthesis of 
N
RO
71, 96-102
N
RO
103, 104
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compound 96 and 103 are shown in Schemes 2 and 3. Compound 97 was synthesized in 
laboratory (Scheme 3), however data was reported for it earlier in the same assay and was 
hence not investigated again. 
 
Scheme 2. Synthesis of compound 96a 
 
aReagents: (a) Pyrrolidine, benzene; (b) pyrrolidine; (c) Et3N, pyrrolidine, benzene. 
 
For the synthesis of compound 96 three different routes were attempted. In Route 1 
(Scheme 2) a hydrochloride salt of 96 was attempted but it was extremely sticky and could 
not be recrystallized. In Route 2 (Scheme 2) pyrrolidine was used as solvent and this route 
was attempted twice. In the first attempt a hydrochloride salt was tried and led to the 
formation of a sticky salt, so an oxalate salt was attempted that precipitated (not a very free 
flowing powder) only after were Et2O and MeOH washings. During the second attempt of 
Route 2 (Scheme 2) the final product was obtained as the oxalate salt of pyrrolidine that 
was characterized by NMR and had a mp (melting point) of 115-117 °C. The reaction was 
then modified (Route 3, Scheme 2) such that one equivalent of Et3N and one equivalent of 
pyrrolidine were used. The reaction generated Et3N as a hydrobromide salt as a side 
b
N
O
Br
O
105
96
c
a Route 1
Route 2Route 1
Route 3Route 1
x
x
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product that was insoluble in benzene and was removed by filteration. This route thus 
prevented the use of an excess of pyrrolidine and prevented the formation of the 
pyrrolidine salt.  
 
Scheme 3. Synthesis of compounds 97 and 103a 
 
aReagents: (a) Pyrrolidine, benzene; (b) piperidine, benzene. 
 
 
 
 
CH3
N
OCH3
Br
O
106 103
b
a
N
O
97
CH3
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ii. In vitro uptake inhibition in rat brain synaptosomes 
This assay was perfomed in Dr. Baumann’s laboratory at NIDA. 
 
Subjects. Male Sprague−Dawley rats (Charles River, Wilmington, MA, USA) weighing 
250−350 g were housed three per cage with free access to food and water and maintained 
on a 12 h light/dark cycle with lights on from 7:00 a.m. to 7:00 p.m.  
 
Animal facilities were accredited by the Association for the Assessment and Accreditation 
of Laboratory Animal Care, and procedures were carried out in accordance with the 
Institutional Animal Care and Use Committee and the National Institutes of Health 
guidelines on care and use of animal subjects in research (National Research Council, 
2011). 
 
Procedure. [3H]Transmitters (specific activity ranging from 30 to 50 Ci/mmol) were 
purchased from PerkinElmer (Shelton, CT, USA). All other chemicals and reagents were 
acquired from Sigma-Aldrich (St. Louis, MO, USA). Rats were euthanized by CO2 
narcosis, and brains were processed to yield synaptosomes as previously described.182 Rat 
caudate tissue was used for DAT assays, whereas rat whole brain minus caudate and 
cerebellum was used for SERT assays. In uptake inhibition assays, 5 nM [3H]DA and 5 nM 
[3H]5-HT were used to assess transport activity at DAT and SERT, respectively.  
 
The selectivity of uptake assays was optimized for a single transporter by including 
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unlabeled blockers to prevent uptake of [3H]transmitter by competing transporters.  
Uptake inhibition assays were initiated by adding 100 µL of tissue suspension to 900 µL 
Krebs−phosphate buffer (126 mM NaCl, 2.4 mM KCl, 0.83 mM CaCl2, 0.8 mM MgCl2, 
0.5 mM KH2PO4, 0.5 mM Na2SO4, 11.1 mM glucose, 0.05 mM pargyline, 1 mg/mL 
bovine serum albumin, and 1 mg/mL ascorbic acid, pH 7.4) containing test drug and [3H] 
transmitter. Uptake inhibition assays were terminated by rapid vacuum filtration through 
Whatman GF/B filters, and retained radioactivity was quantified by liquid scintillation 
counting. Statistical analyses were carried out using GraphPad Prism (v. 6.0; GraphPad 
Scientific, San Diego, CA, USA). IC50 values for inhibition of reuptake were calculated 
based on nonlinear regression analysis. 
 
iii. Correlational Studies  
QSAR studies were performed using the α-substituent volume and lipophilicity. Volume 
(vol) was calculated using SYBYL-X 2.1 (Tripos Inc., St. Louis, MO). All the molecules 
were sketched using SYBYL-X 2.1 and were energy minimized with the Tripos Force 
Field option. Then numbers for volume were generated for the entire molecules using the 
MolCAD plus option within the SYBYL program. Because 71 and 96-102 differed only in 
the nature of their α substituent, differences in total volume reflect the volume of that 
substituent. Lipophilicity (π) values for individual substituents were obtained from the 
primary literature.183 Linear regressions and statistical analyses were performed between 
both these parameters and in vitro reuptake inhibition potency at DAT (pIC50 values) 
using the software Prism 5.04 (GraphPad, San Diego, CA, USA), and correlations with a p 
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<0.05 were considered statistically significant. pIC50 values, volume, and π values used in 
this investigation are shown in Table 11. 
 
f. Results 
Each of the compounds investigated displayed activity as reuptake inhibitors at DAT with 
varying potencies (see Table 11). Removal of the extended side chain (i.e., compound 96) 
(IC50= 3250 nM) resulted in a compound that was 185 times less potent than the parent 
compound α-PVP (71), which had an IC50 of 17.5 nM. Decreasing the α-n-propyl side 
chain of α-PVP (71) to α-n-ethyl (i.e., compound 98) made it about 4-fold less potent (IC50 
= 63.3 nM) than α-PVP (71) and a further decrease in potency by about 11-fold was 
observed when this extended side chain was decreased to its methyl analog (97, IC50 = 
196.7 nM). However, increasing the α-n-propyl chain length of α-PVP (71) by one carbon 
atom to the α-n-butyl analog (100, IC50 = 11.6 nM) increased potency marginally (about 2-
fold).  
 
Another objective was to investigate the steric bulk that can be tolerated at the α-position. 
The isopropyl analog (i.e., compound 99) (IC50 = 92.3 nM) was 5-fold less potent than α-
PVP (71) but the other two bulky substituted compounds (i.e., compounds 101 (IC50 = 17.1 
nM) and 102 (IC50 = 8.3 nM)) were comparable and twice as potent to α-PVP (71), 
respectively. 
 
 97 
Table 11. Volume and π values used in the QSAR investigation and potency of α-PVP 
(71) and its analogs (96-104) as inhibitors at DAT.a 
                     
Compound 
number 
R Volume 
(Å3) 
Lipophilicity 
(π)183 
 
IC50 nM (SEM) 
96 -H 175.39 0    3,250 ±418 
97 -CH3 189.05 0.46       196.7b 
98 -CH2CH3 211.61 1.02         63.3b 
71 -CH2CH2CH3 229.00 1.55 17.5 ±1.7 
99 -CH(CH3)2 231.20 1.53   92.3 ±11.6 
100 -CH2(CH2)2CH3 246.19 2.13   11.6 ±0.6 
101 -C5H9 253.22 2.14    17.1 ±2.5 
102 -C6H11 270.47 2.82       8.3 ±1.1 
103 -CH3   2,490 ±241 
104 -CH2CH2CH3   128 ±13 
a Compounds had no activity at SERT at 10,000 nM. b Data reported earlier.171 
 
Ring expansion at the terminal amine, (i.e., expanding from a pyrrolidine to a piperdine) 
resulted in compounds with decreased potency. Compounds 103 (IC50 = 2490 nM) and 104 
N
RO
71, 96-102
N
RO
103, 104
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(IC50 = 128 nM) were 10-fold less potent than their pyrrolidine counterparts 97 and 71, 
respectively. 
 
Cursory inspection of the results from the in vitro uptake studies at DAT suggested a 
relationship between potency and the size of the α-substituent. Hansch analysis was 
conducted between the pIC50 values of the compounds excluding 103 and 104, because 
they had piperidine rings instead of pyrrolidine and the volume and lipophilic character of 
the α-substituent. Statistically significant correlations were observed with both parameters; 
r = 0.909, p = 0.0017 for volume and r = 0.917, p = 0.0013 for lipophilic character (Figure 
22). However, the two parameters investigated were intercorrelated (r = 0.997, p < 0.0001). 
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Figure 22. Relationship between pIC50 for inhibition of DAT versus substituent volume in 
Å3 (upper panel; r = 0.909, p = 0.0017) and lipophilicity (π) (lower panel; r = 0.917, p = 
0.0013) for compounds 71 and 96-102. 
 
e. Discussion 
In the current examination we used α-PVP (71) as a parent compound and examined the 
effects of chain length and steric bulk at the α-position, and ring expansion of the 
pyrrolidine ring. A systematic decrease in chain length from n-propyl (71) to ethyl (98), 
methyl (100), and eliminating the chain altogether (71), resulted in a systematic decrease in 
potency (to 185-fold). However homologation of the side chain resulted in a compound, 
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100, that had comparable potency to α-PVP (71) indicating that reuptake activity is 
optimal with increased chain length at the α-position.  
 
Steric bulk and/or branching were also found to contribute to activity. The branched iso-
propyl analog 99 had activity comparable to the unbranched analog 98. Similarly, the 
cyclopentyl analog 101 had comparable or improved activity to its linear analogs 71 or 
100, and a further increase in steric size with the cyclohexyl analog 102 gave the most 
potent compound examined in this series. All the branched/bulky analogs (i.e., 99, 101, 
102) were about 2- to 24-fold more potent than 97.  
 
The results from Hansch analysis indicated that reuptake activity at DAT was correlated 
with the volume and lipophilic character of the α-position substituent. Due to the 
intercorrelation between the two parameters, additional compounds will need to be 
examined to better understand which of the parameters is most important for activity. 
 
The two 6-membered ring-expanded analogs (i.e., 103 and 104) were less potent than their 
5-membered pyrrolidine counterparts (i.e., 71 and 97) implying that the pyrrolidine ring 
might be optimal for activity and a ring size larger than five is not as well tolerated.  
 
We provided information that increased bulk and chain length at the α-position of MDPV-
like cathinones resulted in increased potency as DAT reuptake inhibitors however access 
into the transporter might be, up to some point, limited by the bulk on the nitrogen and α-
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side chain. Increased lipophilicity might increase diffusion into the CNS; however, making 
the compounds too bulky might hinder their entry into the transporter. Based on our results 
it can be suggested that DAT probably has a hydrophobic cavity that is occupied by the 
extended side chain. Also the transporter seems to accommodate a 5-membered ring better 
as compared to a 6-membered ring. Additional compounds and modeling studies will need 
to be conducted to provide credence.  
 
For example, additional compounds that could be investigated to substantiate that the 5-
membered ring is optimal would be an α-PVP analog with a 4- (azetidine) or 3-membered 
(aziridine) ring. Additional compounds to address the importance of which parameter, 
volume or lipophilicity, and to determine the maximum length and bulk that can be 
tolerated at the α-position, are required and warranted, and are currently being prepared in 
the laboratory.  
 
Meltzer et al.,184 were the only other group to report on the monoamine uptake activity of a 
series of substituted pyrovalerophenones. Although they tested pyrovalerophenones with 
substituents on the aromatic ring, and in our series we used unsubstituted analogs, 
comparisons between their results and ours can be made based on their 3,4-dichloro-α-
PVP analog (107). With respect to 107, they found that their analogs have weak reuptake 
activity at SERT compared to DAT, ring expansion to the piperidine moiety resulted in a 
15-fold decrease in potency, and decreasing the side chain from n-propyl to ethyl resulted 
in a compound with comparable potency.184  
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Other groups have also investigated some of the analogs investigated by us for their in vivo 
effects. For example, compound 97 and 98 produced dose- and time-dependent stimulation 
of locomotor activity,171 and 98 also showed conditioned place preference and fully 
substituted for METH (5) and cocaine in drug discrimination studies.176 But, none of these 
studies investigated SAR (or QSAR) in a systematic manner. 
 
It also can be observed that MDPV-like cathinones are practically inactive at SERT and 
other groups have reported this as well.160 Methylphenidate (6), which is another reuptake 
inhibitor, also is practically inactive at SERT compared to DAT. It has an IC50 = 84 nM for 
DAT but its inhibitory potency for SERT is >50,000 nM.107 The binding cavity (S1) 
indicated in crystal structures of dDAT for nortriptyline, AMPH (S(+)2), METH (S(+)4) 
and cocaine is well conserved between DAT and SERT (will be discussed in the next 
chapter in greater detail). It raises curiosity then, that, even though both transporters share 
a binding cavity that is highly homologous, these compounds are inactive at SERT. The 
crystal structure is a snapshot of the transporter in one of its conformations; it can be 
suggested, then, that it is probably the mechanism in which the two transporters provide 
access to the compounds that might be different. Hypothetically MDPV-like compounds 
N
O
Cl
CH3
Cl
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could bind to this common site, but they just can’t get there. This idea needs to be 
supported by crystallographic or mutagenesis studies.  
 
Overall, we have now provided the first study on the SAR/QSAR of the first synthetic 
cathinone DAT reuptake inhibitor (i.e., MDPV (63)) (see Figure 23). 
 
Figure 23. A summary of structural features (a-d) examined for the inhibition of reuptake 
at DAT. See below text for discussion. 
 
A variety of MDPV (63) analogs was examined and it was found that various structural 
features impact action as DAT reuptake inhibitors (Figure 23). In general a) a tertiary 
amine is preferred, with pyrroilidine being optimal, b) an elongated or bulky chain is 
preferred, with cyclohexyl being optimal, c) the 3,4-methylenedioxy group of MDPV (63) 
makes minimal contribution, d) the carbonyl group contributes to activity. In order to act 
as reuptake inhibitors, synthetic cathinones should bear either a tertiary amine or an 
extended side chain; it would appear that the presence of both is preferred. 
 
 
 
b 
O
O
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N
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d 
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AIM II. Quantitative structure-activity relationship analysis, molecular modeling and 
hydropathic interaction analysis of the pharmacology of p-substituted methcathinone 
analogs 
 
a. Introduction 
MCAT (57), the first synthetic cathinone analog,5 is the parent scaffold for many of the 
new emerging synthetic cathinones such as those found in “bath salts”.22 It exerts its action 
primarily through DAT via the release of DA.5 Its behavioral and in vitro actions were 
described in detail in the Background section.  
 
MEPH (62), one the original “bath salts” components, is the p-methyl analog of MCAT 
(57). However, MEPH (62) possesses a lower in vitro selectivity for DAT over SERT,159 
and in ICSS studies conducted by our collaborators, its abuse-related effects were less 
efficient than that of MCAT (57).146  
 
Most recently, others have found similar results with flephedrone (72) and methedrone 
(73), two other MCAT analogs that differ in their in vitro and behavioral effects.161,162,185 
Flephedrone (72) exerts its action primarily through DAT over SERT whereas methedrone 
(73) demonstrates an opposite selectivity.161,162 In locomotor stimulation assays 
flephedrone (72) has more pronounced effects than methedrone (73) in mice.185 Both of 
these compounds were given temporary U.S. Schedule I status early last year.21 
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MEPH (63), flephedrone (72), and methedrone (73) differ from MCAT (57) only in their 
4-position substituent but produce distinct behavioral and neurochemical effects.  
 
The objective of this next study was to understand the influence of the 4-position 
substituent on MCAT analogs on both their behavioral and neurochemical effects. With 
this purpose, we varied the nature of the 4-position substituent on MCAT (57) across three 
parameters: steric, electronic, and lipophilic (Table 12) so we could conduct QSAR studies 
to understand how the physicochemical nature of the 4-position substituents can influence 
activity at DAT and SERT. 
 
MCAT (57) and its analogs were evaluated for their in vitro actions on DAT and SERT 
using rat synaptosomes, and their in vivo abuse potential was evaluated by an ICSS assay. 
The ICSS assay is a type of a self-administration assay where the animal under study 
presses a lever for an electrical impulse delivered via a microelectrode implanted typically 
in the ventral tegmental area or the medial forebrain bundle. Drugs of abuse such as 
AMPH (2) that are selective for DAT can facilitate low rates of ICSS that are characterized 
by low frequencies of brain stimulation and this characteristic facilitation is an indication 
of the abuse-related effects of the drug. On the other hand, drugs that are selective for 
SERT, such as fenfluramine (7), depress ICSS rates maintained by high frequencies of 
brain stimulation and this effect is a characteristic of their abuse-limiting effects.186 
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 Table 12. 4-Substituted MCAT analogs investigated in in vitro and in vivo assays. 
 
 
Agent Acronym R 
Methcathinone (57) MCAT -H 
Flephedrone (72) 4-F MCAT -F 
Methedrone (73) 4-OCH3 MCAT -OCH3 
4-Chloromethcathinone (74) 4-Cl MCAT -Cl 
4-Bromomethcathinone (75) 4-Br MCAT -Br 
Mephedrone (62) 4-CH3 MCAT -CH3 
4-Trifluoromethylmethcathinone (76) 4-CF3 MCAT -CF3 
 
The three parameters initially used for conducting the QSAR studies were; Taft’s constant, 
lipophilicity and electronic character. Es, Taft’s constant, is a parameter that factors in both 
potential energy-related steric strain effects and kinetic energy-related steric hindrance to 
motion effects. It is calculated by measuring the hydrolysis rates of various esters.187,188 Es 
is a general steric parameter and if a relationship between the pharmacology and Es is 
obtained, other well-defined parameters such as Verloop parameters and substituent 
volume can be examined. Verloop parameters incorporate length (L), minimum (B1) and 
CH3HN
CH3
O
R
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maximum width (B5) of a substituent, and these are computationally calculated.189  The 
ability of a molecule to be accessible to, and to interact with, its target depends upon its 
lipophilicity, and the second parameter to be used is lipophilicity (π). Lipophilicity is the 
ability of a molecule to partition itself between aqueous and organic phases and is measure 
that can judge the ability of a molecule to penetrate a lipid membrane.190 Another 
parameter that can influence the interaction between a molecule and its target is the 
electronic character (σ) of the substituted groups on a molecule. Also known as the 
Hammett σ parameter, it is one of the oldest parameters used in QSAR studies and is 
experimentally derieved from the hydrolysis of substituted benzoic acids.191 It is associated 
with the free energy change when a molecule binds to its target protein.191 In our study of 
the 4-position (para) substitutents, σp values were used. 
 
Verloop parameters are calculated using the STERIMOL program. Initially Verloop 
devised five descriptors, this number was chosen as a compromise between the shape of 
the molecule and avoiding a multitude of descriptors. The initial descriptors were length 
(L) and width (B1-B4), where L is the length of the substituent along the axis of the bond 
between the first atom of the substituent and the parent molecule and B1-B4 are four width 
parameters calculated perpendicular to the length and also to each other.189 B1 is the 
minimum width and B2-B4 is then followed in ascending order. Subsequently, Verloop 
modified these parameters due to redundancy in the width parameters to include a slightly 
modified length parameter, the minimum width B1 and a new parameter B5 that represents 
the maximum substituent width.  
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In addition, we constructed homology models both of hDAT and hSERT to examine the 
results obtained from the QSAR studies. The program HINT (Hydropathic INTeractions) 
was used as a means to further analyze the docking solutions. HINT calculates the 
hydrophobic and polar interactions between a ligand and a protein and provides insight 
into the energy contributions made between the ligand and a protein (i.e., specifically, 
amino acids that might be involved in drug-receptor interactions).192  
 
b. Methods 
i. Synthesis  
This, as were other projects described herein, was a collaborative effort involving other 
members in our laboratory. Others in our laboratory synthesized some the compounds 
employed for this study except for 4-F MCAT (72), and 4-CF3 MCAT (76) was provided 
by Dr. Cozzi. Synthesis of compound 72 is outlined in Scheme 4. 
 
Scheme 4. Synthesis of compound 72a 
 
aReagents: (a) Br2, AlCl3, Et2O; (b) CH3NH2 in EtOH, benzene. 
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ii. In vitro release in rat brain synaptosomes  
This assay was performed in Dr. Baumann’s laboratory at NIDA. A detailed description of 
the methods can be found in Bonano et al.193 
 
iii. Intracranial self-stimulation in rats     
This assay was performed in Dr. Negus’s laboratory at Virginia Commonwealth 
University. A detailed description of the methods can be found in Bonano et al.193 
 
iv. Correlational studies 
  Drs. Bonano and Glennon initially conducted the QSAR studies with Es, π, and σp and 
their methods are reported in Bonano et al.193 They found that significant correlations 
were obtained with Es and in vitro log DAT selectivity and in vivo ICSS facilitation. No 
correlation was evident between activity and π or σp. Consequently, we investigated other 
steric parameters that might better explain the role of these features towards activity. 
These included volume and Verloop parameters. 
 
 For our QSAR studies, substituent volume was calculated using SYBYL-X 2.1 (Tripos 
Inc., St. Louis, MO). The S isomer of each of the compounds was sketched in SYBYL and 
volume values were generated for the entire molecule using the Molcad option within the 
SYBYL program. Verloop’s steric parameters of length (L), minimum width (B1), and 
maximum width (B5) were obtained from the literature.189 Linear regressions and 
statistical analyses were performed using Prism 5.04 (GraphPad, San Diego, CA, USA) 
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between each of these physiochemical parameters and in vitro log EC50 DAT, log EC50 
SERT and in vitro DAT/SERT selectivity and the in vivo ICSS maximum percent baseline 
facilitation, and correlations with a p <0.05 were considered statistically significant. 
Values used for all parameters are shown in Table 13. 
 
Table 13. Values used for all parameters used in the QSAR studies. 
 
Compound 
Vola 
 
(Å3) 
(L)a 
(Å) 
(B1)a 
(Å) 
(B5)a 
(Å) 
Esb σpb πb 
MCAT (57) 150.36 2.06 1.00 1.00 1.24 0 0 
4-F MCAT (72) 153.78 2.65 1.35 1.35 0.78 0.06 0.14 
4-OCH3 MCAT (73) 175.01 3.98 1.35 3.07 0.69 -0.27 -0.02 
4-Cl MCAT (74) 164.43 3.52 1.80 1.80 0.27 0.23 0.71 
4-Br MCAT (75) 169.43 3.83 1.95 1.95 0.08 0.23 0.86 
4-CH3 MCAT (62) 166.89 3.00 1.52 2.04 0.00 -0.17 0.56 
4-CF3 MCAT (76) 178.40 3.30 1.98 2.61 -1.16 0.54 0.88 
aObtained from Verloop et al.189  bObtained from Wolff, M.E.194 
  
v. Homology modeling and docking studies 
Dr. Renata Kolanos constructed the homology model for hDAT and a detailed method for 
its construction has been reported.195 Here, we report the construction of a SERT model. 
A homology model for hSERT was constructed in a manner similar to that employed for 
hDAT using the crystal structure of Drosophila melanogaster (dDAT) (PDB code 4M48) 
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as a template as it shares over 50% homology with its mammalian counterparts and is a 
hybrid of all three monoamine transporters DAT, SERT and NET.117  
 
The sequence for hSERT (accession code P31645) was obtained from the SwissProt-
ExPASY databank and was aligned with dDAT using ClustalX 2.1 (Figure 24).196 One 
hundred models of hSERT were generated using MODELLER 9.10,197 and in each of these 
models the first 76 residues from the N-terminus, 13 residues from the end of the C-
terminus, and 7 residues from extracellular loop 2, were truncated due to lack of the 
corresponding residues in the dDAT template. The two sodium ions and one chloride ion 
was extracted from dDAT and incorporated into each of the hundred models. The sodium 
and chloride ions have been proposed to play a role in the mechanism of action of DAT 
and SERT and they might also affect the overall conformation of the transporter since the 
rotameric states of the side chains of the amino acids around the ions might be 
different.198,199 These ions are also in the ligand-binding pocket and could influence the 
ligand-transporter interactions.117,119 Furthermore the amino acid residues forming the 
binding sites for the two sodium ions and the chloride ion are highly conserved in the 
dDAT, hDAT and hSERT transporters (Table 14). 
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 Figure 24. ClustalX-based alignment of the dDAT crystal structure, hDAT (UniProt ID = 
Q01959) and hSERT (UniProt ID = P31645) primary amino acid sequences. The colored 
boxes represent the transmembrane helical domains. Symbols indicate the degree of amino 
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acid conservation: ‘*’ for a fully conserved position, ‘:’ for strong conservation, ‘.’ for 
weaker conservation, and no symbol for a non-conserved position. 
 
Non-structure water molecules found in the crystal structure of dDAT were omitted from 
each of the models. The S-isomer of each ligand to be docked was sketched using SYBYL-
X 2.1 and energy-minimized using the Tripos Force Field. The binding cavity was defined 
using the nortriptyline molecule that was cocrystallized with dDAT and a 5-Å radius was 
set around it. The automated docking program GOLDSuite 5.2200 was used to dock each of 
the ligands to the one hundred transporter models.  
 
Table 14. Residues interacting with the two sodium ions and the chloride ion in dDAT, 
hDAT, and hSERT. 
 
 dDAT 
crystal 
structurea 
Current 
hDAT 
model 
Current 
hSERT 
model 
Na+1 ---- 
A44 
N49 
S320 
N352 
D79  
A77 
N82 
S321 
N353 
D98 
A96 
N101 
S336 
N368 
Na+2 G42 
V45 
L417 
D420 
S421 
G75 
V78 
L418 
D421 
S422 
G94 
V97 
L434 
D437 
S438 
Cl– Y69 
Q316 
S320 
S356 
Y102 
Q317 
S321 
S357 
Y121 
Q332 
S336 
S372 
 
A total of 10 genetic algorithm-docking runs were performed for each docked ligand, and 
docking simulations were performed without any constraints and were not subjected to 
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early termination. Using clustering techniques and SYBYL Programming Language (SPL) 
scripts (written by Dr. Philip D. Mosier), putative modes of transporter-ligand interactions 
were obtained. The most populated clusters, high Gold Scores and rational interactions 
observed with the ligand and transporter, identified the most favorable transporter-ligand 
complex for each of the docked ligands, and these were then energy minimized using 
SYBYL-X 2.1. 
 
HINT studies were conducted with the assistance of Dr. Mosier both on hSERT and hDAT 
models. The HINT program, found within SYBYL 8.1 (Tripos Inc.) was employed.192 For 
the initial partition phase, the dictionary method was used for the transporter and the 
calculation method for the ligands. In the Intermolecular HintTable calculation phase, the 
‘proton suppress’ button option was deactivated keeping all the other parameters to their 
default values. Only the interactions involving the 4-position substituent with residues on 
the transporter were analyzed and used for correlational studies. 
 
c. Results 
i. Results from in vitro assays 
Results from in vitro synaptosomal release assays indicated that all the 4-position-
substituted MCAT analogs tested were releasers both at DAT and SERT (Table 15 and 
Figure 27) but with varying selectivity for the two transporters. Selectivty for DAT and 
SERT of the compounds spanned a >4000-fold range with MCAT (57) demonstrating the 
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highest selectivity for DAT, whereas 4-CF3 MCAT (76) displayed the least selectivity for 
DAT. 
 
Figure 25. Effects of selected test agents on DAT- and SERT-mediated monoamine 
release in rat brain synaptosomes. All points show mean ± SD for N=3 separate 
experiments.  EC50 values shown in Table 15 were derived from these concentration-effect 
curves.193 
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Table 15. In vitro release activity at DAT and SERT and in vivo behavioral ICSS effects 
of MCAT and its analogs. 
                                                            
Agent R DAT  
 EC50 (nM) 
SERT    
 EC50    (nM) 
DAT 
Selectivity 
ICSS 
Maximum 
% Baseline 
Facilitation 
MCAT (57) -H      12.5±1.1     3,860±520    309 191.9 
4-F MCAT 
(72) 
-F      83.4±1.1     1,290±220      15.4 156.3 
4-OCH3 
MCAT (73) 
-OCH3    506±62        120±18      0.24 110.9 
4-Cl MCAT 
(74) 
-Cl      42.2±5.2        144±22      3.40 114.9 
4-Br MCAT 
(75) 
-Br      59.4±5.1          60.2±6.7      1.01 118.0 
4-CH3 MCAT 
(62) a 
-CH3      49.1±8.3        118±26      2.41 102.5 
4-CF3 MCAT 
(76) b 
-CF3 2,700±300        190±30      0.07 90.9 
aData published previously in Baumann et al.159 bData published previously in Cozzi et 
al.201 All synaptosomal assays were conducted under similar conditions by Dr. Baumann 
and, hence, data are comparable. 
 
ii. Results from ICSS studies 
Our group has reported results for MCAT (57) and MEPH or 4-CH3 MCAT (62) 
previously and, in the current investigation, all the other analogs were tested and their 
results are shown in Table 15 and Figure 26. All the compounds produced a dose-
CH3HN
CH3
O
R
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dependent change in ICSS. 4-F MCAT (72) produced a dose-dependent facilitation of low 
rates of ICSS maintained by low brain frequency stimulations. 4-CF3 MCAT (76) produced 
a dose-dependent depression of high rates of ICSS maintained by high brain frequency 
stimulations. The remaining compounds 4-OCH3 MCAT (73), 4-Cl (74) and 4-Br MCAT 
(75) produced ICSS effects that were a combination of the above two compounds, they 
produced a facilitation of low rates of ICSS but at higher doses they depressed high rates 
of ICSS maintained by high brain stimulation frequencies. For a detailed description of the 
results see Bonano et al.193 
 
iii. Correlational studies 
Initial QSAR studies on Es, π, and σp were reported by us earlier.193 Significant 
correlations obtained were with the steric constant Es and in vitro log DAT selectivity (r = 
0.78, p = 0.04) and in vivo maximal ICSS facilitation (r = 0.81, p = 0.03). There was no 
significant correlation between π and σp for either in vitro log DAT selectivity (r = -0.52, p 
= 0.23 and r = -0.29, p = 0.53, respectively) or in vivo maximal ICSS facilitation (r = -
0.66, p = 0.11 and r = -0.24, p = 0.61, respectively).193 
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Figure 26. Effects of 4-F MCAT (72), 4-OCH3 MCAT (73), 4-Cl MCAT (74), 4-Br 
MCAT (75), and 4-CF3 MCAT (76) on ICSS. Left panels show drug effects on full ICSS 
frequency-rate curves. % MCR is %Maximum control rate. Drug doses are indicated in 
legends in units of mg/kg. Filled points represent frequencies at which reinforcement rates 
were statistically different from vehicle rates as determined by two-way ANOVA followed 
by Holm-Sidak post hoc test, p<0.05. Right panels show summary ICSS data expressed as 
percent pre-drug baseline number of stimulations delivered across all frequencies. 
Upward/downward arrows indicate significant drug-induced increases/decreases in ICSS 
relative to vehicle for at least one brain stimulation frequency as determined by analysis of 
full frequency-rate curves. All data show mean ± SEM for five rats (4-F MCAT (72)) or 
six rats (all other drugs).193 
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Due to a significant correlation between the general steric parameter Es and the in vivo and 
in vitro data, we performed QSAR studies using better-defined steric parameters. Results 
from QSAR analyses using the 4-position substituent volume (Vol), minimum width (B1), 
maximum width (B5) and length (L) are shown in Table 16. 
 
Table 16. Results of correlational analysis between steric parameters, in vitro potencies at 
DAT and SERT, and maximal ICSS facilitation. Significant correlations (p < 0.05) are 
highlighted in bold. 
 
Physicochemical 
Parameter 
log EC50 DAT log EC50 SERT log DAT 
Selectivity 
Maximal ICSS 
Facilitation 
Volume (Vol) r = -0.803 
p = 0.03 
r = 0.825 
p = 0.02 
r = -0.972 
p < 0.01 
r = -0.915 
p < 0.01 
Length (L) r = -0.404 
p = 0.26 
r = 0.903 
p < 0.01 
r = -0.840 
p = 0.03 
r = -0.773 
p = 0.04 
Minimum width 
(B1) 
r = -0.416 
p = 0.28 
r = 0.762 
p = 0.05 
r = -0.727 
p = 0.06 
r = -0.778 
p = 0.04 
Maximum 
Width (B5) 
r = -0.807 
p = 0.03 
r = 0.720 
p = 0.07 
r = -0.917 
p < 0.01 
r = -0.814 
p = 0.03 
 
 
Log EC50 DAT was negatively correlated with volume and maximum width of the 4-
position substituent (i.e., a smaller volume and width of the 4-position substituent 
contributes to increased potency at DAT (Figure 27)). Log EC50 SERT was positively 
correlated with the 4-position substituent volume, length, and maximum width (i.e., larger 
volume, length and width of the 4-position substituent contributes to increased potency at 
SERT (Figure 28)). Log DAT selectivity was negatively correlated with volume, length 
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and maximum width of the 4-position substituent (Figure 29) and maximal ICSS 
facilitation was negatively correlated with all the parameters (Figure 30).  
 
 
Figure 27. Relationships between log EC50 for DAT release and volume, maximum width, 
minimum width and length of the 4-position substituents of MCAT (57, 62, 72-76). 
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Figure 28. Relationships between log EC50 for SERT and volume, maximum width, 
minimum width and length of the 4-position substituents of MCAT (57, 62, 72-76). 
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Figure 29. Relationships between log DAT selectivity and volume, maximum width, 
minimum width and length of the 4-position substituents of MCAT (57, 62, 72-76). 
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Figure 30. Relationships between maximal ICSS facilitation and volume, maximum width, 
minimum width and length of the 4-position substituents of MCAT (57, 62, 72-76). 
 
iv. Molecular modeling and HINT analysis 
Docking studies on the hDAT model were conducted by Dr. Kolanos and are reported in 
Sakloth et al.195 The results from the paper are included here as a means for comparison of 
the hDAT and hSERT models. 
 
The homology model of hDAT (Figure 31A) is consistent with available site-directed 
mutagenesis data.202-205 For hDAT, the docked MCAT solutions show extensive spatial 
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overlap in the putative binding mode (Figure 31A). The models suggest that the charged 
terminal amine of the MCAT analogs interacts favorably with the D79 side chain 
carboxylate group, as has been reported for DA and releasing agents such as S(+)AMPH 
(S(+)2).206,207 Previous mutations of this residue (i.e., D79A, D79G, D79E) suggest that it 
plays a role in the binding of DA; these mutations led to the loss of the DA-reuptake 
function of the transporter.204 In addition, our model shows that a hydrogen bond exits 
between the backbone carbonyl group of F76 and the charged terminal amine. It already 
has been shown that the mutation F76A dramatically reduced the DA uptake Vmax value.203  
 
Other residues, including F76, V152, Y156, S422, and G426, engage in hydrophobic 
interactions with the phenyl ring. Earlier studies of DAT indicated that V152, F156, and 
S422 play a crucial role in the transport of DA. Mutants of hDAT (V152I, V152A and 
V152M) displayed remarkably reduced DA uptake.205 Mutations of the strictly conserved 
residue Y156 (Y156A and Y156C) resulted in inactive transporters.202 Also, S422 has been 
implicated to bind DA through an interaction with its hydroxyl groups; a reported mutation 
of this residue (S422A) resulted in decreased DA uptake.202 
 
 Our model predicts that F76, F320, and F326 interact with the α-methyl group. The N-
methyl group is directed toward a small pocket defined by F76, A77, F320, S321, and 
L322. The 4-position substituent is directed toward S149. Recent studies have indicated 
that, in hDAT, S149 might be important for coordination of the 4-OH group of DA.208 No 
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specific interactions with the carbonyl oxygen atom of MCAT analogs were identified in 
the binding site. 
 
All the compounds adopted an analogous pose in the hSERT-binding pocket (Figure 31B). 
A number of interactions were observed and the most important being the ionic interaction 
of the charged amine with the side chain carboxylate group of D98. This interaction has 
been observed with 5-HT in a previously published model.208 Mutagenesis studies have 
indicated that this residue is important for transporter function: D98G, D98A, D98N 
mutants were found to be inactive in uptake of 5-HT. Only the D98E mutation rendered 
the transporter active, which suggests that the ionic interaction with D98 is important.209,210 
 
We also observed a hydrogen bond between the backbone carbonyl of Y95 and the charged 
amine. Mutation studies of this residue Y95E and Y95R rendered the transporter non-
functional in a 5-HT uptake assay, whereas Y95F, Y95Q, Y95E decreased transporter 
activity as compared to the wild type.210 
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Figure 31. Superimposed poses of all seven MCAT analogs (57, 62, 72-76) in the putative 
binding site of hDAT (A), and hSERT (B). Interacting amino acids within 5 Ǻ are 
indicated. Unfavorable interactions of hDAT S149 with the 4-position substituents (shown 
for the 4-methoxy analog (73); (C) that are not seen in hSERT due to the smaller side 
chain of A169 (again, shown for the 4-methoxy analog; (D). The Connolly surface (shown 
in grey in C and D) represents the channels in both transporters. 
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The aromatic ring is buried in a hydrophobic pocket bound by Y95, I172, Y176, F341, 
S438, and G442. In addition, our model predicts a hydrophobic interaction with the 
aromatic ring of Y95 and G338 with the N-methyl group, and F341 with the α-methyl side 
chain. A pocket of hydrophobic residues lined by A169, I172, A173, T439, and L443 
surrounds the 4-position substituent. Residues (Y95, I172, Y176, F341, S438, G442, A169, 
I172, T439, and L443) that make hydrophobic interactions in our docking studies have 
been mutated previously, and the mutants showed decreased transporter activity in 5-HT 
uptake assays as compared to the wild type.210 
 
The polar, hydrophobic and total HINT scores were only calculated for the 4-position 
substituent both at hDAT and hSERT (Table 17). At hDAT the total and polar scores were 
negative and the hydrophobic scores, though positive, were not that high compared to 
those at hSERT. Though hSERT had negative polar scores, it had higher positive total 
HINT scores. A negative number in HINT studies implies unfavorable interactions and a 
positive HINT score implies favorable interactions. All three HINT scores correlated only 
with log EC50 at SERT (Table 18). 
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Table 17. Calculated HINT scores for interaction of MCAT analogs (57, 62, 72-76) with 
hDAT and hSERT. 
 
 HINT Score at hDAT (4-substituent only) 
 Total Polar Hydrophobic 
MCAT (57)   0      0     0 
4-F MCAT (72) 22   -11   33 
4-OCH3 MCAT (73) -88 -231 143 
4-CH3 MCAT (62)  -23 -154 131 
4-Cl MCAT (74)   2 -132 134 
4-Br MCAT (75) -13 -173 160 
4-CF3 MCAT (76)    -5   -63   58 
  
 HINT Score at hSERT (4-substituent only) 
MCAT (57)   0     0    0 
4-F MCAT (72) 51   -12   63 
4-OCH3 MCAT (73) 125 -154 279 
4-Cl MCAT (74) 136 -102 238 
4-Br MCAT (75)  135 -157 292 
4-CH3 MCAT (62) 78 -173 251 
4-CF3 MCAT (76)  97   -67 164 
 
Table 18. Correlations between HINT scores and log EC50 values at hDAT and hSERT. 
Statistically significant correlations (p<0.05) are highlighted in bold font. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HINT Score log EC50 DAT log EC50 SERT 
Total r = 0.044 
p = 0.93 
r = -0.864 
p = 0.01 
Polar 
Contribution 
r = 0.103 
p = 0.84 
r = 0.841 
p = 0.02 
Hydrophobic 
Contribution 
r = 0.057 
p = 0.90 
r = -0.910 
p < 0.01 
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d. Discussion 
 
The aim of the current investigation was to study the behavioral and neurochemical effects 
of a series of MCAT analogs (57, 62, 72-76) that differed only in their substitution at the 4-
position and identify what physicochemical parameters contributed to their distinct in vitro 
and in vivo actions. The in vivo data revealed that all the analogs were releasers at DAT 
and SERT. MCAT (57) displayed the highest selectivity (i.e., 309-fold) for DAT followed 
by 4-F MCAT (72) that had 15-fold selectivity; 4-CF3 MCAT (76) and 4-OCH3 MCAT 
(73) were the two compounds that displayed the least selectivity towards DAT (0.07 and 
0.24-fold respectively).  The 4-Cl (74), Br (75) and CH3 (62) MCAT analogs had 
intermediate selectivity for DAT (3.40, 1.01 and 2.41, respectively). ICSS data were 
consistent with the in vivo data and indicated that MCAT (57) and 4-F MCAT (72) 
produced an ICSS profile similar to DAT-selective agents such as AMPH (2) (a facilitation 
of low rates of ICSS), and 4-CF3 MCAT (76) and 4-OCH3 MCAT (73) produced ICSS 
profiles similar to those of SERT-selective agents such as fenfluramine (7) (decrease in 
ICSS rates). The 4-Cl (74), Br (75) and CH3 (62) MCATs had intermediate selectivity for 
DAT and SERT and produced mixed effects.  
 
As per Hansch,211 the electronic, hydrophobic and steric features of substituents can 
influence the ways in which molecules can affect biological activity, and identifying 
correlations between the physicochemical properties in relation to their biological activity 
can provide substantial information about the effects of substituents on biological activity.  
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All the structural features of the MCAT analogs, for example the 4-position substituent, 
terminal amine, aromatic ring and the α-methyl group, likely contribute to activity at DAT 
and SERT. However, we focused on the 4-position substituent, as the other structural 
features are constant amongst the series of MCAT analogs investigated (57, 62, 72-76).  
 
Steric factors are important parameters in understanding drug-receptor interactions. The 
binding site for the drug is made up of amino acids oriented in a particular manner such 
that it provides spatial complementarity with the drug. The Taft steric parameter Es was 
one of the first available parameters that integrates the effects of both steric strain and 
hindrance; however, it has been criticized in the manner in which it was developed (for e.g. 
it accounted for the intramolecular as opposed to intermolecular effects), and several 
modifications have been developed since.212 For example, one of the modifications was by 
Hancock to include the hyperconjugation effects (Esc), and Charton found that Es was 
linearly related to the van der Waal’s radius for symmetrical substituents or the minimum 
width for unsymmetrical ones.189,212 There are other parameters, too, that can probe the 
effect of steric factors, for example molar refractivity, and Charton’s parameters.  
 
Verloop used the STERIMOL program to computationally calculate the length, maximum 
width and minimum width of substituents.189 Having first established that steric parameters 
affect the activity of the 4-position substituted MCAT analogs,193 we used the above 
parameters to gain greater insight. The advantage of using Verloop parameters and volume 
is that they were not developed experimentally and are not subject to any experimental 
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assumptions and might provide more accurate results.213 Verloop parameters also have the 
advantage that they address three-dimensional issues of a compound. Since they are 
calculated computationally, they can be used for any group or substituent. The way 
Verloop parameters were calculated measured the dimensions of a substituent along 
several axes and, collectively, these values would provide information regarding the 
molecular shape especially for substituents that are nonsymmetrical. The older parameters 
were all a single value defining the steric nature of a substituent and did not always 
consider non-spherical molecules and were emperically derived.189  
 
 Preliminary QSAR studies indicated that large 4-position substituents contribute towards 
potency at SERT whereas small 4-position substituents contribute towards potency at 
DAT. Amongst the significant correlations observed between volume, maximum width, 
and length, and log DAT selectivity, the correlation with the volume parameter was the 
highest.  
 
Our modeling studies gave rise to new homology models for hSERT and hDAT based on 
the dDAT template. Docking studies indicated that MCAT (57) and its analogs adopt 
analogous poses in the hSERT-and hDAT-binding cavity. Residues identified in our 
studies to make interactions with ligands are consistent with available mutagenesis data. 
The residues at the binding cavity of the 4-position substituent are relatively conserved 
between both hSERT and hDAT except for S149 and V152 in hDAT and A169 and I172 
in hSERT. In our docking studies the 4-position substituent is oriented towards S149 in 
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hDAT and A169 in hSERT. S149 is a more polar residue as compared to the hydrophobic 
A169 and makes the binding pocket less accommodating towards substituents that are 
larger in size and provides an explanation towards decreased DAT selectivity for 
compounds with larger 4-position substituents. And this result is consistent with the in 
vitro data and QSAR data the compounds with larger 4-position substituents e.g. 4-CF3 
MCAT (76) and 4-OCH3 MCAT (73) exhibit the least selectivity for DAT whereas 
compounds with smaller 4-position substituents e.g. MCAT (57) and 4-F MCAT (72) 
exhibit the highest selectivity for DAT. HINT studies denoted that in the case of hSERT 
there are favorable hydrophobic interactions whereas at hDAT there are unfavorable polar 
interactions that contribute towards potency (though not statistically significant). This 
supports the docking studies that the polar residue S149 provides an unfavorable 
environment in the hDAT-binding pocket for larger 4-position substituents as compared to 
A169 that is a relatively smaller and more hydrophobic residue. Mutational studies 
especially of A169 in hSERT and S149 in hDAT should provide evidence to support our 
modeling studies, and such studies are currently underway. Once we completed our 
modeling studies we became aware of a similar study conducted by Severinsen et al.214 
where they studied a series of 1-phenylpiperazine analogues with varying 4-position 
substituents. The residues identified by them to make key interactions with their ligands 
are mostly consistent with ours (Table 19). Table 19 shows that nine of the twelve amino 
acids identified by us in the hDAT model pocket were identified in the earlier study, as 
well as eleven of the twelve amino acids in the hSERT model. It should be noted that their 
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models were constructed using a LeuT template which has a homology of around 20% 
with hDAT and hSERT.119 
Table 19. Amino acid residues implicated from docking studies. 
DAT (present study) DAT (Severinsen et al.)214 
D79 D79 
F76 F76 
V152 V152 
Y156 Y156 
S422 S422 
G426 G426 
F320 F320 
F326 F326 
A77  
S321  
L322  
S149 S149 
 V328 
 A423 
 G153 
  
SERT (present study) SERT (Severinsen et al.)214 
D98 D98 
Y95 Y95 
I172 I172 
Y176 Y176 
F341 F341 
S438 S438 
G442 G442 
G338  
A169 A169 
A173 A173 
T439 T439 
L443 S149 
 V343 
 F335 
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Shortly after we completed and published our studies, new x-ray crystal structures of 
dDAT crystallized with psychostimulants such as AMPH (S(+)2), METH (S(+)5) and 
cocaine were published.118 In order to compare our models to the published crystal 
structures, the structure of dDAT co-crystallized with METH (S(+)5) was used (PDB entry 
code 4XP6). METH (5) differs from our parent compound MCAT (57) by the presence of 
β- keto group, in the latter, and both share a common mechanism of action.  
 
Using SYBYL-X 2.1, 4XP6 was aligned by homology to our energy minimized MCAT 
(S(+)57) ligand merged with both the hDAT and hSERT homology models. Root mean 
square deviation values (RMSD) values were obtained. The degree of similarity between 
two proteins can be calculated based on their RMSD score; similar structures will have low 
scores in the 1-3 Å range and large values imply a greater deviation in similarity.215 The 
RMSD score between dDAT complexed with (+)METH (S(+)5)  and our energy-
minimized models with MCAT (S(+)57) was 1.39 for hDAT and 1.32 for hSERT. These 
low scores indicate a substantial three-dimensional similarity between our models and the 
crystal structure. 
 
In the case of both hDAT and hSERT the residues in the binding cavity are well aligned 
with those of 4XP6. Our results seem consistent with what was reported for METH 
(S(+)5). Wang et al.118 reported that the terminal amine of METH (S(+)5) makes an ionic 
interaction with D46 and the carbonyl group of F319. In our models the terminal amine 
makes the same ionic interaction with the homologous D79 and D98 and the backbone 
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carbonyl of the homologous F76 and Y95 in DAT and SERT, respectively. They also 
report hydrophobic edge-to-face interactions of the phenyl ring with F325. Our models 
predicted the phenyl ring to be engaged in hydrophobic interactions with residues such as 
F76 for hDAT and F341 for hSERT amongst others. 
 
Although the ligands both in SERT and DAT are not perfectly superimposable with 
(+)METH (S(+)5), they are in extremely close proximity (Figure 32A and B). The  α-
methyl and N-methyl groups of (+)METH (S(+)5) seem to align differently from our 
ligands. These differences can be explained based on the fact the side chain of D46 is not 
totally superimposed with D79 or D98; thus, the N-methyl group orients itself to be able to 
form the ionic bond. Also due to the lack of the β-keto group, the METH (S(+)5) molecule 
has a more freely rotatable bond at the  β-position and could cause the α-methyl and N-
methyl groups to be oriented slightly differently. 
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Figure 32. Comparison of the binding pockets of MCAT (S(+)57) docked in (A) hDAT 
and (B) hSERT models with METH (S(+)5) cocrystallized with dDAT. MCAT (S(+)57) is 
indicated in magenta and METH (S(+)5) is indicated in green. Residues labeled in green 
belong to dDAT and purple belong to hDAT and hSERT and images are an overlap of the 
residues within 5Å of the ligand binding pockets of (A) dDAT and hDAT (B) dDAT with 
hSERT. 
 
 
Due to significant intercorrelations observed between the parameters (r > 0.9) investigated 
and a narrow range of values of Verloop parameters for the 4-position substituents 
additional compounds will be needed to better determine which parameter is the most 
important for DAT/SERT selectivity.  
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AIM III. Structure-activity relationship studies on the “bath salts” component 
methylone at dopamine and serotonin transporters 
 
a. Introduction 
Methylone or methlenedioxymethcathinone (MDMC, 61), the β-keto analog of MDMA 
(44) (Figure 33), is one of the original components of the psychoactive “bath salts” 
mixture. Our laboratory, and others, have investigated MDMA (44) or “ecstasy”, a popular 
drug of abuse, previously for its SAR, as well as its pharmacological profile, which was 
discussed in the Background section. 
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Figure 33. Ethylenedioxy analogs of MDMA and MDMC (51 and 77) and N-alkyl chain 
extended analogs of MDMC (78 and 79) investigated in the current study. 
 
MDMC (61), the β-keto analog of MDMA (44), has not been well investigated in terms of 
its SAR. Its recreational use has made it popular and there have been reports of death due 
to its toxicity.216,217 Our group first reported on its MDMA (44) and AMPH-like effects in 
drug discrimination studies around 12 years before it gained recognition as a “bath salts” 
component.145 Other in vivo studies were subsequently conducted after its reemergence as 
“bath salts”. Our group evaluated its effects in ICSS studies,146 and others have reported on 
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its effects in conditioned place preference assays,218 locomotor stimulation185,219 and 
reinforcing properties as well.220 All of these studies indicated that its actions were 
consistent with its abuse potential. 
 
Ethylone (78) (Figure 33), an analog of MDMC (61), has been recently found on the 
clandestine market and has been reported to cause toxic side effects and death.221,222 The 
DEA has solicited information on phenylalkylamine compounds that are not scheduled that 
could be potential drugs of abuse;163 one such compound is EDMA (51) (Figure 33) the 
ethylenedioxy analog of MDMA.  
 
To recapitulate, MDPV (63) and MDMC (61) share a methylenedioxy ring as a common 
structural feature, but MDPV (63) has a pyrrolidine ring and an extended α-n-propyl side 
chain whereas MDMC (61) has an N-methyl group and an α-methyl side chain and, from 
the SAR of MDPV (63), we identified that extending the α-side chain and tertiary nature 
of the terminal amine confers DAT reuptake properties.169,181  
 
With the above backdrop, we sought to understand the effects of ring expansion from a 
methylenedioxy group to an ethylenedioxy group, so we synthesized EDMC (77) and the 
MDMA counterpart EDMA (51). We also wanted to investigate the length of the alkyl 
chain that can be tolerated at the terminal amine such as that found in ethylone (78). 
Because related agents might be identified in the future on the clandestine market and 
possess abuse liability, we also synthesized propylone (79) (Figure 33). 
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b. Methods 
i. Synthesis 
MDMA (44) was on hand, and data for MDMC (61) were reported earlier159 and is 
included here as a means for comparison. The synthesis of compound 51, 77, 78 and 79 is 
outlined in Schemes 5, 6 and 7, respectively. 
 
Scheme 5. Synthesis of compounds 51a 
 
 
 
aReagents: (a) Ammonium acetate, nitroethane; (b) i) LiAlH4, THF ii) Et2O/HCl; (c) ethyl 
chloroformate, Et3N; (d) LiAlH4, THF. 
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Scheme 6. Synthesis of compounds 77a 
 
 
 
aReagents: (a) SnCl4, CH2Cl2, propionyl chloride; (b) Br2, AlCl3, Et2O; (c) benzene, 
CH3NH2 in EtOH. 
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Scheme 7. Synthesis of compounds 78 and 79a 
 
  
 
 
aReagents: (a) SnCl4, CH2Cl2, propionyl chloride; (b) Br2, AlCl3, Et2O; (c) benzene, 
CH3CH2NH2 in MeOH (78)/ n-propylamine (79). 
 
ii. In vitro release and uptake inhibition in rat brain synaptosomes 
 This assay was performed in Dr. Baumann’s laboratory at NIDA, and details have been 
reported in Del Bello et al.223 
 
c. Results 
MDMA (44) was included as a reference compound and was found to be a non-selective 
releaser at DAT and SERT consistent with earlier published results (Figure 34 and Table 
20).159 Its ethylenedioxy analog, EDMA (51), was half as potent at SERT but 8-fold less 
potent at DAT (Figure 34 and Table 20). EDMA (51) was more selective for SERT over 
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DAT by 5-fold. MDMC (61) was slightly more selective for DAT than SERT (2-fold), 
comparatively EDMC (67) was slightly more selective for SERT over DAT (1.5-fold) 
(Figure 34 and Table 20). On comparing the potencies of EDMC (77) and MDMC (61) 
with each other, MDMC (61) was 4- and 1.5-fold more potent at DAT and SERT. MDMA 
(44) was 2-fold more (consistent with earlier published results145,149) and 4-fold more 
potent than MDMC (61) at DAT and SERT respectively. 
 
Figure 34. Effects of MDMA (44), EDMA (51) and EDMC (77) on the release of [3H]5-
HT at SERT and [3H]MPP+  at DAT and SERT. Data are % maximal release expressed as 
mean (±)SD for n = 3-4 separate experiments performed in triplicate (Figure provided by 
Dr. Baumann). 
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Table 20. EC50 values for MDMA (44), MDMC (61), EDMA (51) and EDMC (77) to 
release [3H]5-HT at SERT and [3H]MPP+ at DAT. 
 
Compound EC50 nM (±SD)a 
     SERT        DAT 
   
EDMA (51) 117 (±17)     597 (±50) 
   [102±3]     [108±3] 
   
   
MDMA (44)   61 (±9)        75 (±5) 
   [98±2]      [99±1] 
   
   
EDMC (77) 347 (±38)     496 (±52) 
   [105±3]     [105±4] 
   
MDMC (61)b 242 (±48)     133 (±11) 
 
aEC50 values are mean (±SEM) for n = 3-4 experiments; efficacy 
values [in brackets] are % maximal release expressed as mean 
(±SEM) as described in Methods.223   bEC50 values for MDMC 
(61) were reported earlier159 and are included for comparison 
with EDMC (77). 
  
The N-alkyl chain-extended compounds ethylone (78) and propylone (79) show activity 
different from MDMC (61) (Figure 35 and Table 21). Ethylone (78) has comparable 
activity at DAT and SERT for uptake inhibition. At DAT ethylone (78) is primarily a 
reuptake inhibitor since its efficacy is very low (38%) for release. At SERT, ethylone (78) 
is a weak reuptake inhibitor and a partial releaser. Propylone (79) is a weak reuptake 
inhibitor at both DAT and SERT, the effects at the former being slightly more potent 
(Figure 35 and Table 21). 
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Table 21. EC50 values for ethylone (78) and propylone (79) to release [3H]5-HT at SERT 
and [3H]MPP+ at DAT and IC50 values to inhibit the uptake of [3H]5-HT at SERT and 
[3H]MPP+ at DAT. 
 
Compound IC50 nM (±SD) EC50 nM (±SD) 
     SERT        DAT SERT DAT 
     
Ethylone 
(78) 
  1215 (±90)          973.4 (±123)      617.4(±110) 1122 (±314) 
   [100]        [100] [72] [38] 
     
     
Propylone  
(79) 
  2462 (±317)        1863 (±382) 3128(±1376)      975.9 (±411) 
   [99]       [103] [30] [20] 
     
     
aEC50 values are mean (±SEM) for n = 3 experiments; efficacy values [in brackets] are % 
maximal release expressed as mean as described in Del Bello et al.223  
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Figure 35. Effects of ethylone (78) and propylone (79) on release and uptake of [3H]5-HT 
at SERT, and [3H]MPP+ at DAT. Data are % maximal release expressed as mean (±)SD for 
n= 3 separate experiments performed in triplicate (Figure provided by Dr. Baumann). 
 
d. Discussion 
The ethylenedioxy analogs (51 and 77) seem to be better accommodated at SERT 
consistent with what was reported by us earlier (see Aim II) that SERT than DAT can 
tolerate larger substituents at this position compared to DAT.195 Ring expansion from the 
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five-membered methylenedioxy ring to the six-membered ethylenedioxy ring results in a 
small decrease in potency (less than 8-fold).  
 
It is important to mention here that Shulgin had synthesized EDMA (51) and has self-
tested its effects and called it a “strange and unsatisfactory compound”. He reported that it 
produced only threshold effects at a dose of 250 mg. However, the actions of EDMA (51) 
have not been previously examined at DAT or SERT.85 
 
As the length of the alkyl chain increased at the terminal amine the compounds shifted in 
their activity from releasers to reuptake inhibitors. However, they seem to be weak 
reuptake inhibitors if we compare them to MDPV (63), which has an IC50 of 4.1 nM in the 
same assay.160 We know from our results in AIM I that an extended side chain at the α-
position and the tertiary amine both contribute to the inhibitory potency at DAT. It can 
then be inferred that, since ethylone (78) and propylone (79) lacked the extended side 
chain at the α-position and they are secondary amines instead of tertiary amines, they 
would be relatively weaker inhibitors than MDPV (63) at DAT.  
 
In the case of SERT these compounds are weak inhibitors, implying that increased length 
of the side chain at the terminal amine shifts activity from a releaser to a reuptake inhibitor. 
Also compared to the analogs of MDPV (63) tested in AIM I which were inactive at SERT 
(concentrations up to 10,000 nM), ethylone (78) and propylone (79) were not totally 
inactive and exhibited atleast weak reuptake properties. Ethylone (78) produced releasing 
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effects but with an efficacy less than 100%. Such compounds are referred to as partial 
releasers. Partial releasers are defined as compounds that are “transporter substrates that 
do not release the maximum releasable pool of neurotransmitter even at the highest 
concentrations”.224  
 
The present result for SERT and results from AIM I indicate that compounds lacking a 
bulky/extended side chain and a tertiary amine could confer weak inhibitory properties at 
SERT. Microdialysis studies have shown that transporter inhibitors produce only a small 
increase in extracellular neurotransmitter concentration compared to releasers. Studies 
currently being performed in Dr. Baumann’s laboratory should provide additional 
information about the effects of these drugs on in vivo neurotransmitter levels and their 
mechanism of action.  
 
Compounds to test the effects of simultaneous chain extension at the terminal amine and 
the α-position are currently being synthesized by others in the laboratory. 
 
It continues to appear that newer synthetic cathinones, in this case, analogs of MDMC 
(61), are making their way into the designer drug world and they could be potential 
psychoactive drugs and our study provides useful information about them. 
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AIM IV. Investigation of the N-alkyl chain length of 4-methylamphetamine analogs: 
An examination of its pharmacological effects at the dopamine and serotonin 
transporters 
 
a. Introduction 
Studies conducted thus far suggested that simple structural changes to the cathinone 
molecule could result in distinct behavioral and neurochemical changes. For example, 
MDPV (63) was found to be the first synthetic cathinone to show reuptake inhibition 
properties,9-11 the size of the substituent at the 4-position of MCAT (57) influences their 
selectivity towards DAT and SERT (AIM II),193 and in the case of MDMC (61) the length 
of N-alkyl chain determines the mechanism of action and selectivity of the compounds 
(AIM III).  
 
MCAT (57) is the β-keto analog of METH (5) and, due to their close structural 
resemblance, similar modifications on the METH (5) scaffold could result in either 
different or similar pharmacological profiles to its MCAT analogs.  
 
The goal of the current investigation was to determine the effect of chain extension of the 
N-alkyl group of 4-methylmethamphetamine (4-MA). 4-MA was used as the parent 
compound because the 4-methyl group is found in MEPH (62), and  MEPH (62) was found 
to be non-selective between DAT and SERT, should allow for a rational comparison of 
terminal amine substituents at both the transporters (i.e., DAT and SERT).193  
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We extended the chain length linearly from methyl to butyl on 4-MA (Figure 36) and 
investigated these compounds for their effects in electrophysiological assays in Xenopus 
laevis oocytes expressing hSERT and hDAT, for release/reuptake inhibition through DAT 
and SERT in rat synaptosomes and in the ICSS assay for their abuse related/abuse limiting 
effects. 
 
 
Figure 36. N-Alkyl chain-extended 4-MA compounds investigated in the current study for 
their in vitro and in vivo effects. 
 
b. Methods 
i. Synthesis 
Rakesh Vekariya synthesized compound 80,225 and Dr. Battisti synthesized the 
intermediate 121. The synthesis of 81-83 is outlined in Scheme 8.  
 
Scheme 8. Synthesis of compounds 81-83a 
CH3
N
CH3
RH
80: R = CH3
81: R = CH2CH3
82: R =  CH2CH2CH3
83: R =  CH2CH2CH2CH3
 151 
                                                          
 
 
 
 
 
  
 
aReagents: (a) Nitroethane, ammonium acetate; (b) i) LiAlH4, THF ii) Et2O/HCl; (c) acetyl 
chloride (119)/propionyl chloride (120), CH2Cl2, Et3N; (d) LiAlH4, THF; (e) Fe, aqueous 
acetic acid; (f) glacial acetic acid, n-propylamine (82)/n-butylamine (83), NaCNBH3. 
 
CH3
O
CH3
CH3
N
CH3
RH
82: R = CH2CH2CH3
83: R = CH2CH2CH2CH3
a
121
e
f
CH3
NH2
CH3
CH3
NO2
CH3
CH3
O
116
a
117
b
118
CH3
N
CH3
R
O
H
CH3
N
CH3
RH
119: R = CH3
120: R = CH2CH3
81: R = CH3
82: R = CH2CH3
c d
 152 
In vivo studies required a larger scale of compounds and their initial synthesis used 
LiAlH4. A scale up would require increased quantities of LiAlH4 and the second route to 
synthesizing 82 was shorter.  
 
ii. Transporter-mediated ion currents in DAT- or SERT-expressing oocytes 
The procedure for this experiment is the same as that reported in Kolanos et al. for both 
DAT and SERT.169 These studies were performed in Dr. De Felice’s laboratory at Virginia 
Commonwealth University. 
 
iii. In vitro release and uptake inhibition in rat brain synaptosomes 
The procedure is similar to that reported by Kolanos et al.181 for reuptake inhibition (aim I) 
and the procedure is similar to that reported by Bonano et al.193 for release assays. These 
studies were performed in Dr. Baumann’s laboratory at NIDA. Details can also be found in 
AIM I. 
  
iv.      Intracranial self-stimulation in rats     
The procedure is similar to that reported by Bonano et al.193  These studies were performed 
in Dr. Negus’s laboratory at Virginia Commonwealth University. 
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c. Results 
i. Results from TVEC assay 
An application of DA (5 µM) in Xenopus laevis oocytes expressing hDAT and clamped to 
-60 mV showed a characteristic inward (i.e., depolarizing) current. This was followed by 
the application of each of the 4-MA analogs (10 µM) (Figure 37). Only N-methyl 4-MA 
(80) showed an inward depolarizing current that is characteristic for compounds that act as 
releasing agents (Figure 37). The N-ethyl (81), N-propyl (82) and N-butyl 4-MA (83) 
analogs produced an outward hyperpolarizing current that is characteristic for agents that 
are reuptake inhibitors; however, the compounds differed in the magnitude of their 
hyperpolarizing effects. 
 
Application of 5-HT (5 µM) in Xenopus laevis oocytes expressing hSERT and clamped to 
-60 mV showed a characteristic inward current. This was followed by the application of 
each of the 4-MA analogs (10 µM). All compounds produced inward currents with varying 
magnitudes (Figure 37). N-Methyl (80) and N-ethyl 4-MA (81) produced inward currents 
that were twice as large as those produced by 5-HT. The N-propyl analog, 82, produced a 
current that was comparable to the 5-HT current and the N-butyl analog, 83, analog 
produced a diminished inward current (Figure 37).  
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Figure 37.  Effect of N-substituted 4-MA analogs on membrane currents in oocytes 
transfected with hDAT (A-D) or hSERT (E-H) (Figure provided by Dr. De Felice’s 
laboratory).  N-Me (N-methyl 4-MA, 80), N-Et (N-ethyl 4-MA, 81), N-Pr (N-propyl 4-
MA, 82), and N-Bu (N-butyl 4-MA, 83). 
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ii. Results from monoamine release and uptake inhibition in rat-brain synaptosomes 
All the compounds produced dose-dependent effects for monoamine release and/or of 
reuptake (Figure 38 and Table 22). N-Methyl 4-MA (80) displayed both inhibitory and 
release effects at DAT and SERT (Figure 38 and Table 22) and was more potent for its 
release than reuptake properties by 22-fold at DAT and 2.5-fold at SERT (Figure 38 and 
Table 22). Also N-Methyl 4-MA (80) was non-selective for its release effects at DAT and 
SERT (Figure 38 and Table 22). N-Ethyl 4-MA (81) displayed both inhibitory and 
releasing effects that were almost comparable; it was more selective at DAT over SERT by 
about 5-fold (Figure 38 and Table 22). However, it was less efficacious at DAT (58%) and 
less potent at SERT by 2- to 3-fold than its N-methyl analog 80 (Figure 38 and Table 22).  
N-propyl 4-MA (82) was only 20% as efficacious as a releaser but displayed an inhibitory 
action at DAT, but with lower potency as compared to its N-methyl (i.e., 80) and N-ethyl 
analog (i.e., 81)  (Figure 38 and Table 22). However at SERT, the N-propyl analog had 
comparable potency for release and reuptake effects (Figure 38 and Table 22). The N-butyl 
analog, 83, produced sub-maximal effects at DAT for release and exhibited diminished 
inhibitory potency (Figure 38 and Table 22). At SERT, the compound was inactive as a 
releaser and produced sub-maximal effects (36%) as a reuptake inhibitor (Figure 38 and 
Table 22).  
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Figure 38. Effects of N-alkyl 4-MA analogs on monoamine release and uptake in rat brain 
synaptosomes.  Top panels (A-B) show drug effects on monoamine release.  Abscissae: 
drug concentration in log M.  Ordinates: Percent release of [3H]MPP+ (A) or [3H]5HT (B). 
Bottom panels (C-D) show drug effects on monamine uptake inhibition.  Abscissae: drug 
concentration in log M.  Ordinates: Percent uptake inhibition of [3H]DA (C) or [3H]5-HT 
(D).  EC50 and IC50 values determined from these curves are reported in Table 22.  N-Me 
(N-methyl 4-MA, 80), N-Et (N-ethyl 4-MA, 81), N-Pr (N-propyl 4-MA, 82), and N-Bu (N-
butyl 4-MA, 83). All points show mean (±SEM) of three determinations (figure provided 
by Dr. Baumann’s laboratory).  
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Table 22. EC50 values to promote monoamine release or IC50 values to inhibit monoamine 
uptake for N-substituted 4-MA analogs.  All values were derived from data shown in 
Figure 38.  An EC50 or IC50 value is shown only if the maximal effect was ≥50%.  If the 
maximal effects was <50%, the maximum effect is shown.    
 
 
 
iii. Results from ICSS studies 
All of the examined analogs produced dose-dependent changes in ICSS that differed in 
their DA-mediated abuse-related effects and potencies (Figure 39). N-Methyl 4-MA (80) 
produced facilitation of low rates of ICSS maintained by low brain frequencies at a dose of 
0.32 mg/kg and, at higher doses of 1 mg/kg, produced mixed effects consisting of 
facilitation of ICSS at low brain frequencies and depression of high rates of ICSS 
maintained by higher frequencies. N-Ethyl 4-MA (81) produced mixed effects at a dose of 
1 mg/kg and depression of ICSS effects maintained by high brain frequencies at a dose of 
3.2 mg/kg. The N-propyl (i.e., 82) and N-butyl analog (i.e., 83) produced dose-dependent 
decreases in ICSS effects for intermediate to high brain frequencies at doses of 10 and 0.32 
mg/kg respectively. 
 
Drug 
 
EC50  (nM±SEM) 
 
IC50 (nM±SEM) 
 DAT SERT DAT SERT 
N-Methyl 4-MA (80) 41.3±5 67.4±14 909.6±66 170.9±41 
N-Ethyl 4-MA (81) 550.4±132 
(Emax= 62%) 
102.2±16 794.9±125 166.0±29 
N-Propyl 4-MA (82) 20% 650.2±90 3064±366 983.6±219 
N-Butyl 4-MA (83) 29% 0% 13660±360 36% 
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Figure 39.  Effects of N-alkyl 4-MA analogs on ICSS in rats.  Left panels A-D show full 
ICSS frequency-rate curves.  Abscissae: Brain stimulation frequency in log Hz.  Ordinates: 
Percent maximum control response rate (%MCR).  Filled points show drug effects 
significantly different from VEH treatment as determined by two-way ANOVA followed 
by a Holm-Sidak post hoc test (p<0.05).  For all panels, there were significant main effects 
of frequency (p<0.001) and dose (p<0.001) (details not shown).  Frequency-dose 
interactions were also significant (all p<0.001) as follows: N-Me 4-MA, F(36,180)=9.91, 
N-Et 4-MA, F(36,180)=6.38, N-Pr 4-MA, F(36,180)=7.01, N-Bu 4-MA, F(36,180)=2.93.   
Right panels E-H show summary data for the total number of stimulations delivered across 
all brain-stimulation frequencies.  Abscissae: Drug dose in mg/kg.  Ordinates: Total 
number of stimulations per component expressed as percent baseline (% Baseline Total 
Stimulations).  Upward/downward errors indicate that ICSS rates were significantly 
increased/decreased for at least one brain-stimulation frequency as determined by analysis 
of full frequency-rate curves in the left panels.  All points and bars show mean±SEM in six 
rats (figure provided by Dr. Negus’s laboratory). 
 
 
N-Methyl 4-MA N-Methyl 4-MA 
N-Ethyl 4-MA N-Ethyl 4-MA 
N-Propyl 4-MA N-Propyl 4-MA 
N-Butyl 4-MA N-Butyl 4-MA 
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d. Discussion 
 
The effects on selectivity and mechanism of action of N-alkyl substituted 4-MA analogs 
have not been previously investigated at DAT and SERT. It would to appear that as the 
length of the N-alkyl chain is increased there is a change in action from a strong releaser to 
a weak reuptake inhibitor at DAT, but at SERT an increased side chain length shows non-
selective properties as both a releaser and a reuptake inhibitor. 
 
At hDAT, electrophysiological studies suggest that the length of the N-alkyl chain on 4-
MA analogs influences their current. Only N-methyl 4-MA (80) showed the 
electrophysiological signature of a releasing agent (i.e., an inward current) whereas the 
other analogs showed outward hyperpolarizing currents, the signature of reuptake 
inhibitors, the magnitude of which diminished as the N-alkyl chain length increased from 
ethyl (81) to propyl (82) to butyl (83). 
 
In vitro data support the above, with N-methyl 4-MA (80) being the most potent as a 
releaser at DAT. As chain length was increased to N-ethyl (i.e., 81), the compound was 
non-selective as a releaser or a reuptake inhibitor but its efficacy was only 62% as a 
releaser at DAT. This implies that the compound is a “partial releaser” and a weak 
reuptake inhibitor at DAT. There are two possible explanations for this. First, the 
difference in activity might be due to a difference in activity between the two enantiomers, 
with one isomer being more potent as a releaser or reuptake inhibitor, or the isomers could 
have opposite mechanisms of action. The isomers are currently being investigated. A 
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second explanation for this hybrid activity is related to the transport mechanism. N-Propyl 
4-MA (82) and N-butyl 4-MA (83) show weak reuptake inhibition properties. These 
inhibitory effects result in a decrease in potency as chain length is increased at the N-alkyl 
position with N-butyl 4-MA (83) being 150-fold less potent than its corresponding N-
methyl analog.  
 
At SERT, all analogs showed inward depolarizing currents of differing magnitudes, and 
increased chain length at the terminal nitrogen atom resulted in a loss in activity. For 
example, N-butyl 4-MA (83) was inactive as a reuptake inhibitor and had decreased 
efficacy (36%) for release. As chain length was decreased to N-propyl (82) and N-ethyl 
(81) the compounds were efficacious both for release and reuptake and have comparable 
potencies for both actions. A plausible explanation for their dual action of the above two 
compounds is a difference in the activity of the two enantiomers or the mechanism of 
transport. Isomers will need to be examined 
 
The ICSS assay provides a useful tool to assess the abuse liability of a compound.186 In the 
current study it was observed that as chain length was increased there was a decrease in the 
DA-mediated abuse related effects with the potency order being N-methyl (80) > N-ethyl 
(81) > N-propyl (82) > N-butyl (83).  
 
Previous studies conducted by others on analogs of METH (5) (without the 4-methyl 
substituent) also produced results analogous to those observed herein, both in in vivo and 
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in vitro assays. van der Shoot first studied the effects of chain extension on the terminal 
nitrogen of AMPH (2) in mouse locomotor assays and found that as chain length increased 
from methyl to n-butyl, locomotor stimulation properties decreased.226 These assays were 
conducted on racemates. In vitro assays performed on the above AMPH analogs, displayed 
results very similar to ours, with N-ethyl AMPH being less potent than METH (5) as a 
releaser at DAT by about 3.5-fold and N-propyl and N-butyl AMPH were DA reuptake 
inhibitors (N-butyl analog demonstrating a 2.5-fold decrease in activity).224 
 
Cathinone (1) is the β-keto analog of AMPH (2) and the SAR for both display some 
parallels but there have been exceptions.145 On comparing the AMPH series with the 
corresponding cathinone analogs we see that the SAR shows some differences. MEPH  
(62), the cathinone analog of N-methyl 4-MA (80), both showed activity as releasers at 
DAT and SERT. N-Ethyl-4-methylcathinone (MEC, 122) is a SERT substrate and a DAT 
blocker;227 its AMPH analog, 81, displayed activity both as a releaser and a reuptake 
inhibitor at DAT but had a higher efficacy as a DAT reuptake inhibitor than as a releaser 
but was equipotent and efficacious at SERT for both reuptake and inhibition.  
 
CH3
O CH3
HN CH3
122
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It can be observed that simple structural changes contribute to somewhat different actions 
at DAT and SERT and that these differences can, perhaps, be attributed to their mechanism 
at the transporter (i.e., their could be differences in the binding site or the manner in which 
they make their entry into the transporter-binding site (a more detailed discussion is 
provided in the Summary chapter)). 
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AIM V. Effects of psychoactive synthetic cathinones and amphetamine analogs at the 
norepinephrine transporter 
 
a. Introduction 
The norepinephrine transporter (NET) is a target for therapeutic drugs such as the 
norepinephrine reuptake inhibitor reboxetine for depression,228 and atomoxetine for the 
treatment of ADHD.229 NET is also a target for psychostimulant drugs such as cocaine and 
AMPH (2).230,231 The activity of synthetic cathinones at NET is more similar to DAT 
compared to SERT (Table 23). 
 
Table 23. A comparison of the in vitro effects of MCAT (57), MEPH (62), and MDPV 
(63) at DAT, NET and SERT in rat brain synaptosomes. 
 
Compound DAT NET SERT 
MCAT (57)193 EC50 =12.5 nM EC50 = 22 nM EC50 = 3860 nM 
MEPH (62)159 EC50 = 49.1 nM EC50 = 62.7 nM EC50 = 118 nM 
MDPV (63)160 EC50 = 2.3 nM  
(Emax = 24%) 
IC50 = 4.1 nM 
EC50 = 13 nM  
(Emax = 24%) 
IC50 = 26 nM 
EC50 = Inactive 
IC50 = 3349 nM 
 
Since release/inhibition at SERT and DAT result in effects that are distinct from each 
other, it was essential to study the effects of synthetic cathinones at DAT and SERT. 
However, the contribution of NET to the action of these psychoactive compounds could 
not be ignored.  
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We investigated compounds discussed in AIMS II-IV for their in vitro actions to 
release/reuptake inhibition of [3H]MPP+ in rat synaptosomes. 
 
b. Effects of the 4-position substituent of MCAT on release/reuptake inhibition in rat 
synaptosomes 
Compounds described in AIM II (Table 24) were tested for their ability to promote release 
of [3H]MPP+ in rat brain synaptosomes. The in vitro potencies ranged over 40-fold with 
MCAT (57) being the most potent and 4-CF3 MCAT (76) being the least potent (Table 24). 
 
A QSAR analysis was first performed between Es, π, σp and log EC50 NET (Table 25). A 
significant correlation was observed only with Es (r = 0.772, p = 0.04) (Figure 40 and 
Table 25). A further QSAR analysis with Verloop parameters and volume was performed 
which resulted in significant correlations with B5 (r = -0.817, p = 0.02) (Figure 40, Table 
25) and volume (r = -0.878, p = 0.01) (Figure 40, Table 25), indicating that the 4-position 
substituent size could influence the in vitro releasing action at NET. It appears that the 
activity observed at NET is similar to that observed for DAT, (i.e., the in vitro releasing 
activity decreases with an increased size of the substituent at the 4-position).  A significant 
correlation was also observed between log EC50 NET and log EC50 DAT (r = 0.906, p = 
0.0050, n = 7) (Figure 40). A homology modeling study of NET should provide further 
insight.  
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Table 24. In vitro release activity at NET (method similar to that reported in Del Bello et 
al.223) 
 
 
Agent R NET 
EC50 nM 
Methcathinone (57) -H  22±4 
Flephedrone (72) -F  62±10 
Methedrone (73) -OCH3 1 111±24 
4-Chloromethcathinone (74) -Cl  44±9 
4-Bromomethcathinone (75) -Br 100±16 
Mephedrone (62) -CH3  63±17 
4-Trifluoromethylmethcathinone (76) -CF3 900±300 
 
CH3HN
CH3
O
R
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Figure 40. Relationships between (A) Es, (B) volume, (C) maximum width (B5) of the 4-
position substituents of MCAT and log EC50 NET, and (D) relationship between log EC50 
DAT and log EC50 NET for 57, 62, 72-76. 
 
 
 
 
 
 
A B 
C D 
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Table 25. Results of correlational analysis between steric parameters, electronic and 
lipophilic parameters with in vitro potencies at NET for 4-substituted MCAT analogs  (57, 
62, 72-76). Significant correlations (p <0.05) are highlighted in bold. 
 
Physicochemical 
Parameter 
log EC50 NET 
Taft (Es) r = 0.772 
p = 0.04 
Lipophilicity (π) r = -0.472 
p = 0.29 
Electronic (σ) r = -0.3601 
p = 0.43 
Volume (Vol) r = -0.878 
p = 0.01 
Length (L) r = -0.677 
p = 0.1 
Minimum width 
(B1) 
r = -0.676 
p = 0.1 
Maximum 
Width (B5) 
r = -0.817 
p = 0.02 
 
c.  SAR studies for methylone 
We tested the effects of ring expansion from methylenedioxy to ethylenedioxy and 
increased chain length at the N-alkyl position using methylone or 
methylenedioxymethcathinone (MDMC, 61) as the parent scaffold. In vitro assays in rat 
synaptosomes indicated that the ethylenedioxy analogs (51, 77) are less potent than their 
corresponding methylenedioxy analogs (44, 51) by 4.5 and 2-fold respectively (Table 26). 
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Both the ethylenedioxy analogs EDMA (51) and EDMC (67) are equipotent in their 
actions at NET. 
 
As the length of the N-alkyl chain increased, potency for releasing effects decreased (Table 
26). Ethylone (78) produced submaximal effects for release (Table 26) and reuptake 
inhibition (IC50 = 5820 nM, efficacy  (≈100%). Propylone (79) was inactive for its 
releasing effects but produced very weak reuptake properties (IC50 = 28,540 nM, efficacy 
less than 50%). 
  
At NET, the ethylenedioxy ring is tolerated but the methylenedioxy ring is preferred and 
an increased chain length at the N-alkyl position shifts the activity of the compound from a 
releaser to a weak reuptake inhibitor. 
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Table 26. EC50 values for EDMA (51), MDMA (44), EDMC (77), MDMC (61), ethylone 
(78) and propylone (79) to release [3H]MPP+ at NET. 
 
Compound NET 
EC50 nM (±SD)a 
 
EDMA (51) 325 (±61) 
[91 (±2)] 
  
MDMA (44) 72 (±13) 
[95 (±3)] 
  
EDMC (77) 327 (±54) 
[84 (±4)] 
  
MDMC (61)b 152 (±33) 
 
  
Ethylone (78) 4251(±1622) 
[64%] 
IC50 = 5820(±1244) 
[≈100%] 
 
  
Propylone (79) 0% 
IC50 = 28540(±12580) 
[less than 50%] 
 
 
aEC50 values are mean (±SEM) for n = 3-4 experiments; efficacy 
values [in brackets] are % maximal release expressed as mean 
(±SEM) as described in Methods.223   bEC50 values for MDMC 
(61) were reported earlier159 and are included for comparison 
with EDMC (77). 
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d. SAR studies for N-alkyl 4-MA analogs at NET 
N-alkyl 4-methyl amphetamine analogs were investigated for their effects to release 
[3H]MPP+  and inhibit the uptake of [3H]NE in rat brain synaptosomes.  It can be observed 
that releasing effects are optimal when the N-alkyl chain is either a methyl (80) or ethyl 
(81) group (Figure 41, Table 27). However, N-methyl 4-MA (80) is about 3-fold more 
potent than N-ethyl 4-MA (81) (Table 27). N-propyl (82) and N-butyl 4-MA (83) both 
displayed weak inhibitory effects for reuptake inhibition and sub maximal effects for 
release (Figure 41, Table 27). Similar to what was observed in AIM IV for DAT, the 
increased N-alkyl chain length on 4-MA transitions the compound from a full releaser 
>>partial releaser>>weak reuptake inhibitor. 
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Figure 41. Effects of N-substituted 4-MA analogs on NET monoamine release and uptake 
in rat brain synaptosomes. All points show mean±SEM of three determinations. Top panel 
(A) shows drug effects on monoamine release.  Abscissae: drug concentration in log M.  
Ordinates: Percent release of [3H]MPP+ (A). Bottom panels (B) show drug effects on 
monamine uptake inhibition.  Abscissae: drug concentration in log M.  Ordinates: Percent 
uptake inhibition of  [3H]NE (B). EC50 and IC50 values determined from these curves are 
reported in Table 27.  All points show mean±SEM of three determinations. N-Me (N-
methyl 4-MA, 80), N-Et (N-ethyl 4-MA, 81), N-Pr (N-propyl 4-MA, 82), and N-Bu (N-
butyl 4-MA, 83). All points show mean (±SEM) of three determinations (figure provided 
by Dr. Baumann’s laboratory). 
 
 
 
 
 
 
 
 
Monoamine release 
Monoamine reuptake 
Concentration (log M) 
A 
B 
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Table 27. EC50 values to promote monoamine release or IC50 values to inhibit monoamine 
uptake for N-substituted 4-MA analogs.  All values were derived from data shown in 
Figure 41.  An EC50 or IC50 value is shown only if maximal effect was ≥50%.  If maximal 
effects were <50%, then maximum effect is shown.    
 
 
 
 
 
 
 
 
 
Overall the SAR at NET for its releasing action can be summarized as (Figure 42): a) the 
length of the N-alkyl chain that can be accommodated is N-ethyl but N-methyl is optimal 
b) smaller substituents such as –F, and CH3 contribute to optimal activity at the 4-position 
and c) a carbonyl group is tolerated at the β-position. We have not studied the effects of 
chain extension at the α-position in NET, but we expect an activity similar to DAT (AIM 
I).  
 
 
 
Drug 
 
NET EC50  
(nM±SEM) 
 
 
NET IC50  
(nM±SEM) 
 
N-Methyl 4-MA (80) 66.9±8.4 438.3±41.6 
N-Ethyl 4-MA (81) 182.4±19.9 685.4±78.8 
N-Propyl 4-MA (82) 742±171.9  
(Emax= 56%) 
2916±321.3 
N-Butyl 4-MA (83) 23% 6009±1188.9 
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Figure 42. Summary of the SAR investigated at NET. 
 
An overall correlation analysis was conducted (Figure 43) between the log EC50 DAT and 
log EC50 NET (r = 0.755, p = 0.002, n = 14) and log EC50 SERT and log EC50 NET (r = 
0.090, p = 0.8, n = 14) for 14 compounds (except propylone (79), N-propyl 4-MA (82), 
and N-butyl 4-MA (83) since their EC50 were not calculated due to poor efficacy).  
It is striking that there are two outliers (compounds 76 and 78) in the correlation between 
log EC50 DAT and log EC50 NET. These two compounds have a slight difference in 
activity at DAT and NET, 4-CF3 MCAT (76) is 3-fold more potent at DAT then at NET 
and ethylone (78) at DAT and NET is primarily a weak reuptake inhibitor, however they 
differ in their efficacies for release, 38% at DAT and 64% at NET.  
CH3
Y
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c
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Figure 43. Correlation analysis between (A) log EC50 DAT and log EC50 NET (r = 0.755, 
p = 0.002, n = 14), and (B) log EC50 SERT and log EC50 NET (r = 0.090, p = 0.8, n = 14) 
for 14 compounds. Compounds included for the above correlation are 44, 51, 57,61, 62, 
72, 73, 74, 75, 77, 76, 80, 81, and 78. 
 
It can be concluded that effects at NET are similar to those observed at DAT. Koldsø et 
al.208 reported on the similarities of the DAT, NET and SERT substrate-binding cavities 
based on homology models constructed using the LeuT template. They report that the 
sequence identity in the substrate-binding pocket of hSERT to hDAT and hNET is 57% 
and 68%, respectively, and the sequence identity between hNET and hDAT is 86%.208 
Ethylone (78) 
4-CF3 MCAT (76) 
A 
B 
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Sequence identity refers to the extent to which two sequences have the same residues at the 
same position in an alignment. Schlessinger et al.232 also constructed a homology model of 
NET and described the substrate-binding site as small and hydrophobhic.232 It was reported 
by our group that the substrate-binding cavity of hDAT was small and relatively more 
polar whereas hSERT has a more hydrophobic and relatively larger substrate-binding 
pocket.195 Koldsø et al.233 recently published a homology model of NET based on the new 
dDAT crystal structure with DA in the binding cavity, and NE docked similarly to DA in 
the substrate-binding site. These findings are consistent with our in vitro correlations of 
activity at DAT and NET. 
 
A homology modeling study on NET would provide additional information regarding their 
binding modes and provide a comparison with those at DAT and SERT. These studies are 
planned to be conducted. 
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 AIM VI. Comparison of the structural features of methylphenidate and synthetic 
cathinones and investigation of the role of the carbonyl group on synthetic 
cathinones: A preliminary investigation 
 
a. Introduction 
Methylphenidate (6, Ritalin®) is a known medication for ADHD (additional information 
discussed in the Background), and others have studied its SAR previously for reuptake 
inhibition at DAT, NET and SERT.234-237 Its selectivity for monoamine transporters is in 
the order DAT > NET >> SERT and its binding affinities (IC50) at DAT, NET and SERT 
were 84, 514 and >50,000 nM, respectively as reported by one study.107  However, it has 
not been investigated for comparison with synthetic cathinones. Its mechanism of action, 
(i.e., DA reuptake inhibition), is the same as that of the psychoactive drug MDPV 
(63).9,10,107 It was of interest to understand and compare the structural features of the two. 
Methylphenidate (6) has three structural features that are distinct from MDPV (63); 1) it 
has a methyl ester group instead of a carbonyl group at the benzylic position (β-position), 
2) it lacks the extended α-alkyl chain, and 3) it has a 6-membered piperidine ring instead 
of a 5-membered pyrrolidine ring (Figure 44). It might be noted, however, that 
methylphenidate (6) is a secondary amine, and the amine substituent is also a portion of the 
α-alkyl substituent. 
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The aim of the current investigation was two-fold: 
1. To compare the two structural features of methylphenidate (6) (i.e., the ester and the 
piperidine ring) to the corresponding features of MDPV (63) (i.e., the carbonyl and 
pyrrolidine ring) (Figure 44). We synthesized compounds that were hybrids of the two (84 
and 85). In 84, the ester of methylphenidate (6) was replaced by a carbonyl group, whereas 
85 is a MDPV-type analog where the carbonyl group has been replaced by an ester. Also, 
85 lacks an α-substituent in order to avoid problems with diastereoisomerism. It has 
already been shown (AIM I) that an α-H is less than optimal. However, if 85 shows 
activity, this will provide an impetus for examining specific optical isomers in the future. 
 
Figure 44. Structural comparison of MDPV (63) and methylphenidate (6). 
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2. To investigate the role of the carbonyl group on synthetic cathinones. 
a. To better understand if the sp2 nature of the carbonyl carbon atom of synthetic 
cathinones is a contributor to activity, we synthesized the methoxy analogs 86 and 87 
where the hybridization state of the carbon atom is sp3.  
 
b. We synthesized one of the bioisosteres of a carbonyl group (i.e., the oxime analog 88). 
Bioisosteres are compounds or groups that have similar chemical and physical properties 
and produce similar biological effects.164 
 
b. Methods 
i. Synthesis 
Dr. Jain synthesized compound 85 and Dr. Kolanos synthesized compound 88; their 
synthesis is described in Scheme 11 and 12, respectively. The synthesis of 84, 87, and 88 is 
shown in Scheme 9 and 10, respectively. 
 
Scheme 9. Synthesis of compound 84a 
 
aReagents: a) i) PCl5, CH2Cl2 ii) AlCl3, benzene. 
 
N
H
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Scheme 10. Synthesis of compound 85a 
 
 
aReagents: (a) HCHO, K2CO3, DMF; (b) pyrrolidine, DMF; (c) i) 10N HCl, ii) MeOH, 
HCl. EtOH. 
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Scheme 11. Synthesis of compounds 86 and 87a 
 
aReagents: (a) KBr, KBrO3, conc. H2SO4, MeOH; (b) (CH3)2NH2  in MeOH, benzene; (c) 
Et3N, pyrrolidine, benzene. 
 
 
Scheme 12. Synthesis of compound 88a 
 
 
aReagents: (a) i) CH3NH2 in EtOH, benzene, ii) HCl/Et2O (b) NH2OH.HCl, pyridine, 
EtOH. 
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ii. Electrophysiological studies  
These studies were conducted in Dr. De Felice’s laboratory at Virginia Commonwealth 
University and the procedure is similar to that reported in AIM I. Compounds were 
investigated for their electrophysiological properties at a concentration of 10 µM in 
Xenopus oocytes expressing hSERT and hDAT. 
 
c. Results and discussion 
Hybrid compounds 84 and 85 were strong reuptake inhibitors at hDAT. Compound 84 
retained the piperidine ring from methylphenidate (6) but has the cathinone feature (i.e., 
the carbonyl group). Compound 85 retains the ester side chain of methylphenidate (6) and 
has the pyrrolidine ring feature of MDPV (63). Preliminary data suggest that at hDAT, for 
reuptake inhibition, the ester and carbonyl functional groups are both tolerated. At hDAT, 
84 was a potent hyperpolarizing agent at 10 µM. Compound 85 showed a similar effect, 
but the action was less pronounced. At hSERT, these compounds didn’t produce any 
effects at 10 µM but 85 was a weak inhibitor at a very high concentration of 50 µM. A 
further examination of the in vitro quantitative effects of 84 and 85, particularly with 
methylphenidate (6) for comparison, will provide additional information regarding their 
potencies and confirm which structural features are the most important for activity at 
hDAT and hSERT. Nevertheless, these preliminary findings establish a tantalizing 
structural link between methylphenidate (6) and the cathinones. In addition, although it 
was not known whether these hybrid molecules would be effective at DAT, it was 
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hypothesized that if they were, they would act as reuptake inhibitors. That is, 84 possesses 
an α-alkyl chain that is larger than methyl, where as 85 is a tertiary amine. 
 
Synthetic cathinones having tertiary amines are known to confer hDAT reuptake inhibition 
properties (AIM I). Compounds 86 and 87 both have tertiary amines and are both strong 
reuptake inhibitors at hDAT, suggesting that the methoxy functional group can be tolerated 
at this position. Compound 86 however shows a more pronounced effect compared to 87 
since it has the pyrrolidine ring. A comparison of the corresponding carbonyl analogs 
would provide information as to whether the methoxy or the carbonyl group is a greater 
contributor to potency. At hSERT both showed moderate to weak activity at 10 µM. The 
α-chain extended analogs of 86 and 87 should result in more potent DAT reuptake 
inhibitors. 
 
Previous studies in AIM I suggested that the extended side chain at the α-position is a 
contributor to activity as a DAT reuptake inhibitor, however 84, 85, 86 and 87 lack this 
extended side chain but act as DAT reuptake inhibitors. A comparison of compounds with 
the extended side-chain at the α-position should indicate the importance of an extended 
side-chain at the α-position for such compounds as hDAT reuptake inhibitors. 
 
The corresponding secondary amine analog of 87 (i.e., compound 129) was also 
synthesized. Currently we have no biological data but we expect that in comparison to 86 
and 87 it would either be a releaser. 
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Compound 88 differs from MCAT (57) in the bioisosteric replacement of the carbonyl 
group with an oxime. MCAT (57) produced its action selectively through DAT, however 
oxime analog 88 showed no release activity but extremely weak reuptake inhibition 
activity at hDAT at 10 and 50 µM. Whereas at hSERT it displayed releasing action at 50 
µM which was blocked by fluoxetine. This suggests that bioisosteric replacement of the 
carbonyl group with an oxime can convert a DAT selective compound to a SERT selective 
compound and also change activity at DAT from a releaser to a reuptake inhibitor. Other 
bioisosteres for the carbonyl group might show different/similar effects at DAT and SERT.  
 
This is a preliminary investigation and additional in vitro and in vivo studies will provide 
information regarding the potencies of these compounds. Furthermore, based on these 
preliminary data, optimization of structural features selective for DAT vs SERT and vice 
versa is now being considered. 
 
 
 
 
HN CH3
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AIM VII. Understanding the role of a charged terminal amine: A preliminary 
investigation 
 
a. Introduction 
Recent crystal structures of DA, AMPH (S(+)2), METH (S(+)5), and cocaine 
cocrystallized with dDAT all showed an ionic interaction of the terminal amine with D46 
in the substrate-binding pocket (primary binding site or S1).118 Since this aspartate is 
conserved across DAT, NET and SERT, formation of an ionic bond could be an important 
contributor to their mode of interaction and, perhaps, mechanism of action for monoamine 
release/reuptake inhibition. 
 
The goal of this study was to understand the role of the nitrogen atom in contributing 
towards activity at DAT and SERT. We chose MCAT (57) as our parent compound since it 
is the chief scaffold for newer synthetic cathinones on the clandestine market: 
 
1. We synthesized the desnitrogen analog 89 of MCAT (57) because, lacking a basic 
nitrogen atom, this compound cannot form the ionic interaction with D79 in hDAT and 
D98 in hSERT. 
2. Amines at physiological pH will be protonated and will likely form an ionic interaction 
with the conserved aspartate residue. If this ionic interaction is important for activity, then 
replacement of a protonated tertiary amine with an isosteric sulfonium group could result 
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in retention of action. The sulfonium salt 90 was synthesized such that it is permanently 
charged and would maintain the ionic interaction at the substrate-binding site.  
    
 
b. Methods 
The synthesis of 89 and 90 is shown in Scheme 13 and 14 respectively. 
i. Synthesis 
Scheme 13. Synthesis of compound 89a 
 
aReagents:  (a) AlCl3, benzene. 
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Scheme 14. Synthesis of compound 90a 
 
 
aReagent: (a) (CH3)2S. 
 
ii. Electrophysiological studies  
These studies were conducted in Dr. De Felice’s laboratory at Virginia Commonwealth 
University and the procedure is similar to that reported in AIM I. The compounds were 
investigated for their electrophysiological properties at a concentration of 10 µM in 
Xenopus oocytes expressing hSERT and hDAT. 
 
c. Results and discussion 
The desnitrogen analog of MCAT, 89, exhibited weak reuptake properties at hDAT; the 
removal of the nitrogen atom converted the compound from a potent releasing agent to a 
weak reuptake inhibitor. At hSERT the compound was inactive.  
 
From this preliminary investigation we learnt that, at hDAT, the nitrogen atom is an 
important contributor to release activity, and at hSERT the nitrogen atom is essential for 
activity.  
Br
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O
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a
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However, for reuptake inhibition at hDAT, the nitrogen atom may not be essential. Meltzer 
et al.236 reported in a study of methylphenidate (6) analogs that lacked the nitrogen atom, 
for example compound 131 where the nitrogen atom was replaced by an sp3 hybridized 
carbon atom, possessed DAT reuptake properties and was 9-fold less potent compared to 
methylphenidate (6) in radiolabelled binding assays using [3H]WIN 35,428. This suggested 
that the nitrogen atom might not be required for reuptake activity but contributes to 
potency. However, these analogs were substituted at the 3- and 4-positions with Cl and 
these functionalities might be potential contributors to activity. To test the contribution of 
the chloro groups on our parent molecule we prepared and evaluated analog 132 and it 
showed no activity at 10 µM at hDAT. At a higher concentration (50 µM) it produced 
weak effects as a reuptake inhibitor. This indicated that the chloro groups were not 
contributing significantly to activity at hDAT. A comparison of the potencies of 89 and 
132 will give a better indication regarding the contribution of the 3,4-dichloro groups. 
Also, removal of nitrogen atom on a DAT reuptake inhibitor such as α-PVP might better 
substantiate the role of nitrogen for reuptake inhibitors.  
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The sulfonium analog 90 produced no effects at 10 µM but at higher concentrations (50 
µM) it produced a weak effect for reuptake inhibition at hDAT and hSERT.  
 
It can be implied that the ionic interaction made by a protonated nitrogen atom is optimal 
for activity. Though a sulfonium group, in theory, is capable of making an ionic interaction 
it has an atomic size of 1 Å whereas nitrogen has an atomic size of 0.65 Å.238 Due to this 
size difference the sulfonium analog (90) might not be well accommodated in the 
substrate-binding site, contributing to its weak action. Another possibility is that 
equilibrium between protonated and unprotonated forms of cathinone analogs play a role 
in these actions. 
 
Others in our laboratory239 have examined the quaternary amine analogs of MDPV (63), a 
DA reuptake inhibitor, and MEPH (62), a DA releasing agent, (i.e., 133 and 134, 
respectively). 
 
                                 
It was found that the quaternary analog of MDPV (63), 133, is a weak reuptake inhibitor at 
hDAT and a strong reuptake inhibitor at hSERT. MDPV-like analogs were shown to be 
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exclusively selective for DAT over SERT in AIM I. Compound 133 was the first 
cathinone-like SERT reuptake inhibitor to be identified. MEPH (62) is a non-selective 
releasing agent at DAT and SERT but converting it to its quaternary analog 134, showed 
strong reuptake activity at DAT and a weak reuptake activity at SERT. This suggests that 
compounds that have a permanent charge (i.e., quaternary amine analogs) can be 
accommodated at DAT and SERT.  
 
After this current AIM was completed, a paper by Sandtner et al.240 was published and they 
reported on the  quaternary analog of MDA, 135. They reported similar results, compound 
135 was a reuptake inhibitor at DAT and SERT and they provided an explanation for their 
reuptake activity based on its difference in binding mode compared to MDA (43). 
According to their results 135 cannot make strong electrostatic interactions with Na+ and 
the conserved aspartate in the primary binding site due to its low surface charge density 
and this could contribute to its reuptake action. 
 
Overall, our preliminary investigation suggests that the nitrogen atom is an important 
contributor to releasing activity at hSERT and hDAT. It also suggests that an ionic 
CH3
N+CH3H3C
CH3
135
O
O
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interaction at the substrate-binding site might be more important for releasers than for 
reuptake inhibition action. This requires further investigation. 
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V. Summary 
 
 
 
Monoamine transporters have similar mechanisms of action however they differ in their 
selectivity towards compounds that exert their mechanism of action through them. We 
studied synthetic cathinones (β-keto analogs of PAA) and a few AMPH analogs at DAT, 
SERT and NET and identified structural features that contributed to their action and 
selectivity. 
 
Below is a summary of the SAR studies conducted at DAT and SERT (Figure 45) (a 
summary of the actions at NET were discussed in AIM V and they are similar to the SAR 
described for DAT). 
 
Figure 45. Structural features on the phenylalkylamine scaffold investigated at DAT and 
SERT. 
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Structure-activity relationship summary at DAT 
A. Terminal amine  
For reuptake inhibition 
• Nature of the amine: Tertiary > secondary > primary, R1 = R2 = CH3 > R1 = H, R2 =     
CH3 > R1 = R2 = H 
• Ring: 5-membered > 6-membered 
• Aliphatic chain: methyl > ethyl > n-propyl > n-butyl 
• Absence of nitrogen confers weak reuptake properties 
• Quaternary amines are tolerated 
Bulky and tertiary amines seem optimal for activity 
 
For release 
• Aliphatic chain: methyl > ethyl > n-propyl > n-butyl. As chain length increases 
compound transitions from a full releaser to a partial releaser to a weak reuptake 
inhibitor. 
• Presence of nitrogen required for activity 
 
B. α-position 
For reuptake inhibition 
• Aliphatic chain: n-butyl > n-propyl > ethyl > methyl > H 
• Bulk: cyclohexyl > cyclopentyl > i-propyl 
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Optimal reuptake activity with both an extended/bulky side chain and a tertiary amine 
however the analog where R1 is cyclized to the α-position also shows reuptake activity. 
 
For release 
• Activity optimal with methyl group 
 
C. β-position 
For reuptake inhibition 
• C=O > H 
• Methoxy and methyl ester tolerated 
• Oxime confers weak action 
 
For release 
• H > C=O 
 
D. Phenyl ring 
For reuptake inhibition 
• Methylenedioxy ring at the 3- and 4-position is tolerated but unsubstituted ring is 
also sufficient 
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For release 
• Optimal activity when unsubstituted but smaller sized substituents such as –F are 
tolerated at the 4-position. 
 
Structure-activity relationship summary at SERT 
A. Terminal amine 
• Bulky and tertiary amines are inactive at SERT, except for quaternary amines, they 
confer reuptake properties 
• Aliphatic chain: methyl > ethyl > n-propyl > n-butyl (for release and reuptake 
inhibition). 
• Presence of nitrogen required for activity 
B. α-position 
• Linear chain and bulk result in inactive compounds 
• Release and inhibition optimum with methyl 
C. β-position 
• H > C=O for release 
• Oxime confers releasing action 
D. Phenyl ring 
• Favors larger substituents such as 4-methoxy and trifluromethyl and 3,4-
ethylenedioxy for release activity 
Transporters are dynamic proteins and all the regions could affect transporter function. It 
has been suggested that ligands can influence different transporter conformations and 
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stabilize different conformational states that contribute towards distinctive activity.124,241,242 
It can be observed from our studies that structural features on synthetic cathinones can 
influence transporter activity and selectivity. Ligand selectivity for a transporter can be 
dependent on one or more of these factors, such as entry of the ligand through the 
extracellular pathway, its binding site, binding pose and interaction with other proteins.243  
 
MDPV-like reuptake inhibitors discussed in AIM I were exclusively selective for DAT 
versus SERT. The hypothesis discussed in AIM I was that there could be a difference in 
the way that ligands enter the transporter that accounts for the MDPV-like compounds to 
be inactive at SERT. This hypothesis is supported by recent studies published by Andersen 
et al.243 for a group of DAT-and NET-selective inhibitors. In this study they compared the 
non-conserved residues in the primary binding site (S1) and residues lining the 
extracellular pathway (mainly EL4 and S2 sites) for hDAT and hNET. They reported that 
for hDAT, residues outside the binding sites confer selectivity for the compounds 
investigated (bupropion (136), cocaine, rimcazole, JHW 007, GBR 12,909) (i.e., residues 
lining the extracellular pathway (mainly EL4 and S2 sites) that lead to the primary binding 
site (S1 site)).  
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They hypothesize that a “selectivity filter” formed by specific residues in the extracellular 
pathway could confer selectivity. It is important to mention that one of the hDAT 
inhibitors that were investigated was a cathinone analog (i.e., bupropion (136)). It is then 
tempting to speculate that perhaps the entry through the extracellular pathway might be an 
important contributor to inhibitor selectivity for cathinone-like compounds. A possible 
hypothesis based on the Andersen et al.243 study is that the “selectivity filter” is different 
for DAT and SERT. Either it is made of residues that are non-conserved between DAT or 
SERT or the “selectivity filter” is located at different positions in DAT and SERT and thus 
both transporters could confer some differences in the ligands it can provide access to. 
Therefore, compounds such as MDPV-like inhibitors cannot pass through this filter on 
SERT and are not given access to the transportor thus rendering them inactive. A similar 
study such as that reported by Andersen et al.243 with cathinone-like molecules would 
address differences in inhibitor selectivity for DAT, NET and SERT.  
 
It is important to recognize here that other proteins such as cholesterol could also 
contribute to the transporter action. Cholesterol has been proposed to play a role in 
stabilizing the outward conformation of dDAT.117 However its role in the binding of 
substrates and inhibitors has yet to be investigated.  
 
Results from AIM II suggested that differences in the selectivity of compounds could be 
addressed based on their interactions and binding modes at their binding site. We identified 
through homology modeling and docking studies that MCAT (57) and its 4-position 
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substituted analogs bind to the primary binding site (S1). Selectivity of their actions for 
DAT versus SERT was dependent on the size of the 4-position substituent that could be 
explained based on differences in the binding pocket of the transporters. hDAT 
accommodates compounds with small substituents at the 4-position (e.g. MCAT (57) and 
4-F MCAT(72) due to a small, more, polar, binding pocket around the 4-position, whereas 
hSERT accommodates larger 4-position substituents (e.g. 4-OCH3 MCAT (73) and 4-CF3 
MCAT (76)). Shortly after our work was published the crystal structures of dDAT with 
AMPH (S(+)2), DA, and METH (S(+)5) identified this same binding site. We also predict 
that this is the reason why the six-membered ethylenedioxy analogs (i.e, EDMA (51)) and 
EDMC (77) investigated in AIM III were less potent than their five-membered 
methylenedioxy analogs (i.e., MDMA (44) and MDMC (61)) at SERT versus DAT.  
 
In AIMS III and IV we observed how minimal structural changes on the N-alkyl chain for 
cathinone and AMPH-like compounds could change the activity of the compounds from a 
full releaser to a partial releaser and eventually a weak reuptake inhibitor. Partial releasers 
differ from full releasers such that they do not release the maximal pool of releasable 
neurotransmitter even at the highest concentrations. Compounds that are fully efficacious 
(100%) for release have smaller structural features than reuptake inhibitors and are 
somewhat similar un structure to endogenous substrates, for example N-methyl 4-MA (80). 
As the structural features are expanded/enlarged compounds start to lose their efficacy for 
release and show partial release and weak reuptake activity; for example, ethylone (78) is a 
partial releaser and a weak reuptake inhibitor at SERT and N-ethyl 4-MA (81) is a partial 
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releaser and a weak reuptake inhibitor at DAT. It is important to note here that these 
compounds were tested as their racemates; studies currently being conducted on their 
enantiomers (prepared by others in our laboratory) should address whether each 
enantiomer has different or similar effects. Compounds that act as releasers are transported 
through the transporter, whereas inhibitors are not, such that they latch the transporter in a 
conformation that prevents the reuptake of the endogenous neurotransmitter. The exact 
mechanism of action of “partial releasers” is, however, still under investigation, but some 
of the theories regarding their mechanism of action are: 
 
1. Rothman et al.244 studied a few phenylalkylamine partial releasers and reported the 
mechanism of their partial release could be attributed to the fact that these compounds have 
a slower rate of efflux than full releasers and they are slower in elevating extracellular DA 
and 5-HT levels in microdialysis studies. They suspect that partial releasers bind to the 
transporter, but modify the transporter conformation in such a way that could affect reverse 
transport. 
 
2. A review by Reith et al.224 reported that partial releasers could bind to a probable S3 site 
below the primary binding  site. 
 
3. Sandtner et al.240 explained that the partial releasing activity of 47 at SERT can be 
explained based on its binding mode. They identified that 47 binds in two modes, the first 
similar to 5-HT and the other was a reverse mode. They hypothesized that by adopting 
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substrate- and inhibitor-like binding modes at all concentrations, 47 would always inhibit a 
fraction of 5-HT even at saturation concentrations. Due to this, it shows activity as a partial 
releaser and a weak reuptake inhibitor. If the individual enantiomers of our compounds 
(e.g. N-ethyl 4-MA (81)) show differing activity (i.e., if one is a reuptake inhibitor and 
other a releaser) then a possible explanation could be based on the hypothesis presented by 
Sandtner et al.240  
 
 
4. Shi et al.125 have proposed that simultaneous binding of another substrate molecule to 
the extracellular S2 and the primary binding site (S1) can trigger the release of substrate 
and ions to the intracellular compartment. If the enantiomers of N-ethyl 4-MA (81), for 
example, have the same activity a proposed hypothesis for our compounds could be related 
to the above mechanism. For example, for N-ethyl 4-MA (81) the second molecule of N-
ethyl 4-MA (78) might not simultaneously bind and facilitate the conformational change 
for inward movement of the transporter. Thus, due to this, the transporter might retain a 
conformation that results in weak reuptake activity and this conformation would probably 
interfere with reverse transport and result in slow efflux of the corresponding monoamine. 
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We have not constructed a homology model of hNET thusfar, but AIM V suggested that 
synthetic cathinones have similar activity at DAT and NET. These similarities could be 
attributed to their higher sequence identity compared to that between DAT and SERT.  
 
 AIMS VI and VII are only preliminary investigations and additional studies and 
compounds are required to obtain conclusive results. However, it was suggested that the 
nitrogen atom of cathinone analogs is an essential feature for release properties as 
compared to reuptake activity. A plausible explanation for this could be that one of the key 
interactions releasers need to make to be transported through the transporter is with the 
conserved aspartate. But, for reuptake inhibitors, this interaction might not be key to the 
transporter conformation required for reuptake action. Another plausible explanation could 
be related to the weak base hypothesis for monoamine release. According to this 
hypothesis amines such as AMPH (2) and cathinone (1) are weak bases and have a pKa of 
9-11. At physiological pH they are protonated and disrupt the acidic pH in the synaptic 
vesicle to cause the release of monoamines. If this hypothesis were true then compounds 
lacking the nitrogen (e.g. 89 and 90) would not be able to act via this mechanism to release 
DA/5-HT/NE; this implies that a nitrogen atom would be vital for release action. 
 
Overall it can be observed that synthetic cathinones are not uniform in their actions and 
selectivity and require a case-by-case study at monoamine transporters as previously 
suggested.145 Each compound should also be investigated on a case-by-case basis for their 
action at the transporter level. 
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The rapid growth of NPSs is a tremendous concern to public health; synthetic cathinones 
constitute a majority of these, and it was thus crucial to understand their mechanisms of 
action. Our work has been very timely and informative. We studied the first generation of 
“bath salts” and subsequent generations (even before they were found on the clandestine 
market), and have also provided predictions for newer cathinone analogs. We were 
successful in classifing drugs based on their mechanism of action, delineating structural 
features that could be potential contributors to selectivity, explained how differences in 
transporter action and selectivity might account for differences in activity.  
 
When this project was initiated in 2010 there were only three main ‘bath salts’ components 
(i.e., methylone (61), mephedrone (62) and MDPV (63)), and only and the availability of 
the prokaryotic LeuT crystal structure as a template (around 20% homology to DAT, 
SERT and NET) to conduct studies at the transporter level. Five years later there are a few 
hundred synthetic cathinones and the availability of crystal structures of the eukaryotic 
dDAT co-crystallized with psychostimulants such as cocaine and (+)AMPH (S(+)2). It 
might be parenthetically noted that our first hSERT model (not described here) was 
constructed on the basics of the LeuT crystal structure. Once the dDAT structure was 
reported, a new model (i.e., that described herein) was constructed. Years of continued 
contribution of research in the field of cathinone and AMPH-like molecules gets us one 
step closer to fundamentally understanding these drugs at the cellular level. Our research 
has provided some of the integral pieces of the yet-to-be-fully-assembled puzzle towards 
understanding the actions of synthetic cathinones at monoamine transporters. 
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VI. Follow-up studies 
 
 
 
Discussed in this chapter are compounds that were synthesized after we had received data 
on our initial AIMS. That is, this study was not one of the original Aims.These compounds 
were intended to either provide further direction to the overall project, engage or extend 
some of the results we obtained, or act as leads to new projects. It should be noted that 
most of the compounds await biological testing. Hence, most of these are follow-up 
studies; biological data are sparse and are currently being obtained. 
 
a. Role of increased bulk at the α-position of cathinone analogs 
Studies in AIM I suggested that one of the features that contributed to reuptake activity at 
DAT is the presence of bulk at the α-position. In vitro potency (pIC50 DAT) was 
significantly correlated with the volume and/or lipophilicity of the α-substituent (r > 0.9). 
However, volume and lipophilicity were highly intercorrelated (r > 0.9); so, we needed to 
synthesize additional analogs to determine which of the two parameters was most 
important. One of the analogs that we synthesized was compound 137, that has a very 
bulky adamantyl group at the α-position and, although it has a secondary amine, due to the 
increased bulk at that position we expect that the compound would be a reuptake inhibitor 
at DAT and inactive at SERT.  
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Scheme 15. Synthesis of compound 137a 
 
 
 
aReagents: (a) Acetophenone, FeBr2, DMSO, t-BuOK; (b) 1-phenyl-1-
trimethylsiloxyethylene, BF3.etherate; (c) thionyl chloride; (d) AlCl3, benzene; (e) Br2, 
AlCl3, Et2O; (f) CH3NH2 in water, KI, K2CO3, DMF. 
 
 
Initially, to synthesize intermediate 141 a literature procedure for the same compound was 
followed (Route 1, Scheme 15).245 The reaction mixture was divided into two parts; to the 
first, fraction column chromatography was attempted but did not yield the compound. 
Instead, what was isolated were only fractions of yellow oils. Since 141 was reported to be 
a solid246 these fractions were not characterized. To the other part, what was observed was 
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that upon the addition of MeOH a solid precipitated that had a melting point above 200°C 
(the mp of 141 is reported as 66-67 °C).246 This reaction has been reported to follow a 
radical nucleophilic reaction, and a possible explanation for this reaction not working is 
that there could be a problem with forming the radical.   
 
Another attempt (Route 2, Scheme 15) was one reported that used 1-fluroadamantane.246 1-
Fluroadamnatane was not easy to synthesize and procedures for its synthesis required 
electrochemical methods247 or required the use of reagents such as IF5 and a specialized 
reaction vessel.248 Since 1-iodoadamantane (138) was readily available, the reaction was 
attempted using it as a starting material (Route 2, Scheme 15). This reaction was also 
unsuccessful and the product was an uncharacterized yellow oil. A possible explanation for 
the reaction failure could be the use of 1-iodoadamantane (138) instead of 1-
fluroadamantane since the reactivity of the former would be less.  
 
The third route that was attempted (Route 3, Scheme 15) was devised based on similar 
compounds previously synthesized in the laboratory. This route, though, had two steps 
more than Routes 1 and 2; however, it provided compound 137. Compound 137 is yet to 
be evaluated. 
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b. Role of the 4-position substituent of MCAT to release/inhibit uptake of 
monoamines in rat brain synaptosomes 
 
In AIM II it was concluded that the steric nature (i.e., size = bulk/volume) of the 4-position 
substituent of MCAT (57) analogs influenced their neurochemical and behavioral 
actions/potency at DAT and SERT. We found that the in vivo and in vitro data were highly 
correlated with the size of their 4-position substituent; however, the parameters used in our 
study (B1, B5, L, and volume) ranged only over a narrow range and were highly 
intercorrelated (r > 0.9; see AIM II). To address the above we synthesized two additional 
agents: 4-t-butylmethcathinone  (4-t-Bu MCAT (143)) and 4-benzylmethcathinone  (4-Bz 
MCAT (144)). Their syntheses are outlined in Scheme 16.  
 
Scheme 16. Synthesis of compounds 143 and 144a 
 
aReagents: (a) Propionyl chloride, AlCl3, CH2Cl2; (b) Br2, AlCl3, Et2O; c) CH3NH2 in 
EtOH, benzene. 
 
These compounds were tested for their in vitro effects in rat synaptosomes (Figure 46, 
Table 28). 4-Bz MCAT (144) was essentially inactive at both DAT and SERT (Figure 46 
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and Table 28). 4-t-Bu MCAT (143) showed weak activity at DAT for release (efficacy less 
than 50%) and reuptake, and was inactive at SERT (Figure 45 and Table 28).  
 
The Verloop parameters for the 4-position substituents of 143 and 144 and their volume 
are shown in Table 28. 
 
Table 28. Verloop parameters, volume and in vitro data at DAT and SERT. 
 
Compound 
 
Vol 
 
L 
 
B1 
 
B5 
DAT 
EC50 
nM 
SERT 
EC50 
nM 
DAT 
IC50 
nM 
SERT 
IC50 
nM 
4-t-Bu MCAT 
(143) 
218.17 4.11 2.59 2.97 941.9 * 2207 ** 
4-Bz MCAT 
(144) 
234.46 3.63 1.52 6.02 ** ** ** ** 
*Inactive at concentrations up to 1 µM 
** >10,000 nM 
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Figure 46. Effects of 4-t-Bu MCAT (143) and 4-Bz MCAT (144) on monoamine release 
and uptake in rat brain synaptosomes.  Top panels show drug effects on monamine uptake 
inhibition.  Abscissae: drug concentration in log M.  Ordinates: Percent uptake inhibition 
of [3H]MPP+ or [3H]5-HT. Bottom panels show drug effects on monoamine release.  
Abscissae: drug concentration in log M.  Ordinates: Percent release of [3H]MPP+ (A) or 
[3H]5-HT (B). EC50 and IC50 values determined from these curves are reported in Table 28.  
All points show mean (±SEM) of three determinations (Figure provided by Dr. Baumann’s 
laboratory).  
 
Both compounds were docked and analyzed in homology models of hDAT and hSERT 
using methods described in AIM II. The transporter models chosen for hDAT and hSERT 
were the same as those as in AIM II and docking solutions obtained through clustering 
techniques for that transporter model were analyzed.  
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At hDAT*, the docking studies showed that 4-t-Bu MCAT (143) and 4-Bz MCAT (144) 
occupied the same binding site as MCAT (57) but with different orientations (Figures 47A, 
B and D). Similar interactions were observed both for 4-t-Bu MCAT (143) and 4-Bz 
MCAT (144) (Figures 47A and B). For both compounds the terminal amine made an 
interaction with the D79, an additional bifurcated hydrogen bond interaction was also 
observed with the backbone carbonyl of F320 and S321. Another hydrogen bond was 
observed between the carbonyl group and the side chain of S422. The N-CH3 group was 
oriented in a manner such that it made a hydrophobic interaction with F76. The phenyl ring 
was oriented in a manner such that it made a π-π interaction with Y156 and an edge to face 
interaction with F326 for 4-t-Bu MCAT (143) and for 4-Bz MCAT (144) only the edge to 
face interaction with F326 was seen. A hydrophobic pocket lined by I148, F326, F155, 
S149, V152, G153, Y156, G425, G426, A423 and G153 surrounded the 4-t-Bu substituent. 
The 4-Bz group is large and was oriented differently in a hydrophobic pocket and was 
surrounded by I484, A489, V145, A480, I148, V152, S149, S429, I484, I146, F326, G153, 
G425, G426 such that it formed a π-π interaction with F326.  
             
*The docking studies were performed with the assistance of Dr. Kolanos.  
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Figure 47. Docking studies of 4-t-Bu MCAT (143) and 4-Bz MCAT (144) at the putative 
binding site of hDAT. A) Putative binding mode of 4-t-Bu MCAT (143), B) Putative 
binding mode of 4-Bz MCAT (144), C) Unfavorable interactions due to S149 and F326, 
D) Superimposed poses of MCAT (57, green), 4-t-Bu MCAT (143, magenta), and 4-Bz 
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MCAT (144, purple). Pink and green circles in A-C are sodium and chloride ions 
respectively. Interacting amino acids are within 5Å are indicated for A an B. 
 
4-Bz MCAT (144) is inactive at DAT as a releasing agent or reuptake inhibitor at a 
concentration of 1 µM and a possible explanation is that the 4-Bz substituent of 144 is too 
large to be accommodated in the hDAT binding-pocket. Figure 46C indicates that the 4-
benzyl substituent is too close to S149 and F326 and this probably leads to unfavorable 
interactions that contribute towards the compound being inactive at DAT. Crystal 
structures of dDAT complexed with cocaine and AMPH (S(+)2) show that reuptake 
inhibitors and releasers both occupy the same binding-site.118 The reuptake inhibitor 4-t-Bu 
MCAT (143) is proposed to occupy the same binding site as MCAT (57).  
 
At hSERT, 4-t-Bu MCAT (143) and 4-Bz MCAT (144) are oriented differently (Figure 
48A, B and C). The docking pose of 4-t-Bu MCAT (143) showed that the terminal amine 
formed a cation-π interaction with Y95 and an additional hydrogen bond with the 
backbone of Y95. The carbonyl group additionally made a H-bond with the side chain of 
Y95. Hydrophobic residues F335, F341 and Y176 surrounded the phenyl ring and residues 
S497, G458, Y175, F335, V501, Q498, T497, and I179 surrounded the 4-t-Bu substituent. 
The docking pose of 4-Bz MCAT (144) did not indicate a lot of interactions except for a 
cation-π interaction with Y95. Residues R104, A401, W103, Q493, G100, N101, G332, 
A331, F335 and S336 surrounded the diphenylmethane group. 4-t-Bu MCAT (143) and 4-
Bz MCAT (144) did not form an interaction with D98 and adopted a binding pose different 
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than that of MCAT (57) (Figure 47C). This could perhaps be the reason why these 
compounds are inactive at hSERT. 
 
 
Figure 48. Docking studies of 4-t-Bu MCAT (143) and 4-Bz MCAT (144) at the putative 
binding site of hSERT. A) Putative binding mode of 4-Bz MCAT (144), B) Putative 
binding mode of 4-t-Bu MCAT (143), C) Superimposed poses of MCAT (57, green), 4-t-
Bu MCAT (143, magenta), and 4-Bz MCAT (144, purple). Pink and green circles in A-C 
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are sodium and chloride ions respectively. Interacting amino acids are within 5Å are 
indicated for A an B. 
 
 
Table 29. Calculated HINT scores for interaction of MCAT analogs with hDAT and 
hSERT. 
 
 HINT Score at hDAT (4-substituent only) 
 Total Polar Hydrophobic 
4-t-Bu MCAT (143)   52      -352     404 
4-Bz MCAT (144) 146        40     186 
 HINT Score at hSERT (4-substituent only) 
4-t-Bu MCAT (143)   -170     -351    181 
4-Bz MCAT (144)   -175    -215      40 
 
At hDAT, based on HINT scores (Table 29) and docking studies, we cannot conclusively 
explain the in vitro activity of 4-t-Bu MCAT (143) and 4-Bz MCAT (144). Perhaps 4-Bz 
MCAT (144) is so large that it does not even enter the transporter whereas 4-t-Bu MCAT 
(143) enters the transporter but is too large to be transported and possess release properties. 
 
 In the hSERT model, the compounds were oriented in a completely different manner than 
MCAT (57) and, together with negative HINT scores (Table 29), suggest, perhaps, why 
these compounds are inactive. Future studies involving molecular dynamics should address 
how these molecules interact with the transporter. 
 
c. Hybrid compounds 
AIM II indicated that the presence of a methoxy group at the 4-position of MCAT (i.e., 
methedrone, 66) confers selectivity for SERT over DAT. AIM I indicated that pyrrolidine- 
containing compounds, for e.g. 97, are reuptake inhibitors at DAT and inactive at SERT. 
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Our aim was to convert a DAT selective compound, to a compound possessing hybrid 
properties for both DAT and SERT. Hybrid compounds should produce effects different 
from dual releasers and reuptake inhibitors since they would increase extracellular DA/5-
HT levels at a different rate.224 Such compounds could also have some therapeutic 
potential.224 Compound 151 has the pyrrolidine feature for DAT selectivity and the 4-
methoxy substituent that confers SERT selectivity. We expect compound 151 to be a 
reuptake inhibitor at DAT and a weak reuptake inhibitor (or a partial releaser) at SERT. Its 
synthesis is shown in Scheme 17. Compound 151 is yet to be pharmacologically 
investigated. 
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Scheme 17. Synthesis of compound 151a 
 
 
 
aReagents: (a) Br2, AlCl3, Et2O; b) pyrrolidine. 
 
 
 
d. Role of the pyrrolidine ring on AMPH-like compounds 
It is known that PAA-like compounds can act as releasers and tthat he presence of a 
pyrrolidine ring on the cathinone scaffold confers reuptake properties. According to 
Heinzelman and Aspergren, PAAs with tertiary amines confer interesting pharmacological 
properties.249 They also described that some pyrrolidine-containing PAAs have 
sympathomimetic effects (bronchodilation).249 Patents by G.M.B.H reported on the central 
stimulation properties of several pyrrolidine-and piperidine-containing PAAs.250,251  
However the mechanism of action of pyrrolidine-containing PAAs has not been reported; 
hence, we prepared analog 154 to investigate its action at monoamine transporters.  
 
The synthesis of this compound was attempted by two routes (Scheme 18). The first route 
of catalytic hydrogenation was attempted since 97 was previously synthesized and was on 
hand. However this route has not been reported for the synthesis of 154. Route 1 (Scheme 
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18) was attempted twice, first on a small scale (0.14 g), which gave a product that was a 
mixture of two uncharacterized compounds. Purification by distillation was not attempted 
because only 0.04 g of the crude product was obtained. In the second attempt a larger 
quantity of 97 was used (0.30 g) which gave a mixture of uncharacterized crude product 
(0.15 g) that could not be successfully purified by Kugelrohr distillation. 
The second route attempted (Route 2, Scheme 18) was reported for compound 154250 and 
successfully yielded 154 (Scheme 18). 
Compound 154 is yet to be pharmacologically evaluated. 
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Scheme 18. Synthesis of compound 154a 
 
 
aReagents: (a) Pd/C, CH3COOH, HClO4; (b) KCN, Et2O; c) benzylmagnesium chloride, 
Et2O. 
 
  
e. Effect of the α-side chain of MCAT for monoamine release action 
 
AIM I indicated that decreased side chain length at the α-position on MDPV-like reuptake 
inhibitors resulted in loss of potency. The effect of decreased side chain at the α-position 
on MCAT (57) has not been investigated at DAT, SERT and NET. For AMPH-like 
releasers such as PEA (23), a lack of central effects has been reported.77 Hyde et al.142 
reported that 156 caused an increase in blood pressure however its mechanism of action 
CH3
N
N
H
N
H3C CN
b cCH3CHO +
CH3
O
N
aRoute 1
Route 2
154155
97
X
 217 
remains uninvestigated.142 We therefore synthesized the desmethyl analog of MCAT (57) 
(i.e., compound 156) to investigate its effects at monoamine transporters. 
Scheme 19. Attempted synthesis of compound 156a 
 
aReagents: (a) CH3NH2 in EtOH, benzene (b) CH3NH2 in EtOH, CH3CN; (c) CH3NH2 in 
EtOH, benzene; (d) CH3NH2 in EtOH, toluene. 
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The synthesis of 156 was attempted by different routes. Route 1 has been reported for 
similar compounds142 and was attempted due to the availability of 105 in the laboratory. In 
route 1 (Scheme 18) an attempt was made to form the hydrochloride salt first since it was 
reported142 but it was sticky and did not precipitate. Consequently, an oxalate salt was 
attempted but it too was sticky.  
 
Route 2 was reported for the same compound.252 The reaction mixture was divided in two 
portions before the work up. The first portion was worked up according to the procedure 
for this route and an attempt was made to form the hydrochloride salt, but it was sticky and 
did not precipitate. The second portion was worked up as reported in Hyde et al.142 (work 
up for the same compound is reported) and that gave a precipitate that had a mp >230°C 
which, likely was methylamine hydrochloride (lit.253 mp 231-233 °C). 
 
Route 3 has been reported for the same compound.142 The reaction led to a tarry product 
that was washed with CHCl3 as reported in the procedure and additional charcoal filtering 
yielded the product. The yield was poor (less than 1% yield without recrystallization). To 
scale up the reaction it was attempted yet another time however the melting point was low 
and not sharp (201-208 °C) and the compound obtained was not clean (as seen on TLC) 
and due to the low yield (less than 1%) compound could not be purified further.  
 
The procedure for Route 4 was not reported and toluene was used as a solvent. The work 
up of this reaction followed the procedure described by Hyde et al.142 for the same 
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compound and resulted in a solid mp 198-200 °C but due to extremely low yields ( less 
than 1%) it could not be characterized by NMR. 
 
The above reactions gave difficulty in forming the salt or resulted in the formation of tarry 
products and hence resulted in very low yields. Another synthetic route,254   reported for 
similar compounds was attempted (Scheme 20) to synthesize 156.254  Even though this 
route had two steps more in the final step of the hydrochloride salt is formed in situ and 
hence it would be a solution to the salt formation problem. Compound 156 was then 
successfully obtained by this method (Scheme 20). 
Compound 156 has yet to be investigated. 
Scheme 20. Synthesis of compound 156a 
 
 
aReagents: (a) Trifluroacetic anhydride, CH2Cl2; (b) oxalyl chloride, benzene, pyridine; (c) 
i) AlCl3, benzene ii) conc. HCl, i-PrOH. 
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VII. Experimentals 
 
 
 
 
Melting points (mp) were measured on a Thomas-Hoover melting point apparatus using 
glass capillary tubes and are uncorrected. 1H NMR spectra were recorded on a Varian 400 
MHz spectrometer using tetramethylsilane (TMS) as an internal standard. Peak positions 
are given in parts per million (d). Elemental analysis was performed by Atlantic Microlab 
Inc. (Norcross, GA) for the elements indicated and the results are within 0.4% of 
calculated values. 
 
Infrared spectra were obtained on a Thermo Nicolet iS10 FT-IR. Flash chromatography 
was performed on CombiFlash Companion/TS (Telodyne Isco Inc., Lincoln, NE) using 
packed silicagel (Silica Gel 230-400 mesh) columns (RediSep Rf Normal-phase Silica 
Flash Column, Teledyne Isco Inc., Lincoln, NE). All reactions were monitored by thin-
layer chromatography (TLC) on silica gel GHLF plates (250 m, 2.5 x 10 cm; Analtech 
Inc., Newark, DE). 
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1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)-N-methylpropan-2-amine Hydrochloride 
(51). A solution of 112 (0.30 g, 1.13 mmol) in anhydrous THF (12 mL) was added in a 
dropwise manner to a stirred suspension of LiAlH4 (0.13 g, 3.40 mmol) in anhydrous THF 
(12 mL) at 0 °C under an N2 atmosphere. After completion of the addition, the reaction 
mixture was heated at reflux for 3 h, and then quenched at 0 °C by the dropwise addition of 
Et2O (50 mL), H2O (3 mL) and 15% NaOH (0.50 mL). The mixture was stirred, filtered 
and the filtrate was dried (Na2SO4). The solvent was evaporated under reduced pressure to 
give a yellow oily residue that was dissolved in absolute EtOH (5 mL) and converted to its 
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization 
from i-PrOH afforded 0.03 g (11%) of 51 as a white solid: mp 150-151 °C; 1H NMR 
(DMSO-d6) δ 1.25 (d, J = 6.5 Hz, 3H, CH3), 2.54 (s, 3H, CH3), 2.52-2.5 (m, 1H, CH), 
3.08-3.13 (m, 1H, CH), 3.26-3.30 (m, 1H, CH), 4.22 (s, 4H, CH2), 6.66 (dd, J = 8.2, 1.9 
Hz, 1H, ArH), 6.74 (d, J = 1.9 Hz, 1H, ArH), 6.80 (d, J = 8.2 Hz, 1H, ArH), 8.86 (s, 3H, 
NH3+, D2O ex); Anal. Calcd for (C12H17NO2·HCl) C, 59.14; H, 7.44; N, 5.75.  Found: C, 
58.91; H, 7.42; N, 5.53. 
 
1-(Benzo[d]-1,3-dioxol-5-yl)-2-(pyrrolidin-1-yl)propan-1-one Hydrochloride (65). This 
compound is reported in the literature and was synthesized according to the literature 
procedure.255 Pyrrolidine (0.24 mL, 2.90 mmol) was added to a stirred solution of 94 (0.37 
g, 1.45 mmol) in anhydrous benzene (3 mL) at room temperature under an N2 atmosphere. 
The reaction mixture was allowed to stir at room temperature for 6 h followed by heating 
at reflux for 2 h. The reaction mixture was allowed to cool to room temperature, Et2O (5 
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mL) was added, and the mixture was washed with H2O (3 x 5 mL). The organic portion 
was dried (MgSO4) and solvent was removed under reduced pressure. The obtained residue 
(0.29 g) was converted to the hydrochloride salt using a saturated solution of HCl/Et2O 
which upon recrystallization from absolute EtOH/Et2O afforded 0.14 g (40%) of 65 as a 
white powder: mp 244-246 °C (lit.255 mp 242-243 °C); IR (Diamond, cm-1) 3378 (N-H), 
1672 (C=O), 1456 (CH2O), 1254 (C-O); 1H NMR (DMSO-d6) δ 1.52 (d, J = 7.0 Hz, 3H, 
CH3), 1.96 (m, 4H, CH2), 2.98–3.12 (m, 1H, CH2), 3.12–3.26 (m, 1H, CH2), 3.50–3.60 (m, 
1H, CH2), 3.60–3.70 (m, 1H, CH2) 5.39 (m, 1H, CH), 6.23 (s, 2H, CH2O), 7.18 (d, J = 8.2 
Hz, 1H, ArH) 7.56 (d, J = 1.6 Hz, 1H, ArH), 7.73 (dd, J = 8.2, 1.7 Hz, 1H, ArH), 10.50 (s, 
1H, NH+).  
 
1-(Benzo[d]-1,3-dioxol-5-yl)-2-(dimethylamino)propan-1-one Hydrochloride (66). This 
compound is reported in the literature and was synthesized according to the literature 
procedure.256 Dimethylamine (2M in MeOH, 1.16 mL, 2.32 mmol) was added to a stirred 
solution of 94 (0.30 g, 1.16 mmol) in anhydrous benzene (3 mL) at room temperature 
under an N2 atmosphere. The reaction mixture was allowed to stir at room temperature for 
4 h followed by heating at reflux for 3 h. The solvents were evaporated under reduced 
pressure. The residue was dissolved in Et2O (5 mL) and the solution was washed with H2O 
(3 x 5 mL). The organic portions were combined, dried (MgSO4), and the solvent was 
evaporated under reduced pressure. The obtained residue (0.20 g) was converted to the 
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization 
from absolute EtOH/Et2O to afford 0.05 g (20%) of 66 as a white powder: mp 253-255 °C 
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(lit.256 mp  252-254 °C) (MeOH/EtOH); 1H NMR (DMSO-d6) δ 1.47 (d, J = 7.1 Hz, 3H, 
CH3), 2.83 (br s, 6H, CH3), 5.29 (q, J = 14.2, 7.08 Hz, 1H, CH), 6.19 (s, J =1.0 Hz, 2H, 
CH2), 7.4 (d, J = 8.2 Hz, 1H, ArH) 7.53 (s, J =1.6 Hz, 1H, ArH), 7.73 (dd, J = 8.3, 1.8 Hz, 
1H, ArH), 10.33 (s, 1H, NH+).  
 
1-(Benzo[d]-1,3-dioxol-5-yl)-2-(methylamino)pentan-1-one Hydrochloride (68). This 
compound is reported in the literature and was synthesized according to the literature 
procedure.257 Methylamine (33% in EtOH, 0.35 mL, 2.80 mmol) was added to a stirred 
solution of 95 (0.20 g, 0.70 mmol) in anhydrous benzene (2 mL) at room temperature 
under an N2 atmosphere in a sealed tube. The reaction mixture was allowed to stir at room 
temperature for 36 h. The solvent was then evaporated under reduced pressure and the 
residue dissolved in EtOAc (5 mL) and washed with H2O (5 mL). The H2O layer was 
extracted with EtOAc (3 x 2 mL). The organic portion was dried (MgSO4), and solvent 
was evaporated under reduced pressure. The obtained residue (0.15 g) was converted to the 
hydrochloride salt which upon recrystallization from absolute EtOH/Et2O afforded 0.04 g 
(24%) of 68 as a white powder: mp 224-225 °C (lit.257 mp 221-225 °C ); 1H NMR (DMSO-
d6) δ 0.80 (t, J = 7.2 Hz, 3H, CH3), 1.03–1.30 (m, 2H, CH2), 1.76–1.80 (m, 2H, CH2), 2.54 
(s, 3H, CH3), 5.11 (t, J = 5.4 Hz, 1H, CH), 6.19 (s, 2H, CH2O), 7.13 (d, J = 8.2 Hz, 1H, 
ArH) 7.53 (d, J =1.6 Hz, 1H, ArH), 7.71 (dd, J = 8.2, 1.7 Hz, 1H, ArH), 9.14 (s, 1H, NH+).  
 
1-(4-Fluorophenyl)-2-(methylamino)propan-1-one Hydrochloride (72). This compound 
is reported in the literature and was synthesized according to the literature procedure.258 
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Methylamine (33% in EtOH, 6.30 mL, 51.60 mmol) was added to a stirred solution of 108 
(3.00 g, 12.19 mmol) in anhydrous benzene (30 mL) at room temperature under an N2 
atmosphere. The reaction mixture was allowed to stir at room temperature for 20 h. The 
solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc (15 
mL) and the solution was washed with H2O (3 x 5 mL). The organic portions were 
combined and acidified with 2M HCl (20 mL, pH=1). The aqueous portion was basified 
with 3M NaOH (20 mL, pH=14), and extracted with EtOAc (15 mL). The combined 
organic portions were washed with H2O (3 x 5 mL), dried (MgSO4), and evaporated to 
dryness under reduced pressure to yield a residue that was converted to the hydrochloride 
salt which upon recrystallization from absolute EtOH afforded 0.07 g (20%) of 72 as a 
white powder: mp 223-224 °C (lit.258 mp  222 °C); 1H NMR (DMSO-d6) δ 1.44 (d, J = 7.2 
Hz, 3H, CH3), 2.60 (s, 3H, CH3), 5.16 (q, J = 14.6, 7.2 Hz, 1H, CH), 7.46 (t, J = 8.8 Hz, 
2H, ArH), 8.12 (dd, J = 5.4, 2.1 Hz, 2H, ArH), 9.22 (s, 1H, NH+).  
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)-2-(methylamino)propan-1-one Hydrochloride 
(77). This compound is reported in the literature (no physical data).257 Methylamine (33% 
in EtOH, 1.62 mL, 13.08 mmol) was added to a stirred solution of 115 (0.88 g, 3.27 mmol) 
in anhydrous benzene (12 mL) at room temperature under an N2 atmosphere in a sealed 
tube. The reaction mixture was allowed to stir at room temperature for 36 h. The reaction 
mixture was filtered and the solvent was then evaporated under reduced pressure and the 
residue dissolved in Et2O (25 mL) and washed with H2O (3 x 5 mL). The organic portions 
were combined and acidified with 2M HCl (10 mL). The aqueous portion was basified 
with saturated NaHCO3 (25 mL), and extracted with Et2O (3 x 10 mL). The combined 
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organic portions were washed with brine (3 x 5 mL), dried (Na2SO4), and evaporated to 
dryness under reduced pressure to yield a residue  (0.15 g) as a free base that was 
converted to the hydrochloride salt which upon recrystallization from absolute EtOH/Et2O 
afforded 0.04 g (6%) of 77 as a buff-colored powder: mp 218-219 °C; 1H NMR (DMSO-
d6) δ 1.43 (d, J = 7.1 Hz, 3H, CH3), 2.57 (s, 3H, CH3), 4.33 (m, 4H, CH2O), 5.07 (m, 1H, 
CH), 7.05 (d, J = 8.4 Hz, 1H, ArH), 7.56 (dd, J = 5.7, 1.9 Hz, 2H, ArH), 9.28 (s, H, NH+). 
Anal. calcd for (C11H15NO2 x HCl) C, 55.93; H, 6.26; N, 5.43.  Found: C, 56.01; H, 6.12; 
N, 5.33. 
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)-2-(ethylamino)propan-1-one Hydrochloride 
(78). Ethylamine (2M in MeOH, 10.50 mL, 21.00 mmol) was added to a stirred solution of 
94 (1.14 g, 4.43 mmol) in anhydrous benzene (15 mL) at 0 °C in a sealed tube. The 
reaction mixture was allowed to stir at room temperature for 24 h and then the solvents 
were evaporated under reduced pressure. The residue was dissolved in Et2O (25 mL) and 
the organic layer was washed with H2O (3 x 15 mL) and separated. The organic layer was 
acidified with 1M HCl (25 mL, pH=1), and then the aqueous portion was separated and 
basified with 1M NaOH (30 mL, pH=14) and extracted with Et2O (3 x 20 mL).  The 
organic portions were combined, dried (Na2SO4), and evaporated under reduced pressure 
to yield 1.46 g of the free base which was converted into the hydrochloride salt using a 
saturated solution of HCl/Et2O which upon recrystallization from absolute EtOH/i-PrOH 
afforded 0.66 g (25%) of 78 as a buff-colored solid: mp 223-226 °C; 1H NMR (DMSO-d6) 
δ 1.25 (t, J = 7.2 Hz, 3H, CH3), 1.44 (d, J = 7.1 Hz, 3H, CH3), 2.83-3.04 (m, 2H, CH2), 
5.11 (q, J = 14.2, 7 Hz, 1H, CH), 6.19 (s, 2H, OCH2), 7.13 (d, J = 8.2 Hz, IH, ArH), 7.56 
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(d, J = 1.7 Hz, 1H, ArH), 7.73 (dd, J = 8.3, 1.8 Hz, 1H, ArH), 9.20 (br s, 2H, NH2+); Anal. 
Calcd for (C12H15N·HCl·0.2H2O) C, 55.16; H, 6.33; N, 5.36.  Found: C, 55.28; H, 6.42; N, 
5.24. 
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)-2-(propylamino)propan-1-one Hydrochloride 
(79). Propylamine (0.72 mL, 28.86 mmol) was added to a stirred solution of 94 (1.14 g, 
4.43 mmol) in anhydrous benzene (6 mL) at 0 °C in a sealed tube. The reaction mixture 
was allowed to stir at room temperature for 18 h followed by heating at 45 °C for 6 h. The 
solvents were evaporated under reduced pressure. The residue was dissolved in Et2O (15 
mL) and the organic layer was washed with H2O (2 x 5 mL) and separated. The organic 
portion was acidified with 1M HCl (25 mL, pH=1), the aqueous portion was separated and 
washed with Et2O (2 x 10 mL) and then basified with 1M NaOH (20 mL, pH=14) and 
extracted with Et2O (3 x 10 mL).  The organic portions were combined, dried (Na2SO4), 
and evaporated under reduced pressure to yield 0.43 g of the free base which was 
converted into the hydrochloride salt using a saturated solution HCl/Et2O which upon 
recrystallization from absolute EtOH/i-PrOH afforded 0.21 g (18%) of 79 as a buff-colored 
solid: mp 202-203 °C; 1H NMR (DMSO-d6) δ 0.92 (t, J = 7.4 Hz, 6H, CH3), 1.45 (d, J = 
7.1 Hz, 3H, CH3), 1.75-1.65 (m, 2H, CH2), 2.96-2.67 (m, 2H, CH2), 5.13 (d, J = 7 Hz, 1H, 
CH), 6.19 (s, 2H, CH2), 7.13 (d,  J = 8.2 Hz, 1H, ArH), 7.56 (d, J = 1.7 Hz, 1H, ArH), 7.72 
(dd, J = 8.3, 1.8 Hz, 1H, ArH), 9.00 (s, 1H, NH+), 9.60 (s, 1H, NH+); Anal. Calcd for 
(C13H17N·HCl) C, 57.46; H, 6.68; N, 5.15.  Found: C, 57.42; H, 6.79; N, 5.09. 
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N-Ethyl-1-(p-tolyl)propan-2-amine Hydrochloride (81). In a three-necked flask 
equipped with a CaCl2 guard tube a solution of 119 (0.62 g, 3.24 mmol) in anhydrous THF 
(15 mL) was added in a dropwise manner to a stirred suspension of LiAlH4 (0.18 g, 4.86 
mmol) in anhydrous THF (20 mL) at 0 °C under an N2 atmosphere. After completion of the 
addition, the reaction mixture was heated at reflux for 18 h. The reaction was worked up at 
0 °C by the addition of Et2O (50 mL), and then by the dropwise addition of H2O (1 mL), 
15% NaOH (1 mL) and H2O (3 mL). The mixture was stirred, filtered and the filtrate was 
washed with water (10 mL) and dried (Na2SO4). The solvent was evaporated under 
reduced pressure to give 0.20 g of a yellow oily residue that was converted to its 
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization 
from i-PrOH/Et2O afforded 0.08 g (12%) of 81 as a white solid: mp 160-161 °C; 1H NMR 
(DMSO-d6) δ 1.31 (d, J = 6.5 Hz, 3H, CH3), 1.47 (t, J = 7.2 Hz, 3H, CH3), 2.72-2.74 (m, 
2H, CH2), 2.78-2.84 (m, 1H, CH), 3.28-3.15 (m, 2H, CH2), 3.56 (s, 3H, CH3), 7.36 (s, 4H, 
ArH), 9.26 (br s, 2H, NH2+); Anal. Calcd for (C12H19N·HCl·0.1H2O) C, 66.87; H, 9.45; N, 
6.50.  Found: C, 66.84; H, 9.30; N, 6.37. 
 
N-Propyl-1-(p-tolyl)propan-2-amine Hydrochloride (82). Method A: In a three-necked 
flask equipped with a CaCl2 guard tube a solution of 120 (0.42 g, 2.05 mmol) in anhydrous 
THF (20 mL) was added in a dropwise manner to a stirred suspension of LiAlH4 (0.12 g, 
3.07 mmol) in anhydrous THF (10 mL) at 0 °C under an N2 atmosphere. After completion 
of the addition, the reaction mixture was heated at reflux for 17 h, and then quenched at 0 
°C by diluting with Et2O (20 mL), and dropwise addition of H2O (1 mL), 15% NaOH (1 
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mL) and H2O (3 mL). The mixture was stirred, filtered and the filtrate was washed with 
water (2 x 10 mL), separated and dried (Na2SO4). The solvent was evaporated under 
reduced pressure to give 0.30 g of a yellow oily residue that was converted to its 
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization 
from i-PrOH/Et2O afforded 0.10 g (21%) of 82 as a white solid: mp 183-184 °C; 1H NMR 
(DMSO-d6) δ 0.93 (t, J = 7.4 Hz, 3H, CH3), 1.08 (d, J = 6.5 Hz, 3H, CH3), 1.68 (q, J = 7.5, 
2H, 15 Hz, CH2), 2.28 (s, 3H CH3), 2.56-2.53 (m, 1H, CH), 2.91-2.87 (m, 2H, CH2), 3.10 
(d, J = 13 Hz, 1H, CH), 3.33-3.29 (m, 1H, CH), 7.36 (s, 4H, ArH), 9.26 (br s, 2H, NH2+, 
D2O ex.); Anal. Calcd for (C13H21N·HCl) C, 68.55; H, 9.74; N, 6.15.  Found: C, 68.37; H, 
9.67; N, 6.11. 
 
Method B: 
In a 3-neck flask, glacial acetic acid was added slowly to a stirred solution of n-
propylamine (52.0 mL, 641.25 mmol) in MeOH (100 mL) in an ice bath until pH ≈ 6. 
Once all the glacial acetic acid was added, 121 (1.00 g, 6.75 mmol) was added, followed 
by the portionwise addition of NaCNBH3 (1.25 g. 19.91 mmol). The ice bath was removed 
and the contents were allowed to stir at room temperature for 20 h. The reaction mixture 
was then basified by the addition of saturated aqueous solution of NaOH (300 mL, 
pH=14), and extracted with Et2O (4 x 50 mL). The combined organic portion was washed 
with H2O (3 x 50 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure 
to yield 1.20 g of a yellow oil which was converted to its hydrochloride salt using a 
saturated solution of HCl/Et2O which upon recrystallization from absolute EtOH/Et2O 
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afforded 0.60 g (36%) of 82 as a white solid: mp 180 °C; 1H NMR (DMSO-d6) δ 0.93 (t, J 
= 7.5 Hz, 3H, CH3), 1.10 (d, 3H, CH3), 1.74-1.64 (m, 2H, CH2), 2.28 (s, 3H, CH3), 2.59 (q, 
J = 12.9, 10.5 Hz, 1H, CH), 2.91-2.86 (m, 2H, CH2), 3.39-3.20 (m, 2H, CH2), 7.13 (s, 4H, 
ArH), 9.05 (br s, 2H, NH2+).  
 
N-Butyl-1-(p-tolyl)propan-2-amine (83). In a 3-neck flask, glacial acetic acid was added 
slowly to a stirred solution of n-butylamine (60 mL, 641.25 mmol) in MeOH (100 mL) in 
an ice bath until pH ≈ 6. Once all the glacial acetic acid was added, 121 (1.00 g, 6.75 
mmol) was added, followed by the portionwise addition of NaCNBH3 (1.25 g. 19.91 
mmol). The ice bath was removed and the contents were allowed to stir at room 
temperature for 20 h. The reaction mixture was then basified by the addition of a saturated 
aqueous solution of NaOH (250 mL, pH=14), and extracted with Et2O (3 x 50 mL). The 
combined organic portion was washed with H2O (3 x 20 mL), dried (Na2SO4), and 
evaporated to dryness under reduced pressure to yield 1.50 g of a yellow oil which was 
converted to its hydrochloride salt using a saturated solution of HCl/Et2O which upon 
recrystallization from absolute EtOH/Et2O afforded 0.70 g (42%) of 83 as a white solid: 
mp 206-208 °C; 1H NMR (DMSO-d6) δ 0.91 (t, J = 7.4 Hz, 3H, CH3), 1.09 (d, J = 6.5 Hz, 
3H, CH3), 1.38-1.33 (m, 2H, CH2), 1.60-1.68 (m, 2H, CH2), 2.28 (s, 3H, CH3), 2.59 (q, J = 
10.4, 13. 0 Hz, 1H, CH), 2.90-2.94 (m, 2H, CH2), 3.09-3.30 (m, 2H, CH2), 7.14 (s, 4H, 
ArH), 8.85 (br s, 2H, NH2+, D2O ex); Anal. Calcd for (C14H23N·HCl·0.15 H2O) C, 68.77; 
H, 10.02; N, 5.73.  Found: C, 68.67; H, 10.13; N, 5.84. 
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Phenyl(piperidin-2-yl)methanone Hydrochloride (84). Pipecolic acid (123) (0.50 g, 3.87 
mmol) was added to a suspension of PCl5 (0.81 g, 3.87 mmol) in anhydrous CH2Cl2 (15 
mL) at 0 °C under an N2 atmosphere. The reaction mixture was allowed to warm to room 
temperature and stirred for 3 h. The solvent was evaporated under reduced pressure. The 
residue was dried under high vacuum for 1 h and washed with toluene and acetone to yield 
pipecolic acid chloride as a yellow-colored solid (0.66 g): mp 131-137 °C; IR (Diamond, 
cm-1) 1768 (COCl). Pipecolic acid chloride is known259 but was synthesized according a 
procedure for a similar compound.260 AlCl3 (1.56 g, 11.61 mmol) was added to a 
suspension of the above acid chloride in anhydrous benzene under an N2 atmosphere and 
stirred at room temperature for 18 h followed by heating at 60 °C for 24 h. The reaction 
mixture was allowed to warm to room temperature and a mixture of 1M HCl (5 mL) and 
ice (7 g) was added. The organic layer was separated. The aqueous layer was washed with 
EtOAc (20 mL). The aqueous portion was basified with 3M NaOH (50 mL), and extracted 
with CH2Cl2 (3 x 25 mL). The combined organic portions were dried (Na2SO4), and 
evaporated to dryness under reduced pressure to yield a solid residue (0.12 g): mp 84-87 
°C (lit.261 mp 89-91 °C (EtOAc)). This was converted to the hydrochloride salt using a 
saturated solution of HCl/Et2O which upon recrystallization from MeOH/EtOAc afforded 
0.08 g (10%) of the product as a white crystals: mp 221-222 °C (lit.261 mp  225-227 °C 
(MeOH/EtOAc)); 1H NMR (DMSO-d6) δ 1.47 (m, 1H, CH), 1.77 (m, 4H, CH2), 2.11 (m, 
1H, CH), 2.97 (m, 1H, CH), 3.23 (m, 1H, CH), 4.94 (t, J = 9.8 Hz, 1H, CH), 7.62 (t, J = 
7.9 Hz, 2H, ArH), 7.76 (m,1H, ArH), 8.05 (dd, J = 7.2 Hz, 2H, ArH), 9.9 (br s, 2H, NH2+, 
D2O ex). 
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Methyl 2-phenyl-3-(pyrrolidin-1-yl)propionate Hydrochloride (85). This compound is 
reported in the literature and was synthesized according to the literature procedures.262,263  
A solution of ethyl 2-phenyl-3-(pyrrolidin-1-yl)propionate (126) (3.00 g, 12 mmol) in HCl 
(10N, 15 mL) was microwave (50 W, 120 °C, 2 h) irradiated. The reaction mixture was 
diluted with MeOH (10 mL), and the solvent was evaporated under reduced pressure to 
yield 2.10 g of a crude solid of which 1.10 g was dissolved in anhydrous MeOH (20 mL) 
to which HCl gas was bubbled for 5 min and the reaction was allowed to stir at reflux for 
10 h. The reaction mixture was evaporated under reduced pressure to yield a crude solid 
which upon recrystallization from i-PrOH afforded 0.30 g (22%) of 85 as a buff-colored 
solid: mp 192-194 °C (lit.262 mp 196 °C); 1H NMR (DMSO-d6) δ 1.83-1.95 (m, 4H, CH2), 
2.90-2.92 (m, 1H, CH), 3.03-3.05 (m, 1H, CH), 3.32-3.34 (m, 1H, CH), 3.49-3.52 (m, 2H, 
CH2), 3.66 (s, 3H, CH3), 3.89-3.94 (m, 1H, CH), 4.36-4.39 (m, 1H, CH), 7.36-7.43 (m, 5H, 
ArH), 10.64 (br s, 1H, NH+).  
 
1-(2-Methoxy-2-phenylethyl)pyrrolidine Oxalate (86). Et3N (0.47 mL, 4.65 mmol) was 
added in a dropwise manner to a stirred solution of 128 (1.00 g, 4.65 mmol) in anhydrous 
benzene (10 mL) under an N2 atmosphere. The stirred reaction mixture was heated at 
reflux for 48 h. The reaction mixture was allowed to cool to room temperature followed by 
removal of solvents under reduced pressure. The residue obtained was dissolved in Et2O 
(15 mL) and washed with H2O (3 x 20 mL). The organic portion was separated and washed 
with 2M HCl (35 mL, pH=1), and the aqueous portion was basified with 3M NaOH (30 
mL, pH=14), and extracted with Et2O (2 x 25 mL). The combined organic portion was 
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washed with brine (2 x 10 mL), dried (Na2SO4), and evaporated to dryness under reduced 
pressure to yield 0.39 g of the free base as a yellow oil which was converted to its oxalate 
salt using a saturated oxalic acid solution in Et2O which, upon recrystallization from i-
PrOH, afforded 0.28 g (21%) of 86 as a buff-colored solid: mp 134-135 °C; 1H NMR 
(DMSO-d6) δ 1.94 (br s, 4H, CH), 3.11 (s, 3H, CH3), 3.34-3.45 (m, 6H CH), 4.64 (dd, J = 
10.5, 2.5 Hz, 1H, CH), 7.36-7.39 (m, 5H, ArH); Anal. Calcd for (C13H19N·1.4C2H2O4) C, 
57.27; H, 7.17; N, 4.23.  Found: C, 57.07; H, 6.43; N, 4.23. 
 
2-Methoxy-N,N-dimethyl-2-phenylethan-1-amine Hydrochloride (87). This compound 
is reported in the literature264 and was synthesized according to the literature procedure  
except that the literature reported a citrate salt.265 Dimethylamine (2M in MeOH 4.65 mL, 
9.30 mmol) was added in a dropwise manner to a stirred solution of 128 (1.00 g, 4.65 
mmol) in anhydrous benzene (10 mL) under an N2 atmosphere. The stirred reaction 
mixture was heated at reflux for 72 h and allowed to cool to room temperature. Solvents 
were removed under reduced pressure and residue dissolved in Et2O (15 mL) and washed 
with H2O (2 x 10 mL). The organic portion was separated and washed with 2M HCl (20 
mL, to pH 1), the aqueous portion was basified with 3M NaOH (to pH 14), and extracted 
with Et2O (2 x 20 mL). The combined organic portion was washed with brine (3 x 10 mL), 
dried (Na2SO4), and evaporated to dryness under reduced pressure to yield 0.23 g of the 
free base as a yellow oil that was converted to its hydrochloride salt using saturated 
solution of HCl/Et2O which, upon recrystallization from i-PrOH, afforded 0.10 g (11%) of 
87 as a white solid: mp 228-229 °C (lit.264 mp 233 °C (EtOH/EtOAc); 1H NMR (DMSO-
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d6) δ 2.81 (s, 6H, CH3), 3.16 (s, 4H, CH), 3.35 (m, 2H, CH), 4.78 (dd, J = 2.5, 10.5 Hz, 1H, 
CH), 7.38-7.46 (m, 5H, ArH), 10.35 (s, 1H, NH+). 
  
2-(Methylamino)-1-phenylpropan-1-one oxime Hydrochloride (88). A solution of 57 as 
its hydrochloride salt (1.00 g, 5.0 mmol) (on hand from previous studies), hydroxylamine 
hydrochloride (0.75 g, 10.5 mmol) and pyridine (4.0 mL, 50.0 mmol) in absolute EtOH (25 
mL) was allowed to stir at room temperature for 18 h and then at 45 °C for 48 h. Solvent 
was removed under reduced pressure. The residue was treated with a saturated solution of 
gaseous NH3 in MeOH and solvent was removed under reduced pressure. The solid residue 
was extracted with hot acetone (3 × 30 mL). Solvent was removed under reduced pressure. 
The residue was purified by flash chromatography (silica gel; CH2Cl/MeOH saturated with 
gaseous NH3; 9:1). The obtained solid was suspended in acetone, stirred overnight and 
collected by filtration: mp 197–205 °C. 1H NMR spectra showed that the solid contains a 
mixture of isomeric oximes (2:1). The solid was dissolved in absolute EtOH and converted 
to the hydrochloride salt by adding a saturated solution of gaseous HCl in Et2O. The 
precipitate (0.20 g) was collected by filtration and recrystallized three times from a mixture 
of acetone/absolute EtOH to afford 0.12 g (11%) of the product as white crystals: mp 209–
213 °C (lit.266 mp 198–201 °C, EtOH/Et2O/acetone); 1H NMR (DMSO-d6) δ 1.31 and 1.57 
(d, 3H, CH3), 2.56 and 2.63 (s, 3H, CH3), 4.32–4.40 (two q, 1H, CH), 7.41–7.52 (m, 3H, 
ArH), 7.66–7.68 (m, 2H, ArH), 9.35 (br s, 2H, NH2+), 11.51 (s, 1H, OH). Anal. Calcd 
(C10H14N2O·HCl) C, 55.95; H, 7.04; N, 13.05. Found: C, 55.69; H, 6.89; N, 12.88. 
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2-Methyl-1-phenylbutan-1-one (89). This compound is known and was synthesized 
according to the literature procedure.267 In a 2-neck flask fitted with a CaCl2 guard tube, a 
solution of 2-methylbutyrl chloride (130) (1.00 g, 8.30 mmol) in anhydrous benzene (1 
mL) was added in a dropwise manner to a suspension of AlCl3  (1.20 g, 9.13 mmol) in 
anhydrous benzene (2 mL) under an N2 atmosphere at room temperature. The contents 
were allowed to stir at room temperature for 4 h and quenched by the addition of ice (7 g) 
and conc. HCl (6 mL). The aqueous layer was extracted with Et2O (2 x 10 mL), the 
combined organic portion was washed with saturated aqueous solution of NaHCO3 (5 x 5 
mL), dried (Na2SO4), and solvent was evaporated under reduced pressure to yield a crude 
yellow-colored oil (0.70 g) which was purified by Kugelrohr distillation (149 °C at 1 Torr) 
to afford 0.33g (25%) of 89 as a colorless oil: bp 240 °C at 760 mm of Hg (lit.267 bp 133–
135 °C at 24 mm of Hg); 1H NMR (CDCl3-d6) δ 0.92 (t, J = 7.5 Hz, 3H, CH3), 1.20 (m, 
3H, CH3), 1.45-1.55 (m, 1H, CH), 1.79-1.89 (m, 1H, CH), 3.36-3.44 (m, 1H, CH), 7.44 (t, 
J =  7.9 Hz, 2H, ArH), 7.56 (t, J = 6.8 Hz, 1H, ArH), 7.95 (d, 2H, ArH). 
 
Dimethyl(1-methyl-2-oxo-2-phenylethyl)sulphonium Bromide (90). This compound is 
reported in the literature and was synthesized according to the literature procedure.268 In a 
2-neck flask, an excess of dimethylsulfide (2 mL) was added to a solution of 2-
bromopropiophenone  (106) (0.50 g, 2.35 mmol) under an N2 atmosphere and the reaction 
mixture was heated at 65 °C for 5 h, cooled to room temperature and the precipitate formed 
was collected by filtration to yield 0.15 g of the product which upon recrystallization from 
MeOH/Et2O afforded 0.14 g (22%) of 90 as a buff-colored solid: mp 130-131 °C (lit.268 mp 
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129 °C); 1H NMR (DMSO-d6) δ 1.69 (d, J = 7.3 Hz, 3H, CH3), 2.95 (d, J = 10.6 Hz, 6H, 
CH3), 5.90 (q, J = 6.4, 17.5 Hz, 1H, CH), 7.65 (t, J = 15.6, 8.0 Hz, 2H, ArH), 7.77-7.81 
(m, 1H, ArH), 8.06 (dd, J = 8.2, 0.9 Hz, 2H, ArH). 
 
1-(Benzo[d]-1,3-dioxol-5-yl)propan-1-one (92). This compound is reported in the 
literature269 and was synthesized according to the literature procedure except that SnCl4 
was used in place of AlCl3.269 SnCl4 (1.80 mL, 15.36 mmol) was added in a dropwise 
manner at 0-5 °C to a stirred solution of propionyl chloride (1.30 mL, 15.36 mmol) and 
1,3-benzodioxole (91) (1.50 g, 12.28 mmol) in anhydrous CH2Cl2 (10 mL). The contents 
were allowed to stir at 0-5 °C for 10 min under an N2 atmosphere. The reaction mixture 
was quenched by the careful addition of ice (10 g) and conc HCl (8 mL). The organic 
portion was separated, washed with water and dried (MgSO4). The solvent was evaporated 
under reduced pressure to yield a crude dark-yellow oil which was purified by Kugelrohr 
distillation followed by recrystallization from hexane/Et2O to afford 2.19 g (28%) of 92 as 
a white powder: mp 35–38 °C (lit.269 mp 38–39 °C, (EtOH)); bp 165 °C, 1 Torr; IR 
(Diamond, cm-1) 1666 (C=O), 1436 (CH2O), 1241(C-O); 1H NMR (CDCl3-d6) δ 1.21 (t, J 
= 6.8 Hz, 3H, CH3), 2.92 (q, J = 14.6, 7.3 Hz, 2H, CH2), 6.04 (s, 2H, CH2), 6.84 (d, J =8.2 
Hz, 1H, ArH), 7.44 (d, J = 1.6 Hz, 1H, ArH), 7.56 (dd, J = 8.1, 1.7 Hz, 1H, ArH).  
  
1-(Benzo[d]-1,3-dioxol-5-yl)pentan-1-one (93). This compound is reported in the 
literature and was synthesized according to the literature procedure.270 SnCl4 (3.60 mL, 
30.70 mmol) was added in a dropwise manner at 0-5 °C to a stirred solution of valeroyl 
 236 
chloride (3.60 mL, 30.70 mmol) and 1,2-methylenedioxybenzene (91) (3.00 g, 24.56 
mmol) in anhydrous CH2Cl2 (22 mL). The reaction mixture was allowed to stir at 0-5 °C 
for 20 min under an N2 atmosphere. The reaction mixture was quenched by the careful 
addition of ice (21 g) and conc. HCl (16 mL). The organic layer was separated, washed 
with H2O (8 mL), and dried (MgSO4). The solvent was evaporated under reduced pressure 
to yield a yellow oil which was purified by Kugelrohr distillation followed by column 
chromatography (silica gel; hexane/EtOAc; 90:10) to yield 1.60 g (32%) of the product as 
a pale-yellow oil: bp 171 °C, 1 Torr (lit.270 bp 120 °C, 5 mm of Hg ): 1H NMR (CDCl3-d6) 
δ 0.94 (t, J = 7.2 Hz, 3H, CH3), 1.35-1.44 (m, 2H, CH2), 1.73-1.5 (m, 2H,CH2), 2.88 (t, J = 
7.3 Hz, 2H, CH2), 6.03 (s, 2H, CH2O), 6.80 (d, J = 7.9 Hz, 1H, ArH), 7.43 (d, J = 1.6 Hz, 
1H, ArH), 7.56 (dd, J = 8.1, 1.7,  Hz, 1H, ArH).  
1-(Benzo[d]-1,3-dioxol-5-yl)-2-bromopropan-1-one  (94). This compound is reported in 
the literature and was synthesized according to the literature procedure except that AlCl3 
was used.271 Bromine (0.01mL, 0.19 mmol) was added in a dropwise manner to a stirred 
solution of 92 (0.27 g, 1.51 mmol) and AlCl3 (0.01 g, 0.08 mmol) in anhydrous Et2O (10 
mL) at 0 °C under an N2 atmosphere. The reaction mixture was allowed to stir at 0 °C for 
10 min, and then allowed to warm to room temperature. When the color of the solution 
changed from orange to pale yellow the remaining quantity of bromine (0.07 mL, 1.35 
mmol) was added in a dropwise manner. The reaction mixture was allowed to stir at room 
temperature for 10 min. The reaction mixture was quenched with a saturated solution of 
NaHCO3 (15 mL). Organic portion was separated, washed with brine (1 x 10 mL) and 
dried (MgSO4). Solvent was removed under reduced pressure and the residue was dried 
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under high vacuum to afford 0.20 g (70%) of 94 as a sticky pale-orange solid: mp 41-43 °C 
(lit.256 mp 52-53 °C (MeOH)); 1H NMR (CDCl3-d6) δ 1.81 (d, J = 6.6 Hz, 3H, CH3), 5.14 
(q, J =13.2, 6.6 Hz, 1H, CH), 5.99 (s, 2H, CH2), 6.80 (d, J = 8.2 Hz, 1H, ArH), 7.42 (s, J = 
1.7 Hz, 1H, ArH), 7.56 (d, J = 1.7 Hz, 1H, ArH). 
 
1-(Benzo[d]-1,3-dioxol-5-yl)-2-bromopentan-1-one (95). This compound is reported in 
the literature272 (using a 3-step procedure starting from piperonal) but was synthesized here 
according to a procedure for a similar compound.273 Bromine (0.06 mL, 1.16 mmol) was 
added in a dropwise manner to a stirred solution of 93 (0.80 g, 3.87 mmol) and AlCl3 (0.03 
g, 0.20 mmol) in anhydrous Et2O (6 mL) at 0 °C under an N2 atmosphere. The reaction 
mixture was allowed to stir at 0 °C for 10 min and then allowed to warm to room 
temperature. When the color of the solution changed from orange to a pale yellow, the 
remaining bromine (0.14 mL, 2.70 mmol) was added in a dropwise manner. The reaction 
mixture was allowed to stir at room temperature for 10 min. The reaction mixture was 
quenched with a saturated solution of NaHCO3 (20 mL). The organic portion was 
separated, washed with brine (10 mL), and dried (MgSO4). The solvent was evaporated 
under reduced pressure to yield a yellow oil (1.10 g) which was purified by column 
chromatography (silica gel; hexane/EtOAc; 95:5) to afford 0.65 g (60%) of 95 as a pale-
yellow oil:  1H NMR (CDCl3-d6) δ 0.97 (t, J = 14.8, 7.4 Hz, 3H, CH3), 1.58-1.44 (m, 1H, 
CH2), 2.07-2.18 (m, 2H, CH2), 5.06 (t, J = 14.3, 6.8 Hz, 1H, CH) 6.05 (s, 2H, CH2O), 6.87 
(d, J = 8.2 Hz, 1H, ArH) 7.48 (d, J = 1.7 Hz, 1H, ArH), 7.82 (dd, J = 8.2, 1.7 Hz, 1H, 
ArH). 
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1-Phenyl-2-(pyrrolidin-1-yl)ethan-1-one Oxalate (96). The compound is reported in the 
literature as its hydrochloride salt274 but the oxalate salt was made here because the 
hydrochloride was extremely hygroscopic. The procedure followed was modified such that 
Et3N was used.275 Pyrrolidine (0.84 mL, 10.04 mmol) was added to a stirred solution of 2-
bromoacetophenone (105) (2.00 g, 10.04 mmol) and Et3N (1.0 mL, 10.04 mmol) in 
anhydrous benzene (15 mL) under an N2 atmosphere at room temperature. The contents 
were allowed to stir at room temperature for 24 h. The reaction mixture was filtered and 
solvent evaporated under reduced pressure to yield 1.8 g (96%) the crude free base, of 
which 1.0 g was converted to its oxalate salt using a saturated solution of oxalic acid in 
Et2O and was allowed to stir at room temperature for 48 h. The precipitate was collected 
by filtration to yield a solid which was recrystallized twice from absolute MeOH (10 mL) 
to afford 0.35 g (24%) of 96 as brown crystals: mp 218-220 °C, absolute MeOH; 1H NMR 
(DMSO-d6) δ 1.95 (s, 4H, CH2), 3.23 (m, 4H, CH2), 4.92 (s, 2H, CH2), 7.59 (s, 2H, ArH) 
7.72 (s, 1H, ArH), 7.98 (s, 2H, ArH); Anal. Calcd for (C12H15NO·C2H2O4) C, 60.21; H, 
6.14; N, 5.02.  Found: C, 59.97; H, 6.19; N, 5.00. 
 
1-Phenyl-2-(pyrrolidin-1-yl)propan-1-one Hydrochloride (97). This compound is 
reported in the literature and was synthesized according to the literature procedure.249 
Pyrrolidine  (0.76 mL, 9.20 mmol) was added to a solution of 2-bromopropiophenone 
(106) (1.00 g, 4.60 mmol) in anhydrous benzene (10 mL) under an N2 atmosphere at room 
temperature. The reaction mixture was allowed to stir at room temperature for 14 h 
followed by heating at reflux for 8 h. The reaction mixture was diluted with Et2O (30 mL) 
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and washed with H2O (2 x 15 mL). The organic layer was separated and acidified with 2M 
HCl (to pH 1), and extracted with Et2O (2 x 20 mL). The aqueous portion was basified 
with 3M NaOH (to pH 14) and extracted with Et2O (2 x 25 mL). The combined organic 
portion was washed with brine (3 x 15 mL), dried (Na2SO4), and evaporated under reduced 
pressure to yield a brownish-colored oil that was converted to its hydrochloride salt using a 
saturated solution of HCl/Et2O and upon two recrystallizations from absolute EtOH/Et2O 
afforded 0.70 g (22%) of 97 as a cream-colored solid: mp 202-203 °C (lit.249 mp 197 °C); 
1H NMR (DMSO-d6) δ 1.51 (d, J = 7.1 Hz, 3H, CH3), 1.93 (br s, 4H, CH2), 3.20–3.08 (m, 
2H CH2), 3.53–3.61 (m, 2H, CH2), 7.63 (m, 2H, ArH) 7.77 (t, J = 7.4 Hz, 1H, ArH), 8.04 
(m, 2H, ArH), 10.68 (s, 1H, NH+). 
 
1-Phenyl-2-(1-piperidinyl)-1-propanone Hydrochloride (103). This compound is 
reported in the literature and was synthesized according to the literature.276 Piperidine (0.90 
ml, 9.20 mmol) was added to a stirred solution of 2-bromopropiophenone (106) (1.00 g, 
4.60 mmol) in anhydrous benzene (10 mL) under an N2 atmosphere at room temperature. 
The reaction mixture was allowed to stir at room temperature for 3 h followed by 24 h of 
reflux. The reaction mixture was cooled to room temperature and the solvent removed 
under reduced pressure to yield a brown residue. The residue was dissolved in Et2O (20 
mL) and washed with water (5 x 5 mL), dried (MgSO4), and solvent was evaporated under 
reduced pressure to yield 0.90 g of the crude product that was converted to its 
hydrochloride salt using a saturated solution of HCl/Et2O and upon recrystallization from 
absolute EtOH afforded 0.50 g (43%) of 103 as a white solid: mp 212-213 °C (lit.276 mp 
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212-214 °C ); 1H NMR (DMSO-d6) δ 1.51 (d, J = 7.2 Hz, 3H, CH3), 1.77 (br s, 4H, CH2), 
2.99 (br s, 2H, CH2), 3.12–3.50 (m, 2H, CH2), 4.04 (m, 2H, CH2), 5.34 (q, J = 6.6 Hz, 1H, 
CH), 7.63 (t, J = 7.6 Hz, 2H, ArH) 7.78 (t, J = 7.4 Hz, 1H, ArH), 8.07 (t, J = 8.4 Hz, 2H, 
ArH), 10.06 (s, 1H, NH+).  
 
2-Bromo-1-(4-fluorophenyl)-1-propanone (108). This compound is reported in the 
literature and was synthesized according to the literature procedure except with the 
addition of AlCl3.258 Bromine (0.05 mL, 1.09 mmol) was added in a dropwise manner to a 
stirred solution of 4’-fluoropropiophenone (107) (1.00 g, 6.50 mmol) and AlCl3 (0.05 g, 
0.17 mmol) in anhydrous CH2Cl2 (25 mL) at 0 °C under an N2 atmosphere. The reaction 
mixture was allowed to stir at 0 °C for 10 min, and then allowed to warm to room 
temperature. When the color of the solution changed from orange to pale yellow the 
remaining bromine (0.25 mL, 10.53 mmol) was added in a dropwise manner. The reaction 
mixture was allowed to stir at room temperature for 14 h. The reaction mixture was 
quenched with a saturated solution of NaHCO3 (15 mL). The organic portion was 
separated, washed with H2O (10 mL) and dried (MgSO4). Solvent was removed under 
reduced pressure and the residue was dried under high vacuum to afford 1.43 g (100%) of 
108 as a colorless oil: 1H NMR (CDCl3-d6) δ 1.90 (d, J = 6.6 Hz, 3H, CH3), 5.23 (q, J = 
13.2, 6.6 Hz, 1H, CH), 7.16 (t, J = 8.5 Hz, 2H, ArH), 8.06 (dd, J = 5.4, 2.1 Hz, 2H, ArH).  
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 6-(2-Nitroprop-1-en-1-yl)-2,3-dihydrobenzo[b]-1,4-dioxine (110). Ammonium acetate 
(1.00 g, 13.13 mmol) was added to a solution of 1,4-benzodioxan-6-carboxaldehyde (109) 
(1.00 g, 6.70 mmol) in nitroethane (20 mL), and the reaction mixture was heated at reflux 
for 5 h under an N2 atmosphere. The nitroethane was evaporated under reduced pressure, 
the resultant yellow residue was dissolved in CHC13 (5 mL), the organic layer was washed 
with H2O (3 x 5 mL). The aqueous portion was extracted with CHC13 (3 x 5 mL), and the 
organic portions were combined, dried (Na2SO4) and evaporated to yield a crude yellow oil 
that was recrystallized from MeOH to yield 1.00 g (75%) of 110 as a yellow crystals: mp 
97-98 °C (MeOH), (lit.277 mp 97-98 °C (MeOH)). 
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)propan-2-amine Hydrochloride (111). This 
compound is reported in the literature and was synthesized according to the literature 
procedure.277 A solution of 110 (1.00 g, 4.50 mmol) in anhydrous THF (18 mL) was added 
in a dropwise manner to a stirred suspension of LiAlH4 (0.29 g, 7.52 mmol) in anhydrous 
THF (12 mL) at 0 °C under an N2 atmosphere. After completion of the addition, the 
reaction mixture was heated at reflux for 5 h, and then quenched at 0 °C by the dropwise 
addition of Et2O (50 mL), H2O (3 mL) and 15% NaOH (1.7 mL). The mixture was stirred, 
filtered and the filtrate was dried (Na2SO4). The solvent was evaporated under reduced 
pressure to give a yellow oily residue, which was converted to its hydrochloride salt using 
a saturated solution of HCl/Et2O to afford 0.16 g (64%) of 111 as a white solid: mp 163-
166 °C (lit.277 mp 167-170 °C). Compound was used without any further purification. 
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Ethyl (1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)propan-2-yl)carbamate (112). Et3N in 
anhydrous Et2O (0.4 mL) and ethyl chloroformate (0.14 mL) in Et2O (1 mL) were added to 
a suspension of 111 (0.35 g) in anhydrous Et2O (10 mL) and stirred at room temperature 
for 1 h under an N2 atmosphere. The reaction mixture was filtered and solvent was 
removed under reduced pressure to afford 0.30 g (79%) of 112 as a yellow oil: IR 
(Diamond, cm-1) 3066 (NH), 1754 (N-CO-O-), 1577 (CH2 CH2O), 1274(C-O). The 
compound was used without further characterization for the preparation of 51. 
 
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)propan-1-one (114). This compound is reported 
in the literature AlCl3269 was synthesized according to the literature procedure except that 
SnCl4 was used instead of AlCl3.269 SnCl4 (2.14 mL, 18.32 mmol) was added in a dropwise 
manner at 0-5 °C to a stirred solution of propionyl chloride (1.60 mL, 18.32 mmol) and 
1,4-benzodioxane (113) (2.00 g, 14.64 mmol) in anhydrous CH2Cl2 (20 mL). The reaction 
mixture was allowed to stir at 0-5 °C for 20 min under an N2 atmosphere. The reaction 
mixture was quenched by the careful addition of ice (16 g) and conc. HCl (11 mL). The 
organic layer was separated, washed with H2O (3 x 5 mL), and dried (Na2SO4). The 
solvent was evaporated under reduced pressure to yield 2.15 g (76%) of 114 as a yellow 
oil: 1H NMR (CDCl3-d6) δ 1.20 (t, J = 7.2 Hz, 3H, CH3), 2.91 (d, J = 7.3 Hz, 2H, CH2), 
4.27-4.31 (m, 4H, CH2), 6.90 (d, J = 9.08 Hz, 1H, ArH), 7.50 (s, 2H, ArH). Note- 
Compound has been reported as a low melting solid, mp 39-40 °C.278  
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2-Bromo-1-(2,3-dihydrobenzo[b]-1,4-dioxin-6-yl)propan-1-one (115). This compound 
is known and was synthesized according to the literature procedure except that AlCl3 was 
used.271 Bromine (0.15 mL, 2.96 mmol) was added in a dropwise manner to a stirred 
solution of 114 (2.15 g, 11.80 mmol) and AlCl3 (0.06 g, 0.60 mmol) in anhydrous Et2O (18 
mL) at 0 °C under an N2 atmosphere. The reaction mixture was allowed to stir at 0 °C for 
10 min and then allowed to warm to room temperature. When the color of the solution 
changed from orange to a pale yellow, the remaining bromine (0.45 mL, 8.88 mmol) was 
added in a dropwise manner. The reaction mixture was allowed to stir at room temperature 
for 20 min. The reaction mixture was quenched with a saturated solution of NaHCO3 (40 
mL). The organic portion was separated, washed with brine (3 x 5 mL), and dried 
(Na2SO4). The solvent was evaporated under reduced pressure to yield a yellow oil (3.00 g) 
which was purified by column chromatography (silica gel; hexane/EtOAc; 89:11) to afford 
0.88 g (30%) of 115 as a white solid: mp 77-78 °C (lit.271 bp 180-182 °C at 1.5 mm of Hg); 
1H NMR (CDCl3-d6) δ 2.09 (m, 3H, CH3), 4.46 (br s, 4H, CH2O), 5.38-5.24 (m, 1H, CH) 
7.48 (m, J = 1.7 Hz, 1H, ArH), 7.82 (m, J = 8.2, 1.7 Hz, 2H, ArH).  
(1-Methyl-4-(2-nitroprop-1-en-1-yl)benzene (117). Ammonium acetate (12.60 g, 163.11 
mmol) was added to a solution of p-tolualdehyde (116) (10.00 g, 163.11 mmol) in 
nitroethane (30 mL), and the reaction mixture was heated at reflux for 2.5 h under an N2 
atmosphere. The nitroethane was evaporated under reduced pressure, the resultant yellow 
residue was dissolved in CHC13 (20 mL), the organic layer was washed with H2O (3 x 10 
mL), the organic portions were combined, and dried (Na2SO4). The solvent was evaporated 
under reduced pressure to yield a crude residue which was purified by column 
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chromatography (silica gel; hexane:EtOAc; 100:0) to afford 4.07 g of yellow powder, that 
was recrystallized from hexane to yield 4.00 g (28%) of 117 as a yellow crystals: mp 53-55 
°C, (lit.279 mp 51.5-52.5 °C). 
1-(p-Tolyl)propan-2-amine Hydrochloride (118). Compound is reported in the 
literature280,281 and was synthesized according to the literature procedure.280 In a 3-necked 
flask equipped with a CaCl2 guard tube a solution of 117 (2.00 g, 11.29 mmol) in 
anhydrous THF (30 mL) was added in a dropwise manner to a stirred suspension of 
LiAlH4 (1.70 g, 45.15 mmol) in anhydrous THF (40 mL) at 0 °C under an N2 atmosphere. 
After completion of the addition, the reaction mixture was heated at reflux for 2.5 h, and 
then quenched at 0 °C by diluting with Et2O (50 mL), and then by the dropwise addition of 
H2O (2 mL), 15% NaOH (2 mL) and H2O (6 mL). The mixture was stirred, filtered and the 
filtrate was washed with water (2 x 10 mL), and dried (Na2SO4). The solvent was 
evaporated under reduced pressure to give a 1.40 g of a yellow oily residue, which was 
converted to its hydrochloride salt using a saturated solution of HCl/Et2O to yield 0.90 g 
(45%) of 118 as a white solid: mp 150-151°C (lit.281 mp 158-159 °C (EtOAc, EtOH, Et2O).  
 
N-(1-(p-Tolyl)propan-2-yl)acetamide (119). Acetyl chloride  (0.4 mL, 4.96 mmol) was 
added in a dropwise manner at 0 °C to a stirred solution of 118 (0.90 g, 4.85 mmol), Et3N 
(1.35 mL, 9.70 mmol) in anhydrous CH2Cl2 (25 mL) under an N2 atmosphere. The reaction 
mixture was allowed to stir at room temperature for 16 h. Reaction was washed with 2M 
HCl (2 x10 mL), organic layer was separated and washed with water (2 x 5 mL), and dried 
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(Na2SO4). The solvent was evaporated under reduced pressure to yield a crude residue 
(1.01 g) which was purified by column chromatography (silica gel; hexane/EtOAc; 40:60) 
to afford 0.62 g (67%) of 119 as a white solid: mp 82-83 °C. 
 
N-(1-(p-Tolyl)propan-2-yl)propionamide (120). Propionyl chloride  (0.35 mL, 3.96 
mmol) was added in a dropwise manner at 0 °C to a stirred solution of 118 (0.72 g, 3.88 
mmol), Et3N (1.08 mL, 7.75 mmol) in anhydrous CH2Cl2 (10 mL) under an N2 
atmosphere. The reaction mixture was allowed to stir at room temperature for 17 h. 
Reaction was washed with 2M HCl (2 x10 mL), organic layer was separated and dried 
(Na2SO4). The solvent was evaporated under reduced pressure to yield a crude residue 
(0.58 g) which was purified by column chromatography (silica gel; hexane/EtOAc; 30:70) 
to afford 0.42 g (53%) of 120 as a yellow oil: 1H NMR (CDCl3-d6) δ 1.09-1.13 (m, 6H, 
CH3), 2.14 (q, J = 15.1, 7.6 Hz, 2H, CH3), 2.32 (s, 3H, CH3), 2.81-2.66 (m, 2H CH2), 4.28-
4.21 (m, 1H, CH), 7.08 (m, 4H, ArH). 
 
1-(4-Methylphenyl)-2-propanone (121). The compound is reported in the literature and 
was synthesized according to the literature procedure.282 Compound 117  (12.00 g, 67.70 
mmol) was added portionwise to a solution of iron powder (45.00 g, 812.60 mmol) in 80 
mL of 90% aqueous acetic acid which was heated at 70 °C for 20 minutes. After heating 
for an additional 1 h at 70 °C, the mixture was poured into H2O (200 mL) and CH2Cl2 (100 
mL), and the mixture was stirred for an additional 30 min and filtered through Celite. The 
filter cake was washed with CH2Cl2. The organic phase was separated and washed with 
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brine (30 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 5.90 g 
(59%) 121 as a yellow oil: 1H NMR (CDCl3-d6) δ 2.03 (s, 3H, CH3), 2.28 (s, 3H, CH3), 
3.57 (s, 2H, CH2), 7.00 (d, J = 8.0 Hz, ArH), 7.06 (d, J = 8.0 Hz, 2H, ArH). 
 
Ethyl 2-phenylacrylate (125). This compound is reported in the literature and was 
synthesized according to the literature procedure.263 Formalin (37%, 7.40 mL, 91.00 
mmol) was added to a mixture of ethyl phenylacetate (124) (10.00 g, 61.00 mmol), DMF 
(60 mL) and K2CO3 (8.40 g, 61.00 mmol) and the reaction mixture was allowed to stir at 
110 °C (oil bath) for 5 h, cooled to room temperature, quenched by addition of H2O (250 
mL), and extracted with Et2O (3 x 100 mL). The combined organic portion was washed 
with H2O (3 x 100 mL), aqueous LiCl (5%, 50 mL), brine (50 mL), dried (Na2SO4), and 
solvent was evaporated under reduced pressure to yield 6.00 g (56%) of 125 as a crude, 
yellow-colored oil: 1H NMR (CDCl3-d6) δ 1.25 (t, 3H, CH3), 3.96 (q, 2H, CH2), 5.79 (d, J 
= 1.2 Hz, 1H, CH), 6.26 (d, J = 1.2 Hz, 1H, CH), 7.15-7.22 (m, 5H, Ar). The compound 
was used without further characterization for the preparation of 126. 
 
Ethyl 2-phenyl-3-(pyrrolidin-1-yl)propionate (126). This compound is reported in the 
literature and was synthesized according to a procedure for the same compound.262  
Pyrrolidine (6.50 g, 91.00 mmol) was added to a solution of ethyl 2-phenylacrylate (125) 
(4.00 g, 23.00 mmol) in anhydrous DMF (8 mL) under an N2 atmosphere. The reaction 
mixture was allowed to stir at room temperature for 1 h, diluted with Et2O (100 mL), and 
washed with H2O (3 x 100 mL), dried (Na2SO4), and evaporated under reduced pressure to 
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yield 3.80 g (68%) of the free base of 126 as a yellow-colored oil which was used for 
further reaction without purification.  
 
 (2-Bromo-1-methoxyethyl)benzene (128). This compound is reported in the 
literature283,284  and was synthesized according to the literature procedure.283 Conc. H2SO4 
(2.56 mL, 48 mmol) was added in a dropwise manner at 5 °C to a stirred solution of 
styrene (127) (5.52 mL, 48 mmol) in anhydrous MeOH (50 mL). Portions of KBr (4.11 g, 
34.57 mmol) and KBrO3 (2.89 g, 17.28 mmol) were added over a period of 30 min, and the 
reaction was stirred at 5 °C for 2 h. The solvent was removed under reduced pressure, the 
residue was dissolved in H2O (50 mL) and extracted with CH2Cl2  (3 x 25 mL). The 
combined organic portions were washed with Na2S2O3 (50 mL), dilute NaHCO3 (50 mL), 
brine (25 mL), and dried (Na2SO4). Solvent was evaporated under reduced pressure to 
yield 4.50 g of crude product as yellow-colored oil. 3.40 g of the crude product was 
purified by Kugelrohr distillation to yield 2.30 g (33%) of 128 as a yellow-colored oil; bp 
142 °C, 1 Torr (lit.284 bp 50 °C, 0.5 Torr); 1H NMR (CDCl3-d6) δ 3.24 (s, 3H, CH3), 3.37-
3.49 (m, 2H, CH2), 4.31 (dd, J = 4.3, 8.2 Hz, 1H, CH), 7.31-7.24 (m, 5H, ArH). 
 
2-Methoxy-N-methyl-2-phenylethan-1-amine Hydrochloride (129). Methylamine (33% 
in EtOH, 4.67 mL, 34.87 mmol) was added in a dropwise manner to a stirred solution of 
128 (3.00 g, 13.95 mmol) in anhydrous benzene (10 mL) at 0 °C in an ice bath under an N2 
atmosphere. The reaction mixture was stirred at room temperature for 72 h, followed by 
the removal of solvents under reduced pressure. The residue obtained was dissolved in 
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Et2O (20 mL) and washed with H2O (3 x 20 mL). The organic portion was separated and 
washed with 2M HCl (50 mL, pH=1), and the aqueous portion was basified with 3M 
NaOH (to pH 14), extracted with Et2O (5 x 25 mL) and dried (Na2SO4). Solvent was 
removed under reduced pressure to yield 0.27 g of the free base as a yellow oil which was 
converted into its hydrochloride salt using a saturated solution of HCl/Et2O which upon 
recrystallization from acetone afforded 0.08 g (3%) of 129 as a white solid: mp 158-160 
°C; 1H NMR (DMSO-d6) δ 2.58 (s, 3H, CH3), 3.05-3.19 (m, 2H, CH2), 3.19  (s, 3H, CH3), 
4.60 (dd, J = 10.1, 3.2 Hz, 1H, CH), 7.35-7.46 (m, 5H, ArH), 8.90-9.13 (br s, 2H, NH2+); 
Anal. Calcd for (C10H15NO·HCl.0.3H2O) C, 57.99; H, 8.08; N, 6.76.  Found: C, 57.85; H, 
7.74; N, 6.74. 
 
1-(3,4-Dichlorophenyl)-2-methylbutan-1-one (132). Sec-butyl magnesium chloride (161) 
(2M in Et2O, 12.10 mL) was added in a dropwise manner at 0°C to a stirred solution of 
3,4-dichlorobenzonitrile (162) (3.50 g, 20.34 mmol) in anhydrous THF (12 mL) under an 
N2 atmosphere. The reaction mixture was allowed to stir at room temperature for 2 h, 
cooled to 0°C, quenched by addition of 3N HCl (30 mL, pH=1), and allowed to stir at 
room temperature for 30 min. The reaction mixture was basified with NH4OH solution (50 
mL (1:1), to pH 14 and extracted with CH2Cl2 (5 x 25 mL). The combined organic portion 
was washed with water (3 x 20 mL), dried (Na2SO4). The solvent was evaporated under 
reduced pressure to yield 3.40 g as a brown-colored crude oil which was purified by 
column chromatography (silica gel; hexane/EtOAc; 90:10) to afford 1.00 g of a yellow-
colored oil. This was further purified using Kugelrohr distillation to afford 0.80 g (17%) of 
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132 as a colorless oil: bp 210 °C, 2 Torr; 1H NMR (CDCl3-d6) δ 0.91 (t, J = 7.4 Hz, 3H, 
CH3), 1.19 (d, J = 6.8 Hz, 2H, CH3), 1.46-1.50 (m, 1H, CH), 1.76-1.87 (m, 1H, CH), 3.27-
3.34 (m, 1H, CH), 7.55 (d, J = 8.4 Hz, 1H, ArH), 7.76 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 8.02 
(d, J = 2.0 Hz, 1H, ArH); Anal. Calcd for (C11H12) C, 57.17; H, 5.23.  Found: C, 57.47; H, 
5.30. 
 
2-(Adamantan-1-yl)-2-(methylamino)-1-phenylethan-1-one Hydrochloride (137). 
Excess of methylamine  (2 mL of a 40% solution of methylamine in water) was added to 
stirred solution of K2CO3 (0.56 g, 4.05 mmol), KI (0.68 g, 4.05 mmol) and 142 (0.45 g, 
1.35 mmol) in anhydrous DMF (4 mL) in a sealed tube. The reaction mixture was heated at 
85 °C for 18 h and 120 °C for an additional 24 h. The reaction mixture was then transferred 
to a round-bottom flask and the solvents were evaporated under reduced pressure and the 
residue was dissolved in Et2O (10 mL) and the organic layer was washed with H2O (3 x 5 
mL) and separated. The organic layer was acidified with 1M HCl (25 mL, pH=1), and then 
aqueous portion was separated and basified with 1M NaOH (35 mL, to pH=14) and 
extracted with Et2O (3 x 10 mL).  The organic portions were combined, dried (Na2SO4), 
and evaporated under reduced pressure to yield the free base which was converted into the 
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization 
from i-PrOH/Et2O afforded 0.03 g (25%) of 137 as a buff-colored solid: mp 272 °C; 1H 
NMR (DMSO-d6) δ 1.69-1.53 (m, 12H, CH), 1.91 (s, 3H, CH), 2.32 (s, 2H, CH3), 5.71 (s, 
1H, CH), 7.50-7.43 (m, 5H, ArH). Anal. Calcd for (C12H15N·HCl) C, 71.34; H, 8.19; N, 
4.38.  Found: C, 71.08; H, 8.18; N, 4.33. 
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1-Adamantyl acetyl chloride (140). This compound is reported in the literature and was 
synthesized according to the literature procedure.285 Thionyl chloride (5.25 mL) was added 
in a dropwise manner to 1-adamantyl acetic acid (139) (3.50 g, 18.01 mmol), and the 
reaction mixture was heated at reflux for 2 h. Excess of thionyl chloride was evaporated 
under reduced pressure and a few drops of benzene were added to form an azeotrope to 
yield 3.50 g (93%) of 140 as a yellow oil; IR (Diamond, cm-1) 1788.50 (COCl). 
 
2-(Adamantan-1-yl)-1-phenylethan-1-one (141). In a 3-neck flask, AlCl3 (2.50 g, 18.74 
mmol) was added to a solution of 140 (3.50 g, 16.45 mmol) in anhydrous benzene (40 mL) 
under an N2 atmosphere at room temperature, and the reaction mixture was heated at 50 °C 
for 2 h. Reaction mixture was cooled to room temperature and quenched by the careful 
addition of ice/H2O (15 mL), followed by CH2Cl2 (2 x 25 mL). The organic layer was 
separated and washed with saturated NaHCO3 (2 x 20 mL), brine (2 x 10 mL), dried 
(Na2SO4), and evaporated to dryness under reduced pressure to yield 3.70 g of the crude 
residue which was purified by column chromatography (silica gel; hexane/EtOAc; 86:14) 
to afford 1.20 g (29%) of 141 as a white solid: mp 70-71 °C (lit.246 mp 66-67 °C); 1H NMR 
(CDCl3-d6) δ 1.70-1.62 (m, 12H, CH), 1.95 (s, 3H, CH), 2.72 (s, 2H, CH2), 7.47-7.43 (m, 
2H, ArH), 7.56-7.52 (s, 1H, ArH), 7.95-7.93 (m, 2H, ArH). 
 
2-(Adamantan-1-yl)-2-bromo-1-phenylethan-1-one (142). Bromine (0.04 mL, 0.78 
mmol) was added in a dropwise manner to a stirred solution of 141 (0.71 g, 2.79 mmol) 
and AlCl3 (0.02 g, 0.14 mmol) in anhydrous Et2O (10 mL) at 0 °C under an N2 atmosphere. 
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The reaction mixture was allowed to stir at 0 °C for 10 min, and then allowed to warm to 
room temperature. When the color of the solution changed from orange to pale yellow the 
remaining quantity of bromine (0.10 mL, 1.99 mmol) was added in a dropwise manner. 
The reaction mixture was allowed to stir at room temperature for 30 min. The reaction 
mixture was quenched with a saturated solution of NaHCO3 (pH=7). The organic portion 
was separated, washed with brine (10 mL) and dried (Na2SO4). Solvent was removed 
under reduced pressure and the residue was dried under high vacuum to afford 0.78 g  
(84%) of 142 as a white solid: mp 81–83 °C; 1H NMR (CDCl3-d6) δ 1.71-1.65 (m, 9H, 
CH), 2.00-1.95 (s, 6H, CH), 4.99 (s, 1H, CH), 7.46-7.50 (m, 2H, ArH), 7.61-7.57 (m, 1H, 
ArH), 7.96 (dd, J = 8.6, 1.4 Hz, 2H, ArH). 
 
1-(4-(tert-Butyl)phenyl)-2-(methylamino)propan-1-one Hydrochloride (143). 
Methylamine (33% in EtOH, 1.34 mL, 10.82 mmol) was added to a stirred solution of 149 
(1.45 g, 5.40 mmol) in anhydrous benzene (5 mL) in a sealed tube at 0-5 °C. Reaction 
mixture was allowed to warm to room temperature and stirred at room temperature for 18 
h. The residue was filtered and the filtrate was evaporated under reduced pressure. The 
residue was dissolved in Et2O (20 mL) and the organic layer was washed with H2O (2 x 5 
mL). The organic portions were combined and acidified with 1M HCl (30 mL, pH=1). The 
aqueous portion was basified with 1M NaOH (40 mL, pH=14), and extracted with Et2O (5 
x 5 mL). The combined organic portions were combined, dried (Na2SO4), and evaporated 
to dryness under reduced pressure to yield 0.60 g of a crude yellow oil which was 
converted to its hydrochloride salt (0.39 g) which upon recrystallization from i-PrOH/Et2O 
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afforded 0.10 g (7%) of 143 as a white powder: mp 210-213 °C; 1H NMR (DMSO-d6) δ 
1.24 (s, 9H, CH3), 1.38 (d, J = 7.1 Hz, 3H, CH3), 2.42 (d, J = 1.6 Hz, 1.7H, CH), 3.26 (s, 
1.6H, CH), 5.06 (q, J = 14.2, 7 Hz, 1H, CH), 7.55 (d, J = 8.5 Hz, 2H, ArH), 7.91 (d, J = 
8.5 Hz, 2H, ArH), 9.35 (br s, 2H, NH2+); Anal. Calcd for (C14H21N·) C, 65.74; H, 8.67; N, 
5.48.  Found: C, 65.46; H, 8.79; N, 5.33. 
 
 
1-(4-Benzylphenyl)-2-(methylamino)propan-1-one Hydrochloride (144). Methylamine 
(33% in EtOH, 0.68 mL, 5.47 mmol) was added to a stirred solution of 150 (0.83 g, 2.70 
mmol) in anhydrous benzene (5 mL) in a sealed tube at 0-5 °C. Reaction mixture was 
allowed to warm to room temperature and stirred at room temperature for 15 h and 45 °C 
for 4 h. The residue was filtered and the filtrate was evaporated under reduced pressure. 
The residue was dissolved in Et2O (20 mL) and the organic layer was washed with H2O (3 
x 5 mL). The organic portions were combined and acidified with 1M HCl (20 mL, pH=1). 
The aqueous portion was basified with 1M NaOH (35 mL, pH=14), and extracted with 
Et2O (3 x 15 mL). The combined organic portions were washed with brine (2 x 10 mL), 
dried (Na2SO4), and evaporated to dryness under reduced pressure to yield 0.15 g of a 
crude yellow oil which was converted to its hydrochloride salt using a saturated solution of 
HCl/Et2O and upon recrystallization from i-PrOH/Et2O afforded 0.50 g (7%) of 144 as a 
white powder: mp 185-187 °C; 1H NMR (DMSO-d6) δ 1.43 (d, J = 7.2 Hz, 3H, CH3), 2.57 
(s, 3H, CH3), 4.06 (s, 2H, CH2), 5.11 (q, J = 14.3, 7.1 Hz, 1H, CH), 7.32-7.22 (m, 5H, 
ArH), 7.47 (d, J = 8.3 Hz, 2H, ArH), 7.99 (d, J = 8.3 Hz, 2H, ArH), 9.29 (br s, 2H, NH2+); 
Anal. Calcd for (C17H19NO) C, 70.46; H, 6.96; N, 4.83.  Found: C, 70.15; H, 6.86; N, 4.69.  
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1-(4-(tert-Butyl)phenyl)propan-1-one (147). This compound is reported in the 
literature286,287 and was synthesized according to the literature procedure.287 In a 3-neck 
flask equipped with a CaCl2 guard-tube, propionyl chloride (3.25 mL, 37.25 mmol) was 
added to a solution of t-butylbenzene (145) (5.00 g, 37.25 mmol) in anhydrous CH2Cl2 (5 
mL) under an N2 atmosphere at room temperature. Reaction mixture was cooled to 0 °C 
and AlCl3 (5.00 g, 37.25 mmol) was added slowly over a period of 10 minutes. Reaction 
mixture was then stirred at room temperature for 5 h. Reaction mixture was poured into an 
ice and conc. HCl mixture (10 mL) and stirred for 30 min. The organic layer was separated 
and washed with brine (2 x 5 mL), dried (Na2SO4), and evaporated to dryness under 
reduced pressure to yield 5.20 g of the crude product which was purified by column 
chromatography (silica gel; Hexane/EtOAc; 90:10) and Kugelrohr distillation to afford 
1.85 g (26%) of 147 as a colorless oil: bp (178 °C, 0.5 Torr) (lit.286 bp 162 °C, 5 Torr) 1H 
NMR (CDCl3-d6) δ 1.24 (t, J = 4 Hz, 3H, CH3), 1.35 (s, 9H, CH3), 2.98 (q, 2H, J = 14.5, 
7.3 Hz, CH2), 7.47 (dd, J = 6.8, 1.8 Hz, 2H, ArH), 7.91 (d, J =  8.5 Hz, 2H, ArH). 
 
1-(4-Benzylphenyl)propan-1-one (148). In a 3-neck flask equipped with a CaCl2 guard-
tube, propionyl chloride (2.60 mL, 29.72 mmol) was added to a solution of 
diphenylmethane (146) (5.00 g, 29.72 mmol) in anhydrous CH2Cl2 (5 mL) under an N2 
atmosphere at room temperature. Reaction mixture was cooled to 0 °C and AlCl3 (4.00 g, 
29.72 mmol) was added slowly over a period of 10 min. Reaction mixture was heated to 
reflux for 2 h. Reaction mixture was poured into an ice and conc. HCl mixture (8 mL) and 
stirred for 30 min. The organic layer was separated and the aqueous layer was washed with 
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CH2Cl2 (3 x 10 mL). Organic fractions were combined and dried (Na2SO4), and evaporated 
to dryness under reduced pressure to yield 6.30 g of the crude product which was purified 
by column chromatography (silica gel; Hexane/EtOAc; 88:12) and Kugelrohr distillation 
(210 °C, 0.7 Torr) to afford 2.80 g (42%) of 148 as a white solid: mp 42-43 °C (lit.288 mp 
41.8-43.2 °C); 1H NMR (CDCl3-d6) δ 1.19 (t, J = 7.24 Hz, 3H, CH3), 2.95 (q, 2H, J = 14.5, 
7.2 Hz, CH2), 4.01 (s, 2H, CH2), 7.24-7.16 (m, 3H, ArH), 7.32-7.26 (m, 4H, ArH), 7.87 (d, 
J = 8.3 Hz, 2H, ArH). 
 
2-Bromo-1-(4-(tert-butyl)phenyl)propan-1-one (149). Bromine (0.17 mL, 3.30 mmol) 
was added in a dropwise manner to a stirred solution of 147 (1.85 g, 9.72 mmol) and AlCl3 
(0.49 g, 0.05 mmol) in anhydrous Et2O (5 mL) at 0 °C under an N2 atmosphere. The 
reaction mixture was allowed to stir at 0 °C for 10 min, and then allowed to warm to room 
temperature. When the color of the solution changed from orange to pale yellow the 
remaining quantity of bromine (0.33 mL, 6.42 mmol) was added in a dropwise manner. 
The reaction mixture was allowed to stir at room temperature for 2 h. The reaction mixture 
was quenched with a saturated solution of NaHCO3 (30 mL). The organic portion was 
separated, washed with brine (2 x 5 mL) and dried (Na2SO4). Solvent was removed under 
reduced pressure and the residue was dried under high vacuum to afford 2.14 g of the 
crude product which was purified by column chromatography (silica gel; hexane; 100) and 
then by Kugelrohr distillation to afford 1.45 g (56%) of 149 as a yellow oil: bp 224 °C, 1 
Torr; 1H NMR (CDCl3-d6) δ 1.35 (s, 9H, CH3), 1.90 (d, J = 6.6 Hz, 3H, CH3), 5.29 (q, J = 
13.3, 6.6 Hz, 1H, CH), 7.50 (t, J = 1.8 Hz, 2H, ArH), 7.98 (dd, J = 6.8, 1.8 Hz, 2H, ArH). 
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1-(4-Benzylphenyl)-2-bromopropan-1-one (150). Bromine (0.10 mL, 1.94 mmol) was 
added in a dropwise manner to a stirred solution of 148 (1.45 g, 6.46 mmol) and AlCl3 
(0.006 g, 0.05 mmol) in anhydrous Et2O (5 mL) at 0 °C under an N2 atmosphere. The 
reaction mixture was allowed to stir at 0 °C for 10 min, and then allowed to warm to room 
temperature. When the color of the solution changed from orange to pale yellow the 
remaining quantity of bromine (0.23 mL, 4.46 mmol) was added in a dropwise manner. 
The reaction mixture was allowed to stir at room temperature for 2 h. The reaction mixture 
was quenched with a saturated solution of NaHCO3 (50 mL). The organic portion was 
separated, washed with brine (2 x 5 mL) and dried (Na2SO4). Solvent was removed under 
reduced pressure and the residue was dried under high vacuum to afford 1.30 g of the 
crude product which was purified by Kugelrohr distillation to afford 0.83 g (42%) of 150 
as a yellow oil: bp 240 °C, 1 Torr; 1H NMR (CDCl3-d6) δ 1.89 (d, J = 6.6 Hz, 3H, CH3), 
4.04 (s, 2H, CH2), 5.26 (q, J = 6.4, 13.3 Hz, 1H, CH), 7.32-7.16 (m, 6H, ArH), 7.95 (q, J = 
8.3, 6.4 Hz, 3H, ArH).  
 
1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)propan-1-one Hydrochloride (151). This 
compound is reported in the literature and was synthesized according to the literature 
procedure.249 Pyrrolidine (2.78 mL, 33.24 mmol) was added to a stirred solution of 153 
(4.04 g, 16.62 mmol) in anhydrous benzene (20 mL) at room temperature under an N2 
atmosphere. The reaction mixture was allowed to stir at room temperature for 18 h. Et2O 
(50 mL) was added and the organic layer was washed with H2O (2 x 10 mL). The organic 
portions were combined and acidified with 1M HCl (50 mL, pH=1). The aqueous portion 
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was basified with 1M NaOH (75 mL, pH=14), and extracted with Et2O (3 x 20 mL). The 
combined organic portions were dried (Na2SO4), and evaporated to dryness under reduced 
pressure to yield a crude yellow oil which was converted to its hydrochloride salt using a 
saturated solution of HCl/Et2O and upon recrystallization from absolute EtOH/Et2O 
afforded 0.66 g (15%) of 151 as a white powder: mp 206-207 °C (lit.249 mp 197-199 °C 
with decomposition); 1H NMR (DMSO-d6) δ 1.49 (d, J = 7.1 Hz, 3H, CH3), 1.91-2.06 (m, 
4H, CH2), 2.42 (s, 3H, OCH3), 3.04-3.21 (m, 4H, CH2), 5.42 (t, J = 7.1 Hz, 1H, CH), 7.44 
(d, J = 7.8 Hz, 2H, ArH), 7.94 (d, J = 8.3 Hz, 2H, ArH), 10.58 (s, 1H, NH+). 
 
2-Bromo-1-(4-methoxyphenyl)propan-1-one (153). This compound is reported in the 
literature 289,290 and was synthesized according to the literature procedure except that AlCl3 
was used.290 Bromine (0.10 mL, 1.94 mmol) was added in a dropwise manner to a stirred 
solution of 4’-methoxypropiophenone (152) (5.00 g, 30.45 mmol) and AlCl3 (0.20 g, 1.52 
mmol) in anhydrous Et2O (20 mL) at 0 °C under an N2 atmosphere. The reaction mixture 
was allowed to stir at 0 °C for 10 min, and then allowed to warm to room temperature. 
When the color of the solution changed from orange to pale yellow the remaining quantity 
of bromine (1.50 mL, 28.32 mmol) was added in a dropwise manner. The reaction mixture 
was allowed to stir at room temperature for 30 min. The reaction mixture was quenched 
with a saturated solution of NaHCO3 (50 mL). The organic portion was separated, washed 
again with saturated NaHCO3 (15 mL), brine (15 mL), water (15 mL) and dried (Na2SO4). 
Solvent was removed under reduced pressure and the residue was dried under high vacuum 
to afford 5.20 g of a cream-colored solid which was purified by recrystallization using 
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absolute EtOH to afford 4.00 g (55%) of 153 as a white solid: mp 72-73 °C (lit.289 mp 66-
67 °C); 1H NMR (CDCl3-d6) δ 1.90 (d, J = 6.6 Hz, 3H, CH3), 2.43 (s, 3H, OCH3), 5.28 (q, 
J = 13.3, 6.6 Hz, 1H, CH), 7.29 (d, J = 9.2 Hz, 2H, ArH), 7.93 (d, J = 8.3 Hz, 2H, ArH). 
 
 
1-(1-Phenylpropan-2-yl)pyrrolidine Hydrochloride (154). The compound is reported in 
literature and was synthesized according to the literature procedure.250 A solution of 155 
(0.67 g, 5.39 mmol) in anhydrous Et2O (2 mL) was added in a dropwise manner with 
stirring to a solution of benzylmagnesium chloride, and the reaction mixture was heated at 
reflux for 1.5 h, cooled to room temperature and quenched by the careful addition of ice 
(12 g) conc HCl (10 mL). The organic layer is separated and the aqueous portion was 
basified with NaHCO3 (20 mL) and extracted with Et2O (3 x 15 mL). The combined 
organic portion was dried (Na2SO4) and evaporated to dryness under reduced pressure to 
yield 0.27 g of the free base which was converted into its hydrochloride salt using a 
saturated solution of HCl/Et2O which upon recrystallization absolute EtOH/Et2O afforded 
0.05 g (5%) of the product as white solid: mp 155-157 °C (lit.250 mp 151-152 °C); 1H 
NMR (DMSO-d6) δ 1.07 (d, J = 7.2 Hz, 3H, CH3), 1.92 (s, 4H, CH2), 2.60 (t, J = 23.9, 
12.8 Hz, 1H, CH), 3.19 (d, J = 13.2 Hz, 1H, CH), 3.29 (s, 3H, CH), 3.47 (d, J = 6.7, 5.8 
Hz, 1H, CH), 7.24 (t, J = 13.6, 7.5 Hz, 3H, ArH), 7.31 (d, J = 7.2 Hz, 2H, ArH), 10.97 (s, 
1H, NH+, D2O ex). 
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2-(pyrrolidin-1-yl)propanenitrile (155). The compound is reported in the literature250,291 
and was synthetized according to the literature procedure.250,291 Pyrrolidine (1.42 g, 20.00 
mmol) was acidified by 2M HCl; this was added to a solution of KCN (1.30 g, 20.00 
mmol) in H2O (10 mL). This mixture was added in a dropwise manner at 0 °C to a stirred 
solution of acetaldehyde (0.88 g, 20.00 mmol) in anhydrous Et2O (10 mL) under an N2 
atmosphere. The reaction mixture was allowed to stir at room temperature for 2 h. The 
organic portion was separated, washed with brine (2 x 5 mL) and H2O (2 x 5 mL), dried 
(Na2SO4) and evaporated to dryness under reduced pressure to yield a crude yellow-
colored liquid (0.90 g), which was purified by Kugelrohr distillation to afford 0.670 g 
(73%) of the product as a colorless liquid: bp 40 °C, 0.5 Torr (lit.250 bp 78-80°C, 10 Torr); 
1H NMR (CDCl3-d6) δ 1.48 (d, J = 7.2 Hz, 3H, CH3), 1.84 (s, 4H, CH2), 2.62-2.74 (m, 4H, 
CH2), 3.87 (q, J = 7.2, 14.4 Hz, 1H, CH). 
  
 
2-Methylamino-1-phenylethan-1-one Hydrochloride (156). AlCl3 (2.74 g, 20.54 mmol) 
was added in a portionwise manner to a stirred solution of 160 (3.70 g, 18.17 mmol) in 
anhydrous benzene (40 mL) under an N2 atmosphere. The stirred reaction mixture was 
heated at reflux for 4 h, allowed to cool to room temperature, quenched by addition of 
conc. HCl (12 mL) and ice (10 g). The organic layer was separated, washed with saturated 
NaHCO3 (3 x 15 mL) and brine (2 x 10 mL), dried (Na2SO4), and evaporated under 
reduced pressure to yield 0.80 g (18%) of the intermediate as brownish-orange oil. This 
intermediate was then dissolved in conc. HCl (50 mL) and i-PrOH (75 mL) and stirred at 
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40 °C for 48 h. The solvent was evaporated to yield 0.50 g of residue, which was 
recrystallized twice from absolute EtOH to yield 0.08 g (19%) of 156 as white crystals: mp 
205-207 °C (lit.142 mp 219 °C, EtOH); 1H NMR (DMSO-d6) δ 2.63 (s, 3H, CH3), 4.75 (s, 
2H, CH2), 7.61 (t, J = 7.7 Hz, 2H, ArH), 7.75 (t, J = 7.8 Hz, 1H, ArH), 7.99 (t, J = 7.2 Hz, 
2H, ArH), 9.32 (s, 2H, NH2+); Anal. Calcd for (C9H11N·HCl) C, 58.23; H, 6.51; N, 7.54.  
Found: C, 57.96; H, 6.57; N, 7.40. 
 
N-Trifluoroacetyl sarcosine (159). This compound is reported in the literature 292,293 and 
was synthesized according to the literature procedure.292 Trifluroacetic anhydride (8.60 
mL, 61.78 mmol) was added in a dropwise manner at 0 °C to a stirred suspension of 
sarcosine (158) (5.00 g, 56.16 mmol) in anhydrous CH2Cl2 (14 mL) under an N2 
atmosphere. The reaction mixture was allowed to stir at room temperature for 2 h. The 
solvent was evaporated under reduced pressure to yield 10.38 g (87%) of 159 as a viscous 
yellow oil, which solidifies upon cooling: mp 55-58 °C (lit.293 mp 54.5-55.5 °C); IR 
(Diamond, cm-1) 1662 (CONH), 1778 (CO), 3000 (OH). Compound was used without 
further purification. 
 
N-Trifluoroacetyl sarcosinyl chloride (160). Oxalyl chloride (2.10 mL, 23.76 mmol) was 
added in a dropwise manner over 5 min to a stirred solution of 159 (4.00 g, 21.60 mmol) 
and pyridine (3 drops) in anhydrous benzene (22 mL) under an N2 atmosphere. The stirred 
reaction mixture was heated at reflux for 1 h, allowed to cooled to room temperature and 
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solvents were removed reduced pressure to yield 4.17 g (95%) of the 160 as a brown-
colored liquid; IR (Diamond, cm-1) 1682 (CONH), 1788 (COCl). 
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